🌟 Today's "Members' Stories" features Giulia Bartoli, Former Fellow at Nephrology Department, Bellvitge University Hospital, Barcelona, Spain.
🏆 Giulia shares how the ERA Short-Term Fellowship Programme provided her with valuable clinical experience and opportunities for future collaborations.
📖 Read more 👉 www.era-online.org/membership/members-stories/members-sto…
European Renal Association
The European Renal Association (ERA) is one of the biggest nephrology associations worldwide, with more than 28,000 members. More on Wikipedia
-
ERA - European Renal Association
@ERAkidney
-
ERA - European Renal Association
@ERAkidney
👀 Our special November episodes of A Pinch of Salt continue with a second episode dedicated to another paper published in Nephrology Dialysis Transplantation: “Antibody-mediated rejection—treatment standard”.
🎙️ Rainer Oberbauer hosts Georg A. Böhmig, co-author of the paper, to discuss current challenges and evolving treatment strategies in antibody-mediated rejection after kidney transplantation.
🎧 Listen to the episode and read the full paper for further insights: www.era-online.org/research-education/a-pinch-of-salt-pod… -
ERA - European Renal Association
@ERAkidney
It’s time to start the kidney conversation.
CKD often develops without noticeable symptoms. Asking patients about risk factors, lifestyle and kidney health checks can help identify those at risk earlier.
Are you making every patient conversation count for kidney health?
📖 Explore our Chronic Kidney Disease Clinical Information and Conversation Guide: www.era-online.org/strong-kidneys/protect-your-kidneys-pr…
#strongkidneys #kidneyhealth #ckd #earlydetection #patientcommunication #healthcareprofessionals -
ERA - European Renal Association
@ERAkidney
📊 The latest ERA Registry Annual Report 2024 report is now online!
🔎 Data from 34 countries in Europe and bordering the Mediterranean Sea revealed that in 2024, 79.182 patients initiated kidney replacement therapy (dialysis or kidney transplantation).
🩺Among them, 58% were aged ≥65 years, 64% were male and 23% had diabetes as primary renal disease. Moreover, 82% of these patients started with haemodialysis, 11% with peritoneal dialysis and 6% received a pre-emptive kidney transplant.
🔗 Read the ERA Registry annual report and related CKJ paper to learn more 👉 www.era-online.org/wp-content/uploads/2026/11/ERA-Registr… -
ERA - European Renal Association
@ERAkidney
⚡ Did you start to Feel the Energy? Abstract & Travel Grants submission is now open!
📍 This is your moment to share your research and contribute to Powering Progress in Kidney Health.
🚀 Submit your Abstract by January 27, 2027 👉 www.era-online.org/events/rotterdam-2027/abstracts/?anc=5 -
ERA - European Renal Association
@ERAkidney
📅 On November 12–13, the Young Nephrologists' Platform (YNP) Board gathered in Parma, Italy for their annual face-to-face meeting.
💡 The meeting provided a valuable opportunity for Board members to exchange perspectives, reflect on ongoing activities, and explore new opportunities to strengthen collaboration and engage the young nephrology community.
📸 Take a sneak peek at the meeting! -
ERA - European Renal Association
@ERAkidney
💡 #era27 Scientific Programme: What's the main theme?
🎥 In this exclusive interview, Mario Cozzolino, Chair of the #era27 Scientific Committee, offers a sneak peek into the upcoming programme and the vision behind “Powering Progress in Kidney Health!”
Watch the interview and discover more about the programme 👉 www.era-online.org/events/rotterdam-2027/scientific-progr…This media couldn't be displayed. See it on the original post. -
ERA - European Renal Association
@ERAkidney
👀 This November, discover three special episodes of A pinch of salt, each dedicated to a different paper published in an ERA journal!
🎙️ In this episode, Ana Carina Ferreira takes on the role of host, welcoming Min Hui Tan, co-author of the paper “Top Ten Tips in Managing ANCA Vasculitis” published in CKJ.
🎧 Hit play now 👉 www.era-online.org/research-education/a-pinch-of-salt-pod… -
ERA - European Renal Association
@ERAkidney
✨ Save the date for the Registry CME “Introductory Course on Epidemiology”, taking place in Geneva, Switzerland, on March 18–19, 2027
🌎 Travel Grants available for young attendees (up to 40 years old).
🔒 Registration is FREE and exclusive to ERA members.
👥 Limited to 40 attendees.
Discover more 👉 www.era-online.org/research-education/era-registry/educat… -
ERA - European Renal Association
@ERAkidney
On November 12, starting at 11:00 AM, the ERA website will be temporarily unavailable due to scheduled maintenance. The downtime is expected to last approximately 2–3 hours.
We apologize for any inconvenience and thank you for your understanding. -
ERA - European Renal Association
@ERAkidney
🔥 Be part of the ERA Community in 2027: great minds inspire each other to think differently
✨ 2027 ERA Membership fees are available
🤝 Join the ERA Community or renew now! 👉 www.era-online.org/membership/join-renew/ -
ERA - European Renal Association
@ERAkidney
📢 Be part of the journey to #era27!
🚀 ERA is seeking dedicated reviewers to help evaluate Abstracts for the 64th ERA Congress
🏅 Your efforts will be recognised with a personalized certificate
🗓️ Apply before December 10, 2026 👉 www.era-online.org/events/rotterdam-2027/abstracts/?anc=6 -
ERA - European Renal Association
@ERAkidney
📢 Don't miss the chance to register and submit your abstract for the 10th EUROD Winter Meeting!
🎯 Early bird rates end: November 30, 2026
📅 Abstract submission deadline: November 15, 2026
🏆 Best Young Investigator abstracts can win an ERA travel scholarship!
Discover more 👉 www.eurod.net/news?tx_news_pi1[action]=detail&tx_news_pi1… -
ERA - European Renal Association
@ERAkidney
📢 Join us at our upcoming e-seminar from the series "C3 Glomerulopathy: Evidence, Challenges and Future Directions": "C3 Glomerulopathy: Answers from Recent Clinical Trials and Remaining Uncertainties"
📅 November 17, 2026 at 5:00 PM (CET)
Register now 👉 -
ERA - European Renal Association
@ERAkidney
💥 2027 ERA Open Calls: join the ERA Council!
👥 Ordinary Council Members: 2 vacancies
👤 Ex-Officio Council Members: 1 vacancy
🚀 We encourage women, young members, and those from underrepresented countries to step forward and apply.
⏰ Apply by February 11, 2027 👉 -
ERA - European Renal Association
@ERAkidney
🌟 Today's "Members' Stories" features Yavuz Ayar, ERA Member.
🏆 Yavuz shares the value of being an ERA Member: community, knowledge and collaboration.
📖 Read more 👉 www.era-online.org/membership/members-stories/members-sto… -
ERA - European Renal Association
@ERAkidney
🎬 November issues are now available on the ERA e-learning platform!
Discover the new learning sources with this month’s updates:
🟢 C3 glomerulopathy: From Childhood to Adulthood, Including Transition | 5th YPNN (ESPN) – YNP (ERA) joint e-seminar
📚 Neph-Manual new chapter: Urinalysis as a diagnostic lens for nephrologists
📌 Stay tuned! New educational content will be released every month.
Watch them anytime, anywhere, on the ERA e-learning platform 👉 e-learning.era-online.org/login/index.php -
ERA - European Renal Association
@ERAkidney
🔎 Explore the Highlights of #era26!
💡A new Clinical Kidney Journal (CKJ) Supplement brings together a collection of articles covering key scientific topics presented and discussed during the 63rd ERA Congress that challenged your thinking.
Discover the Supplement 👉
CKJ
@CKJsocial
🧐Which were the 'Highlights of the 2026 European Renal Association Congress'?
🤩Check it out in this new CKJ Supplement:
academic.oup.com/ckj/issue/19/Supplement_1 -
ERA - European Renal Association
@ERAkidney
🩺 A failing kidney allograft: beyond the numbers.
🎙️ In the 84th episode of A pinch of salt, our host Hugo Diniz welcomes Annelies de Weerd to discuss when to define graft failure, how to approach immunosuppression tapering, and how to support patients through this challenging experience.
🎧 Listen now 👉 www.era-online.org/research-education/a-pinch-of-salt-pod… -
ERA - European Renal Association
@ERAkidney
🎉 Congratulations to Aziz Daminov who received the 2026 ERA National Grant during the Annual Conference of the Uzbekistan Society of Nephrology.
🏆 National Societies can award young nephrologists who submit an Abstract with an ERA National Grant.
📌 Ask your National Society for more info! -
ERA - European Renal Association
@ERAkidney
🔎 Why kidney health awareness matters
🎬 In this interview, Charles Ferro, Chair of the Strong Kidneys Committee, shares the latest developments of the “Protect Your Kidneys, Protect Your Future” campaign and highlights the importance of raising awareness about kidney health.
🌍 With the WHO resolution on kidney health and the European Commission’s Safe Hearts Plan, we are entering a pivotal moment for advancing kidney health on the global and European agendas.
Learn more about the campaign 👉 www.era-online.org/strong-kidneys/This media couldn't be displayed. See it on the original post. -
ERA - European Renal Association
@ERAkidney
💡 #kidneywk 2026 offered a valuable opportunity for ERA to strengthen international collaborations and explore new ways to advance nephrology worldwide.
🌍 ERA leadership held fruitful meetings with the Japanese Society of Nephrology (JSN), KDIGO, and the Latin American Society of Nephrology and Hypertension (SLANH), reaffirming a shared commitment to scientific exchange, education and international cooperation.
✍️ A key milestone was the signing of a new Memorandum of Understanding with JSN, marking an important step forward in our partnership.
🤝 These exchanges highlight the importance of working across borders, sharing knowledge and strengthening connections within the global nephrology community.
@jsnorjp
@goKDIGO
@SLANH_ -
ERA - European Renal Association
@ERAkidney
🌟 ERA is present at #kidneywk 2026 in Denver, Colorado
🤝 Stop by Booth 226 to meet the ERA Staff
📍 We can't wait to see you there! 👋 -
ERA - European Renal Association
@ERAkidney
💡 Three organs, one patient, one integrated approach to care.
🎙️ In the 83rd episode of A Pinch of Salt, Amaryllis Van Craenenbroeck (KU Leuven) explores Cardiovascular-Kidney-Metabolic (CKM) syndrome, from integrated care and early prevention to emerging therapies and ongoing debates.
🔗 Episodes are available on Spotify, YouTube, Amazon Music, and more!
🎧 Hit play now 👉 www.era-online.org/research-education/a-pinch-of-salt-pod… -
ERA - European Renal Association reposted
YNP of ERA
@ynptweets
🤔 Is proteinuria harmful after hemodialysis start?
👀 Check out this snapshot summary of another YNP author paper
📝 Beatriz Sanchez Alamo
📱 Post prepared by @jt_nephrology
@NDTsocial @ERAkidney -
ERA - European Renal Association
@ERAkidney
At least 30% of people with cardiovascular disease also have kidney disease, and vice versa. Assessing heart and kidney health together can create opportunities to detect CKD earlier.
That's why we welcome the Commission's proposal to include kidney function in EU cardiovascular health checks under the Safe Hearts Plan. We urge the Council to adopt it at its December meeting and EU countries to put this integrated approach into practice.
📄 Read the Commission’s cardiovascular health checks proposal: eur-lex.europa.eu/resource.html?uri=cellar:80dfe7bc-bb19-…
🔎 View the accompanying annex: eur-lex.europa.eu/resource.html?uri=cellar:80dfe7bc-bb19-…
💚 Find kidney health resources: www.era-online.org/strong-kidneys/protect-your-kidneys-pr…
#strongkidneys #kidneyhealth #integratedcare -
ERA - European Renal Association
@ERAkidney
📢 Join us at YNP – EFIM young internists joint e-seminar: "Amyloidosis: Perspectives from Nephrology and Internal Medicine"
📅 November 4, 2026 at 5:00 PM (CET)
📹 Live e-seminar translated into 7 languages
Register now 👉 www.era-online.org/video-pages/amyloidosis-perspectives-f… -
ERA - European Renal Association
@ERAkidney
🌟Today's "Members' Stories" features Verónica Miguel Herranz, Winner of the 2026 ERA Rosanna Gusmano Award for Young Investigators in Basic Science.
🏆 Verónica shares how this recognition opened up new research opportunities.
📖 Read more 👉 www.era-online.org/membership/members-stories/members-sto… -
ERA - European Renal Association
@ERAkidney
🌱 Greener care, smarter spending
🔎 Read the tweetorial to explore key insights from the article "Greener care, smarter spending: economic opportunities in sustainable nephrology" by Laranjinha et al., published in Clinical Kidney Journal.
👇Discover how sustainable nephrology can reduce environmental impact and healthcare costs.Post not available here, view on X
ERA - European Renal Association
@ERAkidney
📍THE WAY FORWARD
What cannot be measured cannot be managed
1️⃣ Measure
Eco-reporting and clear KPIs within
performance management
2️⃣ Assess the life cycle
Look beyond upfront capital costs
3️⃣ Reward value, not volume
Bundled payments, shared savings,
outcomes-based contracts
ERA - European Renal Association
@ERAkidney
📖 Read the full open-access review: Greener care, smarter spending: economic opportunities in
sustainable nephrology 👉 academic.oup.com/ckj/article/doi/10.1093/ckj/sfag259/8754115 -
ERA - European Renal Association
@ERAkidney
📢 Register and submit your abstract for the 10th EUROD Winter Meeting!
🎯 Early bird rates end: November 30, 2026
📅 Abstract submission deadline: November 15, 2026
🏆 Best Young Investigator abstracts can win an ERA travel scholarship!
Discover more 👉 -
ERA - European Renal Association
@ERAkidney
🔍 Assessing volume status has long relied on clinical judgment and a fair amount of educated guessing. But what if we could actually see congestion?
🎧 In the 82nd episode of A pinch of salt, Faeq Husain-Syed joins host Hugo Diniz to discuss how kidney venous Doppler can make congestion visible and explore a key question: Is Point-of-Care Ultrasound (POCUS) ready for prime time?
Listen now 👉 www.era-online.org/research-education/a-pinch-of-salt-pod… -
ERA - European Renal Association
@ERAkidney
🔎 Don't forget to explore the most read and most cited articles published in Nephrology Dialysis Transplantation over the past 12 months.
👏 Thank you to the authors and peer reviewers whose contributions continue to advance kidney research and care.
Discover more 👉 academic.oup.com/ndt/pages/high-impact-research?login=false
@OxUniPress -
ERA - European Renal Association
@ERAkidney
🎉 Save the date for the 5th ERA Education Meeting!
📅 March 23–24, 2027
📍 Cairo, Egypt
🌍 Get ready for two days of learning, scientific exchange, and networking with the ERA Community! 👉 www.era-online.org/events/era-education-meetings/era-educ… -
ERA - European Renal Association
@ERAkidney
🤝 Strengthening collaboration between ERA and National Societies
📹 In this interview, Rumen Filev, the Secretary of the Bulgarian Nephrology Association (BNA), highlights the value of collaboration with ERA and the key benefits and opportunities offered through the ERA National Society Membership Programme.
Watch the interview and discover more about the Programme 👉 www.era-online.org/membership/join-renew/era-national-soc…This media couldn't be displayed. See it on the original post. -
ERA - European Renal Association
@ERAkidney
🔴 The ERA Autumn Council Meeting is taking place in Segovia, Spain, on October 8-9, 2026
👉 At the heart of the discussions are initiatives and future activities for the ERA Community
📸 Feel the energy of collaboration, where ideas inspire innovation and new opportunities arise -
ERA - European Renal Association
@ERAkidney
🎙️We're back with the trailer for the October episodes of 'A pinch of salt'!
🎧 Catch a sneak peek of the next three episodes dropping on October 8, 2026!
🌍 Available on Apple Podcast, Spotify, YouTube, Amazon Music, and more!
🔗 Listen now: -
ERA - European Renal Association
@ERAkidney
🌟 Today's "Members' Stories" features Nikolaos Vasileios Volis, Former Fellow at Wroclaw Medical University, Poland.
🏆 Nikolaos Vasileios shares his journey of advancing his clinical skills through the ERA Interventional Nephrology Fellowship Programme.
📖 Read more 👉 -
ERA - European Renal Association
@ERAkidney
🎬 October issues are now available on the ERA e-learning platform!
Discover the new learning sources with this month’s updates:
🟢 From Biomarkers to Targeted Therapies: New Horizons in Podocytopathies | e-seminar from the series "Podocytopathies in Focus: Challenges and Advances in Management" supported by Boehringer Ingelheim
📚 Neph-Manual updated chapter: Systemic diseases and acute glomerulonephritis
📌 Stay tuned! New educational content will be released every month.
Watch them anytime, anywhere, on the ERA e-learning platform 👉 e-learning.era-online.org/login/index.php -
ERA - European Renal Association
@ERAkidney
📍 The European Renal and Cardiovascular Medicine Working Group (EuReCa-M) gathered at the ERA Headquarters in Parma for its annual face-to-face meeting on October 1–2.
💡 Focusing on the close interplay between kidney and cardiovascular health, the group discussed ongoing activities and explored new opportunities for research and collaboration.
📸 A snapshot of the EuReCa-M Board together in Parma! -
ERA - European Renal Association
@ERAkidney
🌟Today's "Members' Stories" features Robin Vernooij, Winner of the 2025 ERA Eberhard Ritz Award for Young Investigators in Clinical Science (ex-aequo).
🏆 Robin shares how the ERA Award goes beyond recognition, becoming a real morale boost for his entire team.
📖 Read more 👉 -
ERA - European Renal Association
@ERAkidney
ERA welcomes the @EU_Commission proposal for a Council Recommendation on #cardiovascular health checks under the #safeheartsplan. Kidney tests (creatinine & albuminuria) are included: CKD is silent, closely tied to heart disease, and simple to detect early.
Discover more 👉 eur-lex.europa.eu/resource.html?uri=cellar:80dfe7bc-bb19-… -
ERA - European Renal Association
@ERAkidney
📢 Last weeks to register for the 2026 CKD-MBD CME course "Beyond the Kidney: The Bone-Vascular-Heart Triad in CKD"
🗓️ October 30-31, 2026
📍Mestre-Venice, Italy
View the programme and register now 👉 www.era-online.org/cme-courses/2026-ckd-mbd-cme-course/ -
ERA - European Renal Association
@ERAkidney
🌱 What’s next for sustainable nephrology?
🎬 In this interview, Ivo Laranjinha, Chair of the Sustainable Nephrology Committee, reflects on the Committee’s progress so far, the challenges ahead, and its vision for the future.
Watch the interview and learn more 👉This media couldn't be displayed. See it on the original post. -
ERA - European Renal Association
@ERAkidney
💹Counseling and management of pregnancy in kidney transplant recipients
An important part of any nephrologist practice is the holistic approach of our patients. This e-seminar covers matters of counselling and how to manage pregnant kidney transplant patients.
Speaker: @licia_peruzzi, @gb_piccoli
Panellist: Annelies de Weerd
Moderator: @IlagandolfPost not available here, view on X
ERA - European Renal Association
@ERAkidney
10/ Both mother and father’s disease can impact the baby
‼️Undiagnosed CKD can transmit to the baby
‼️Do not forget transplanted fathers: just as important - need for adequate genetic counseling
ERA - European Renal Association
@ERAkidney
11/ Want more information?
🔥There’s always room for better education, and the change starts with us. Check out the full e-seminar at:
e-learning.era-online.org/mod/page/view.php?id=743
🎙️👑Signing off, on behalf on @ERA social media team @AncaSt13 -
ERA - European Renal Association
@ERAkidney
📢 Join us at 5th YPNN (ESPN) – YNP (ERA) joint e-seminar: C3 glomerulopathy: From Childhood to Adulthood, Including Transition
📅 October 12, 2026 at 4:00 PM (CEST)
📹 Live e-seminar translated into 7 languages
Register now 👉 www.era-online.org/video-pages/5th-ypnn-espn-ynp-era-join… -
ERA - European Renal Association
@ERAkidney
📍 The European Renal Acute Kidney Injury Working Group (ERAKI) met on September 21–22 at the ERA Headquarters in Parma for its annual face-to-face meeting.
👉 The meeting provided an opportunity to take stock of the group’s ongoing work, share perspectives, and look ahead to the next steps in ERAKI’s activities and research initiatives.
📸 A glimpse of the ERAKI Board together in Parma! -
ERA - European Renal Association
@ERAkidney
🙏 We are very proud to announce that the 2026 Renal Run, held during the 63rd ERA Congress in Glasgow, raised £15,350 for Glasgow Children’s Hospital Charity (@GCH_Charity).
🤝 This contribution will support the Renal Ward at Scotland’s largest children’s hospital, helping to fund vital medical equipment, ground-breaking research, play programmes and family support services.
💙 A heartfelt thank you to everyone who took part and contributed. Together, we are helping make a life-changing difference to seriously ill children and their families. -
ERA - European Renal Association
@ERAkidney
🔴 The fourth ERA Education Meeting is happening now in Kaunas, Lithuania!
👉 Stay tuned for key insights and updates from this event! -
ERA - European Renal Association
@ERAkidney
🧂 What if acute heart failure is more about sodium than fluid? And what if a rise in creatinine isn’t always the enemy?
🎙 In episode 81 of A Pinch of Salt, Hugo Diniz discusses this with Jozine ter Maaten, principal investigator of the PUSH-AHF trial.
Listen to the new episode 👉 www.era-online.org/research-education/a-pinch-of-salt-pod… -
ERA - European Renal Association
@ERAkidney
⚠️ Avoid scammers: beware of fake Congress emails
Emails promoting European nephrology congresses are currently circulating. These events and communications have no connection with ERA.
Please remain vigilant, verify the source of any invitation, and always check ERA’s official website and channels for verified information and updates 👉 www.era-online.org -
ERA - European Renal Association
@ERAkidney
🚨 Last weeks to register for the IWG CME Course: “Current options and future opportunities in glomerular diseases”
🗓️ October 16–17, 2026
📍 Łódź, Poland
Discover the Scientific Programme and register now 👉 www.era-online.org/cme-courses/2026-iwg-cme-course/ -
ERA - European Renal Association
@ERAkidney
Supporting patients beyond diagnosis
For people living with kidney disease, support doesn’t stop at diagnosis.
Emily’s experience of living with polycystic kidney disease (PKD) highlights the value of education, practical advice, regular monitoring and ongoing support in helping patients take an active role in their health.
Read Emily’s story: www.era-online.org/publications/living-with-kidney-diseas…
#strongkidneys #kidneyhealth #patientsupport #kidneycare -
ERA - European Renal Association
@ERAkidney
📍 On September 14–15, the Immunonephrology Working Group (IWG) came together at the ERA Headquarters in Parma for its annual face-to-face meeting, a valuable opportunity to review ongoing projects, discuss priorities for the year ahead, and explore new research opportunities.
📸 Here’s a snapshot from the meeting! -
ERA - European Renal Association
@ERAkidney
What`s old and new with anti-glomerular basement membrane (anti-GBM) disease?🔥 And what are the problems in diagnosing and treating anti-GBM disease – more answers in this 🏹e-seminar:
Speaker: Alan Salama
Moderator: @AnnetteBruchfe1
Panellists: Federica Mescia, Marten SegelmarkPost not available here, view on X
ERA - European Renal Association
@ERAkidney
9/ Take-home messages
‼️Anti-GBM disease: still challenging
‼️More understanding of the immunological substrate needed
‼️Prediction tools necessary
ERA - European Renal Association
@ERAkidney
10/ Want more?
There’s always room for better education, and the change starts with us. Check out the full e-seminar at:
e-learning.era-online.org/mod/page/view.php?id=718
🎙️👑Signing off, on behalf on @ERAkidney social media team @AncaSt13 -
ERA - European Renal Association
@ERAkidney
🔎 We are proud to share the latest ERA Registry paper, published in the British Medical Journal (BMJ): Survival benefit of deceased donor kidney transplantation versus continued dialysis: international target trial emulation.
📊 The study of more than 64,000 waitlisted patients found a persistent survival benefit for SCD kidneys but a smaller survival benefit for ECD kidneys in older recipients compared to dialysis, which becomes statistically uncertain in recipients aged 75 years or older receiving ECD/DCD kidneys.
Read the study 👉 www.bmj.com/lookup/doi/10.1136/bmj-2026-100624
@bmj_latest -
ERA - European Renal Association
@ERAkidney
🎉 Congratulations to Patrycja Katarzyna Pokora who received the 2026 ERA National Grant during the Annual Conference of the Polish Society of Nephrology.
🏆 National Societies can award young nephrologists who submit an Abstract with an ERA National Grant.
📌 Ask your National Society for more info! -
ERA - European Renal Association
@ERAkidney
👀 Every nephrology trainee in Europe knows the name: ESENeph.
🎙️ In the 80th episode of A pinch of salt, Hugo Diniz talks to David Lappin about everything trainees need to know: the exam format, its value for your career, and why taking the ESENeph might be worth it.
🎧 Listen to the full episode 👉 www.era-online.org/research-education/a-pinch-of-salt-pod… -
ERA - European Renal Association reposted
YNP of ERA
@ynptweets
1/How should we recognize and manage fibromuscular dysplasia (FMD)?
Check out these 10 practical tips covering diagnosis, imaging, treatment, and follow-up of patients with FMD.
📝 YNP author: Julie Piotte
🧵 by @AgavriloaeiB @CKJsocial @ERAkidney -
ERA - European Renal Association
@ERAkidney
👏The WERA Committee, supported by the ERA Curatorium and ENDI Foundation, offered grants to women for the Women Transforming Leadership Programme and the Oxford Healthcare Leadership Programme at the University of Oxford.
🎉 A huge congratulations to the eight winners and all the best for this exciting journey! -
ERA - European Renal Association
@ERAkidney
🌟 Today's "Members' Stories" features Florian Siegerist, Winner of the 2025 ERA Rosanna Gusmano Award for Young Investigators in Basic Science.
🏆 Florian shares insights from the ERA Award to impact: building the future of translational kidney research.
📖 Read more 👉 -
ERA - European Renal Association
@ERAkidney
🦴 Have nephrologists been missing osteoporosis all along?
🎙️ In this 79th episode of A pinch of salt, our host Hugo Diniz and Hanne Skou Jørgensen discuss DEXA, bone turnover markers, and a practical approach to fracture risk in CKD.
Listen now 👉 www.era-online.org/research-education/a-pinch-of-salt-pod… -
ERA - European Renal Association
@ERAkidney
🌍 How can we improve kidney care and preparedness in disaster situations?
🎙️In this interview, Dina Abdellatif and Ewa Pawlowicz-Szlarska of the Kidney Relief in Disasters Committee discuss the role of the new infographics and how survey insights can help strengthen disaster preparedness and kidney care.
🎥 Watch the interview and learn more 👉 www.era-online.org/about-us/committees/kidney-relief-disa…This media couldn't be displayed. See it on the original post. -
ERA - European Renal Association
@ERAkidney
📢 Don't forget to register for the 2026 CKD-MBD CME course "Beyond the Kidney: The Bone-Vascular-Heart Triad in CKD"
🗓️ October 30-31, 2026
📍Mestre-Venice, Italy
Find out more and view the programme 👉 www.era-online.org/cme-courses/2026-ckd-mbd-cme-course/ -
ERA - European Renal Association
@ERAkidney
🎬 September issues are now available on the ERA e-learning platform!
Discover the new learning sources with this month’s updates:
💻 E-course: Kidney relief in disasters | KRD Committee
📚 New Neph-Manual chapters
• Chronic kidney disease – mineral and bone disorder (CKD-MBD)
• Artificial intelligence in nephrology: clinical integration, workflow and education
• Updated chapters in the Kidney transplantation section
📝 Two new Summary Reports
• Chronic kidney disease–associated pruritus (CKD-aP)
• Management of adult patients with podocytopathies
📌 Stay tuned! New educational content will be released every month.
Watch them anytime, anywhere, on the ERA e-learning platform 👉 e-learning.era-online.org/login/index.php -
ERA - European Renal Association
@ERAkidney
🎧 Get a first listen to what’s coming this September!
🎙️Discover the next episodes, fresh conversations, and the voices bringing new stories and perspectives to A pinch of salt.
🌍 Listen on Apple Podcasts, Spotify, YouTube, Amazon Music, and more!
Listen now 👉 -
ERA - European Renal Association
@ERAkidney
🔔 Don’t miss the Immunonephrology Working Group CME Course: “Current Options and Future Opportunities in Glomerular Diseases”
🗓️ October 16–17, 2026
📍 Łódź, Poland
Discover the Scientific Programme and register now 👉 www.era-online.org/cme-courses/2026-iwg-cme-course/ -
ERA - European Renal Association
@ERAkidney
📢 Join us at the new e-seminar from the series "Podocytopathies in Focus: Challenges and Advances in Management": *From Biomarkers to Targeted Therapies: New Horizons in Podocytopathies*
📅 September 9, 2026 at 5:00 PM (CEST)
Register now 👉 www.era-online.org/e-seminars-webcasts/ -
ERA - European Renal Association
@ERAkidney
💡Discover this interesting ERA Registry article, “Over 500,000 people on kidney replacement therapy in the European Union”, also selected as the Editor’s Choice for the September issue of Nephrology Dialysis Transplantation (NDT).
Access the article here 👉doi.org/10.1093/ndt/gfag017
NDT
@NDTsocial
🤩The September issue is online!
📖academic.oup.com/ndt/issue/41/9
🧐Editor's choice:
Over 500 000 people on kidney replacement therapy in the European Union
🆓doi.org/10.1093/ndt/gfag017 -
ERA - European Renal Association
@ERAkidney
🌟 Today’s “Members’ Stories” features Eleni, Winner of the 2025 ERA Stanley Shaldon Award for Young Investigators in translational science (ex aequo).
🏆 Eleni shares how the ERA Award has opened doors to new European collaborations and stronger partnerships.
📖 Read her story 👉 www.era-online.org/membership/members-stories/members-sto… -
ERA - European Renal Association
@ERAkidney
🔎 Discover the new NDT Supplement: "Measuring albuminuria or proteinuria to diagnose and monitor CKD – Results from the NKF 2025 Albuminuria–Proteinuria Workshop".
Read more 👉 academic.oup.com/ndt/issue/41/Supplement_2
NDT
@NDTsocial
🧐NEW Supplement:
Measuring albuminuria or proteinuria to diagnose and monitor CKD - Results from the NKF 2025 Albuminuria–Proteinuria Workshop
➡️It addresses methodological, clinical, analytical & translational dimensions of urinary protein assessment
l1nq.com/kqvcvv4 -
ERA - European Renal Association
@ERAkidney
One death every 20 seconds: Why CKD needs urgent action
While outcomes for many major chronic diseases are improving, CKD continues to rise. A new global analysis calls for greater emphasis on prevention and earlier detection to help change this trajectory.
Explore resources from our Protect Your Kidneys, Protect Your Future campaign: www.era-online.org/strong-kidneys/protect-your-kidneys-pr…
Read the full study: academic.oup.com/ndt/advance-article/doi/10.1093/ndt/gfag…
#strongkidneys #kidneyhealth #ckdprevention #earlydetection #primarycare -
ERA - European Renal Association
@ERAkidney
🧠 Conclude your summer learning journey with YNP
📖 Explore the collection of YNP e-seminars and take the opportunity to refresh and consolidate your knowledge.
💻 All e-seminars are available on the ERA e-learning platform 👉 e-learning.era-online.org/login/index.php -
ERA - European Renal Association
@ERAkidney
⏰ Don’t forget to apply for the new ERA Artificial Intelligence Committee (AIC)
🔎 The AIC will promote the responsible integration of AI in nephrology, with a strong focus on education, research and scientific leadership.
📣 10 Board Members will be elected to join the new AIC. Candidates must be ERA Full Members.
Apply by September 6, 2026 👉 www.era-online.org/membership/open-calls/ -
ERA - European Renal Association
@ERAkidney
📚 Explore WERA’s learning resources
🔎 One e-seminar, two e-courses, and plenty of practical knowledge are waiting for you on the ERA e-learning platform
Discover more 👉 e-learning.era-online.org/login/index.php -
ERA - European Renal Association
@ERAkidney
🔎 Discover the most read and most cited articles published in Clinical Kidney Journal (CKJ) over the past 12 months.
👏 A big thank you to the authors and peer reviewers whose expertise and contributions continue to advance kidney research and improve patient care.
Discover more 👉 academic.oup.com/ckj/pages/high-impact-research?login=false -
ERA - European Renal Association
@ERAkidney
📌Join us on September 24–25, 2026, in Kaunas, Lithuania, for the fourth ERA Education Meeting.
🎬Inga Bumblyte, Local Representative Lithuania and ERA Education Kaunas Scientific Committee Member, explains what makes this meeting a valuable opportunity for nephrology professionals and shares an interesting fact about the host city.
Register now 👉 www.era-online.org/events/era-education-meetings/era-educ… -
ERA - European Renal Association
@ERAkidney
👉 Discover this new study from the ERA Registry, published in NDT.
💡 This study reveals that, contrary to trends observed in the general population, age- and sex-standardised all-cause and cardiovascular mortality rates among kidney transplant recipients, irrespective of diabetes status, did not improve over time.
🔗 Read the study: doi.org/10.1093/ndt/gfag188
NDT
@NDTsocial
Trends in mortality in adult first kidney transplant recipients with and without diabetes as cause of kidney failure: an ERA Registry study
doi.org/10.1093/ndt/gfag188
@ERAkidney -
ERA - European Renal Association
@ERAkidney
🌟 Today's "Members' Stories" features Nikola Zagorec, Former Fellow at Reference center for hereditary kidney diseases (MARHEA) in Brest, France.
🏆 Nikola shares how he explored the genetic landscape of PKD through the ERA long-term Fellowship.
📖 Read more 👉
ERA - European Renal Association
@ERAkidney
Updated link: www.era-online.org/membership/members-stories/members-sto…
-
ERA - European Renal Association
@ERAkidney
🔎 Expand your knowledge with the IWG e-seminars.
💡 Dive into the ERA e-learning platform and discover fresh insights from leading experts.
Watch now!
.
.
#kidneys #kidneycare #nephrology #era #eracommunity #nephrologist #education -
ERA - European Renal Association
@ERAkidney
🧠 Keep learning with the ERA e-learning platform!
🎥 Discover the G&K Working Group e-seminars and gain insights from leading experts in the field.
Start learning 👉 e-learning.era-online.org/login/index.php -
ERA - European Renal Association
@ERAkidney
🎥 Looking for on-demand learning?
The EuReCa-M Working Group e-seminars are available anytime on the ERA e-learning platform 👉 e-learning.era-online.org/login/index.php -
ERA - European Renal Association reposted
NDT
@NDTsocial
📢NEW publication by the @ERAkidney Immunonephrology Working Group:
Management of Recurrent C3 Glomerulopathy After Kidney Transplantation
🔓doi.org/10.1093/ndt/gfag183 -
ERA - European Renal Association reposted
CKJ
@CKJsocial
🍀NEW publication of the @ERAkidney Sustainable Nephrology Committee:
Greener care, smarter spending:
economic opportunities in sustainable nephrology
👉doi.org/10.1093/ckj/sfag259 -
ERA - European Renal Association
@ERAkidney
🟢Registrations are now open for the 2026 CKD-MBD CME course "Beyond the Kidney: The Bone-Vascular-Heart Triad in CKD"
🗓️October 30-31, 2026
📍Mestre-Venice, Italy
Find out more and view the programme 👉 www.era-online.org/cme-courses/2026-ckd-mbd-cme-course/ -
ERA - European Renal Association
@ERAkidney
🎓 Stay connected with the latest knowledge this summer.
🎥 Catch up on the EuDial Working Group e-seminars on the ERA e-learning platform and hear from leading experts in the field.
Watch now 👉 e-learning.era-online.org/login/index.php -
ERA - European Renal Association
@ERAkidney
⌛ Did you miss any ERN Working Group e-seminars?
Access all the e-seminars on the ERA e-learning platform 👉 e-learning.era-online.org/login/index.php -
ERA - European Renal Association
@ERAkidney
RT @goKDIGO: Check out the new issue of KDIGO Direct: kdigo.co/KDIGO-Direct-July-August-2026
In this issue:
• KDIGO Workshop Report on Expanding Home Hem… -
ERA - European Renal Association
@ERAkidney
🟢Register now for the Immunonephrology Working Group CME Course
“Current Options and Future Opportunities in Glomerular Diseases”
🗓️October 16–17, 2026
📍Łódź, Poland
Discover more and explore the programme 👉 www.era-online.org/cme-courses/2026-iwg-cme-course/ -
ERA - European Renal Association
@ERAkidney
🔎 Don't miss the opportunity to explore the most read and most cited articles published in Nephrology Dialysis Transplantation over the past 12 months.
👏 Thank you to the authors and peer reviewers whose contributions continue to advance kidney research and care.
Discover more 👉 academic.oup.com/ndt/pages/high-impact-research?login=false
@OxfordJournals -
ERA - European Renal Association
@ERAkidney
☀️ If you missed an ERAKI Working Group e-seminar or e-course, you can find them all on the ERA e-learning platform
🎥 Available anytime, anywhere!
Start watching 👉 e-learning.era-online.org/login/index.php -
ERA - European Renal Association
@ERAkidney
🔎 Explore the new ERA–ESC Cardio-Kidney Collection, jointly curated by ERA and the European Society of Cardiology (ESC) @escardio
💡 This collection of scientific articles explores the shared pathophysiological mechanisms linking cardiovascular, kidney, and metabolic disorders, highlighting the urgent need for integrated approaches to prevention and treatment.
Discover the collection 👉 academic.oup.com/ndt/pages/joint-era-and-esc-cardio-kidne… -
ERA - European Renal Association
@ERAkidney
🆕 Open Call for the new ERA Artificial Intelligence Committee
🔎The Committee is dedicated to fostering the responsible integration of AI in nephrology by advancing education, research and scientific leadership.
📣10 Board Members for the new AIC must be elected: help shape ERA's approach to Artificial Intelligence in nephrology. Your voice matters!
🗓️ Deadline: September 6, 2026
Apply now 👉 www.era-online.org/membership/open-calls/ -
ERA - European Renal Association
@ERAkidney
🔍 Today, we're highlighting the study "Ten Tips to preserve and reuse water in nephrology" by Knöller et al., published in the Clinical Kidney Journal.
💧 As dialysis is a highly water-intensive treatment, the study explores practical strategies to help nephrology teams reduce water consumption and promote more sustainable care.
📖 Discover the practical strategies 👇Post not available here, view on X
ERA - European Renal Association
@ERAkidney
⑧ Educate everyone
Sustainability starts with people. 👥
🎓 Train teams.
🤝 Empower patients.
📚 Share best practices.
Create a culture of water stewardship.
ERA - European Renal Association
@ERAkidney
📍Key takeaways
ERA - European Renal Association
@ERAkidney
💬 What practical changes have worked in your experience? Share your thoughts!
Access the article here 👉 academic.oup.com/ckj/article/doi/10.1093/ckj/sfag208/8711151 -
ERA - European Renal Association
@ERAkidney
☀️ Keep your learning going this summer.
🎥 Discover practical knowledge, expert presentations and engaging discussions through the Diabesity Working Group e-seminars.
Browse all available e-seminars on the ERA e-learning platform 👉 e-learning.era-online.org/login/index.php -
ERA - European Renal Association
@ERAkidney
Every consultation is an opportunity to protect kidney health.
Diabetes reviews, hypertension appointments and cardiovascular follow-ups all present valuable opportunities to consider CKD risk and support earlier detection.
Could kidney health be part of today's conversation?
Explore resources from our “Protect Your Kidneys, Protect Your Future” campaign: www.era-online.org/strong-kidneys/protect-your-kidneys-pr…
#strongkidneys #kidneyhealth #ckdprevention #earlydetection #primarycare -
ERA - European Renal Association reposted
YNP of ERA
@ynptweets
Can weight-loss therapies improve cardiorenal outcomes in people with CKD and type 2 diabetes?
@tomwilks444 is the YNP author
👀 Check out our latest snapshot prepared by @jt_nephrology
@ERAkidney @NDTsocial -
ERA - European Renal Association
@ERAkidney
🌟 Today's "Members' Stories" features Ioannis Michelakis, Former Fellow at Oxford University, United Kingdom.
🏆 Ioannis shares the hands-on at the forefront of kidney transplant care with the ERA Fellowship.
📖 Read more 👉 www.era-online.org/membership/members-stories/members-sto… -
ERA - European Renal Association
@ERAkidney
💡 Share your experience and inspire future leaders by becoming a mentor in the YNP Mentorship Programme.
🚀 Watch our interview with Andrzej Wiecek, a mentor in the YNP Mentorship Programme, and discover the transformative impact of mentoring! 💼
Ready to make a lasting difference? Apply by September 15, 2026 👉 www.era-online.org/research-education/young-nephrologists… -
ERA - European Renal Association
@ERAkidney
☀️ If you missed a DESCaRTES Working Group e-seminar, this summer is the perfect time to catch up!
🎬 Revisit expert discussions and explore the latest insights from the DESCaRTES Working Group.
Start watching now on the ERA e-learning platform 👉 e-learning.era-online.org/login/index.php -
ERA - European Renal Association
@ERAkidney
🎉 A huge congratulations to the winners of the ERA-ERAC MSc in Clinical Trials Fellowship!
👏 They have earned the chance to dive into this prestigious two-year programme, gaining advanced training in large-scale randomized clinical trials, with a focus on cardiovascular disease.
🏅 Wishing you all the best as you lead the way in advancing clinical research! -
ERA - European Renal Association
@ERAkidney
More than 500,000 people across Europe receive kidney replacement therapy (KRT). 📊
Latest ERA Registry data reveal wide differences in KRT prevalence between countries, highlighting the need for earlier CKD detection and equitable access to kidney care. 🔍
Watch the infographic and explore the latest insights 👇 -
ERA - European Renal Association
@ERAkidney
🎉 Congratulations to Fotini Demetriou who received the 2026 ERA National Grant during the Annual Conference of the Cyprus Renal Association.
🏆 National Societies can award young nephrologists who submit an Abstract with an ERA National Grant.
📌 Ask your National Society for more info! -
ERA - European Renal Association
@ERAkidney
💪 During #era26, we came together for a surprise flash mob in support of the Strong Kidneys awareness campaign, "Protect Your Kidneys, Protect Your Future."
🫶 This special moment brought the kidney community together to raise awareness of kidney health and highlight the importance of prevention, early detection, and collective action.
🙏 A big thank you to everyone who took part and helped make this initiative such a memorable success. -
ERA - European Renal Association
@ERAkidney
☀️ Missed an e-seminar? We've got your summer covered!
🎬Take a fresh look at the CKD-MBD Working Group e-seminars and revisit the latest expert discussions.
Start watching now on the ERA e-learning platform 👉 e-learning.era-online.org/login/index.php -
ERA - European Renal Association
@ERAkidney
💥 Don't forget to take advantage of the ERA 2026 Mid-term Membership!
💪 Join the ERA Community with more than 30,000 Members.
Become a member 👉 www.era-online.org/membership/join-renew/ -
ERA - European Renal Association
@ERAkidney
🚨 Open Call: Host Centres for ERA Interventional Nephrology Fellowships! 🚨
ERA is seeking centres to host fellows in our Interventional Nephrology Fellowship Programme! ✨ This call will create the list of hosting centres, the call for fellows will follow.
Become a key part of this transformative programme! 👉 www.era-online.org/research-education/fellowships-mentors… -
ERA - European Renal Association
@ERAkidney
🔎 Check out the new joint ERA and ESC Cardio-Kidney Collection
💡This collection of scientific articles, curated as a joint effort by the ERA and the ESC @escardio, sheds light on the critical importance of addressing the intertwined nature of cardiovascular, kidney, and metabolic disorders.
Discover more 👉academic.oup.com/ndt/pages/joint-era-and-esc-cardio-kidne…
NDT
@NDTsocial
❤️Check out our new ERA and ESC cardio-kidney Collection!
@escardio @ERAkidney
academic.oup.com/ndt/pages/joint-era-and-esc-cardio-kidne…
🧐Selected from this collection:
GLP-1-based therapeutics for cardiorenal protection in metabolic diseases
🔓doi.org/10.1093/ndt/gfaf110 -
ERA - European Renal Association
@ERAkidney
📢 Don't forget to register for ERA Education - Kaunas 2026!
📆 Join us on September 24-25, 2026, in Kaunas, Lithuania, for the fourth ERA Education Meeting.
📍Registrations are reserved for ERA Members only.
Register now 👉 www.era-online.org/events/era-education-meetings/era-educ… -
ERA - European Renal Association
@ERAkidney
🎉 Congratulations to Karina Gorchakova who received the 2026 ERA National Grant during the Annual Conference of the Russian Dialysis Society.
🏆 National Societies can award young nephrologists who submit an Abstract with an ERA National Grant.
📌 Ask your National Society for more info! -
ERA - European Renal Association
@ERAkidney
🖌️ At #era26, we presented the Kidney & Bee Adventure initiative, proudly showcasing the children's creativity and enthusiasm through a collection of artworks inspired by what they learned about kidney health.
👏 A big congratulations to Hayley and Imogen from Maidenhill Primary School! Their outstanding artwork will be featured on the cover of NDT. 🏆
Thank you to all the children, all the volunteers and the voters who helped make this initiative a success. 🙏 -
ERA - European Renal Association
@ERAkidney
🌟Today's "Members' Stories" features Michał Gniewkiewicz, Former Fellow at Curry Cabral Hospital, ULS de São José, Lisbon, Portugal.
🏆 Jennifer shares his ERA Fellowship experience in interventional nephrology and vascular access.
📖Read more 👉 www.era-online.org/membership/members-stories/members-sto… -
ERA - European Renal Association
@ERAkidney
🎥 Enjoy the 63rd ERA Congress Webcasts
💻 Registered attendees of #era26 can extend their Congress experience with exclusive access to all webcasts until September 7, 2026.
Log in and start watching now 👉 era-congress.virtual-meeting.org -
ERA - European Renal Association
@ERAkidney
🎬 July issues are now available on the ERA e-learning platform!
Discover the latest expert insights in nephrology with this month’s updates:
🟢 Role of GLP1aR in kidney transplantation | Jointly organised by Diabesity & DESCaRTES & EuReCa-M WGs
🟢 Environmental nephrology and sustainable kidney care | ERA Neph-Manual e-seminar
🟢 Counselling and management of pregnancy in kidney transplant recipients | DESCaRTES WG
📌 Stay tuned! New educational content will be released every month
Watch them anytime, anywhere, on the ERA e-learning platform 👉 e-learning.era-online.org/login/index.php -
ERA - European Renal Association
@ERAkidney
🚀 From Glasgow to #era27!
From June 29 to July 1, we met with our trusted partners Interplan, M Events Cross Media GmbH, and EA Exhibitions in Munich, Germany.
🧠 The ideas are flowing, the plans are taking shape, and the energy behind #era27 is already building. We can't wait for you to feel it. -
ERA - European Renal Association
@ERAkidney
BioMed Alliance invites you to join the online Clinical Trials Workshop on July 10 (14:00-15:30 CET). With negotiations on the EU Biotech Act underway and potential implications for the regulatory framework, including proposed changes to the clinical trials regulation, this is a crucial moment to discuss what these developments mean for clinical research in Europe.
Register by July 6 at 12:00 (CET) 👉 forms.gle/ucFbTJwiZrDwUtBc6 -
ERA - European Renal Association
@ERAkidney
⌛ The treatment landscape for IgA nephropathy is changing rapidly.
🧂In episode 78 of A pinch of salt, Vlado Perkovic joins Hugo Diniz to discuss anti-APRIL and anti-BAFF therapies, the latest visionary and origin data, and what the 2025 KDIGO framework means for practice.
🎙️Listen now 👉 www.era-online.org/research-education/a-pinch-of-salt-pod… -
ERA - European Renal Association
@ERAkidney
✨ #era26 really challenged our thinking!
📹 Watch the video and relive the connections and moments that opened our minds at the 63rd ERA Congress.
🔎 Explore the Congress Review for Facts & Figures, Scientific Programme highlights and more 👉 www.era-online.org/wp-content/uploads/2026/07/ERA26_Congr…This media couldn't be displayed. See it on the original post. -
ERA - European Renal Association
@ERAkidney
Extreme heat is a growing health risk. These 10 tips can help protect patients with CKD.👇
CKJ
@CKJsocial
🥵As Europe faces extreme heat, protecting vulnerable patients has never been more important
Here are ten practical tips for caring for patients with CKD during extreme heat:
🌞doi.org/10.1093/ckj/sfae156
@ERAkidney -
ERA - European Renal Association
@ERAkidney
Movement matters for kidney health. But for many people, moving more can feel overwhelming. That is why even small conversations in routine care can make a real difference.
Emerging evidence suggests that activities such as walking, stair climbing and resistance exercise are all associated with lower mortality risk. The message is simple: everyday movement counts.
Start the conversation with your patients today and spread the message with our “Protect Your Kidneys, Protect Your Future” Social Media Ambassador Toolkit 👉 www.era-online.org/wp-content/uploads/2026/05/ERA_Strong_…
#strongkidneys #kidneyhealth #moveforyourkidneys #ckdprevention #protectyourkidneys -
ERA - European Renal Association
@ERAkidney
🌿 Thank you to all the companies that joined the ERA Sustainability Challenge 2026! 🌿
This initiative rewarded exhibitors and sponsors for their efforts to reduce CO₂e emissions and adopting sustainable booth practices. We sincerely thank all the applicants for their valued participation.
👏 A big shout-out to the top 3 winners for their outstanding contributions: AstraZeneca, Boehringer Ingelheim and EffeEmme.
Together we challenged our thinking for a greener ERA Congress.💚 -
ERA - European Renal Association
@ERAkidney
🔎 Discover the most read and most cited articles published in Clinical Kidney Journal over the past 12 months.
👏 Thank you to the authors and peer reviewers whose contributions continue to advance kidney research and care.
Discover more 👉 academic.oup.com/ckj/pages/high-impact-research -
ERA - European Renal Association
@ERAkidney
🤖 Will AI replace nephrologists?
💡In this 77th episode of A pinch of salt, Hugo Diniz sits down with Wisit Cheungpasitporn @wisit661 to demystify what generative AI can actually do, expose what it definitely can't (yet), and make it approachable for every working nephrologist.
🎧 Hit play now 👉 www.era-online.org/research-education/a-pinch-of-salt-pod… -
ERA - European Renal Association
@ERAkidney
🌟 Beyond the Congress: A partnership between ERA and Glasgow Children's Hospital Charity @FriendsofGRI
🤝 ERA is proud to partner with Glasgow Children's Hospital Charity, helping create an impact that reaches far beyond the Congress
📹 Watch the video to discover more about this meaningful partnershipThis media couldn't be displayed. See it on the original post. -
ERA - European Renal Association
@ERAkidney
🎉 We’re delighted to share the latest Impact Factors and CiteScores for our leading nephrology journals Nephrology Dialysis Transplantation (NDT) and Clinical Kidney Journal (CKJ).
🙏 Our heartfelt gratitude goes to the exceptional contributions of our authors, reviewers, readers, and editorial board. -
ERA - European Renal Association
@ERAkidney
🎉 Congratulations to Stefka Kostyaneva who received the 2026 ERA National Grant during the Annual Conference of the Bulgarian Nephrology Association.
🏆 National Societies can award young nephrologists who submit an Abstract with an ERA National Grant.
📌 Ask your National Society for more info! -
ERA - European Renal Association
@ERAkidney
🔴 Chronic kidney disease (CKD) affects millions of people worldwide and often progresses silently.
⌛ With one person dying from the disease every 20 seconds, increasing awareness of CKD remains essential.
🎥 Watch the video to learn more about CKD, its challenges, and the importance of early diagnosis. -
ERA - European Renal Association
@ERAkidney
🎙️ Straight from the 63rd ERA Congress, the 76th episode of A pinch of salt!
🎧 Join Hugo Diniz, our new podcast host, and guests Alberto Ortiz and Danilo Fliser as they discuss the key findings from the Late Breaking Clinical Trials I session.
🩺 From nurandociguat and semaglutide to IgA nephropathy therapies, advanced CKD anticoagulation, and the first randomised trial of dialysis vs conservative care, this episode is packed with insights you won’t want to miss.
Listen now 👉 www.era-online.org/research-education/a-pinch-of-salt-pod… -
ERA - European Renal Association
@ERAkidney
💥Take advantage of the ERA 2026 Mid-term Membership!
💪 Join the ERA Community with more than 30,000 Members.
Become a Member 👉 www.era-online.org/membership/join-renew/ -
ERA - European Renal Association
@ERAkidney
🌟Today's "Members' Stories" features Gantsetseg Garmaa, former Fellow at University Hospital Cologne, Germany.
🏆 Gantsetseg shares how she explored the genetic kidney disease with the ERA Fellowship.
📖 Read more 👉 www.era-online.org/membership/members-stories/members-sto… -
ERA - European Renal Association
@ERAkidney
📍On June 2, 2026, Roser Torra, ERA President, and Kate Stevens, Local Congress President, visited the Friends of Glasgow Royal Infirmary @FriendsofGRI to discover The Bee Trail, a unique initiative proudly supported by #era26.
🐝 Featuring 24 Jesmonite bees across Glasgow’s Cathedral Precinct, The Bee Trail is the first initiative of its kind in the city and represents a lasting contribution to the local community.
🤝 ERA’s support will be permanently recognised on the official opening plaque. -
ERA - European Renal Association
@ERAkidney
🔎 Discover the most read and most cited articles published in Nephrology Dialysis Transplantation over the past 12 months.
👏 Thank you to the authors and peer reviewers whose contributions continue to advance kidney research and care.
Discover more 👉 academic.oup.com/ndt/pages/high-impact-research?login=false
@OxfordJournals -
ERA - European Renal Association
@ERAkidney
📢 Last days to apply for the ERAC & ENDI Grants for Oxford Leadership Programmes
👩⚕️The WERA Committee, supported by the ERA Curatorium and ENDI Foundation, is offering 6 grants to women for leadership courses at Oxford University:
📌 3 grants for the Women Transforming Leadership Programme
📌 3 grants for the Oxford Healthcare Leadership Programme
📆 Deadline: June 18, 2026
Apply now 👉 www.era-online.org/research-education/fellowships-mentors… -
ERA - European Renal Association
@ERAkidney
🎧 Catch a sneak peek of the next three episodes, dropping on June 18, 2026, and meet one of the new voices of the podcast, Hugo Diniz!
🌍 Available on Apple Podcasts, Spotify, YouTube, Amazon Music, and more!
Listen now 👉 www.era-online.org/research-education/a-pinch-of-salt-pod… -
ERA - European Renal Association
@ERAkidney
🩺 More than 500,000 people across the EU are receiving kidney replacement therapy (KRT) – a figure that has grown by around 150% since 1990.
The latest ERA Registry data highlights both the advances made in treating kidney failure and the challenges that remain.
Key findings include:
📌 Wide variation in KRT prevalence and treatment patterns across the EU
📌 Haemodialysis remains the predominant treatment pathway for patients starting KRT
📌 Survival outcomes differ markedly between treatment modalities, with transplantation associated with better long-term outcomes
As the number of people living with kidney failure continues to rise, strengthening early CKD detection, ensuring equitable access to KRT and reducing disparities in care across Europe will be critical to improving patient outcomes.
👉 www.era-online.org/wp-content/uploads/2026/06/ERA_Registr…
#eraregistry #kidneyhealth #krt #era #kidneyreplacementtherapy #kidneytransplant #dialysis #ckd -
ERA - European Renal Association
@ERAkidney
🧵1/10 Obesity in CKD - part III/III
This #era26 symposium challenged us to think beyond weight loss &BMI ⚖️, and also to reflect on the impact of the increasing 🌍 consumption of Ultraprocessed Foods (UPFs)🍔🍟🥤.
#challengeyourthinking #ckd #obesity
🪑 Ziad Massy @MassyZiad
🪑 Inga Arune Bumblyte
ERA - European Renal Association
@ERAkidney
🧵 2/10 The dangers of Ultraprocessed Foods in CKD: Exploring Possible Solutions. #era26
💬 Carla Maria Avesani
🍔Can UPFs contribute to obesity, CKD progression, and poorer metabolic health? The evidence presented suggests the answer may be yes.
ERA - European Renal Association
@ERAkidney
🧵 3/10 Why might UPFs be harmful ☠️? #era26
👉 Food additives can alter the gut microbiome 🦠
👉 ⬆️ lipopolysaccharide metabolites
👉 ⬆️ intestinal permeability
👉 Chronic inflammation
🦠 Additives, sweeteners, colourants and nanoparticles may disrupt the gut–kidney axis, potentially amplifying metabolic and inflammatory burden in CKD.Post not available here, view on X
ERA - European Renal Association
@ERAkidney
🧵 9/10 Take-home message 💡:
UPFs may represent a "double trouble" in CKD:
👉 Promote obesity and metabolic dysfunction
👉 Alter the microbiome and inflammation
👉 Increase CKD risk and complications
🥗 Small, patient-centred ⬇️ in UPF intake may be one of the most practical nutritional interventions available today. #era26
ERA - European Renal Association
@ERAkidney
🧵10/10 Signing off ✏️ on behalf of the Social Media team, Elsa Morgado @ElsaMorgado10
#era26 #challengeyourthinking #ckd #obesity -
ERA - European Renal Association
@ERAkidney
🧵1/9 Obesity in CKD - part II/III
This #era26 symposium challenged us to think beyond weight loss & BMI ⚖️, and also to reflect on the impact of the increasing 🌍 consumption of Ultraprocessed Foods (UPF)🍔🍟🥤.
#challengeyourthinking #ckd #obesity
🪑 Ziad Massy @MassyZiad
🪑 Inga Arune BumblytePost not available here, view on X
ERA - European Renal Association
@ERAkidney
🧵 8/9 Take-home message💡#era26
Obesity & CKD: things have changed! Every step counts in kidney protection!
1️⃣ Recognize the risk
2️⃣ Assess phenotypes
3️⃣ Treat strategically:
🏃 Lifestyle interventions
💉 Incretin-based therapies
🏥 Metabolic/bariatric surgery
ERA - European Renal Association
@ERAkidney
🧵9/9 Signing off ✏️ on behalf of the Social Media team, Elsa Morgado @ElsaMorgado10
#era26 #challengeyourthinking #ckd #obesity -
ERA - European Renal Association
@ERAkidney
1/6 🧵 #era26 - High impact clinical trials in Nephrology. #challengeyourthinking
🪑 Chairs: Mario Gennaro Cozzolino @MarioCozzolin19, Kaitlin Mayne
GOOD-IDES-02: a randomized controlled phase 3 trial testing imlifidase treatment in anti-GBM disease – outcomes and post hoc analysis
👉Anti-GBM disease remains one of the most devastating nephrological emergencies.
👉Could rapid antibody depletion with imlifidase improve outcomes beyond current standard therapy?
💬 Mårten SegelmarkPost not available here, view on X
ERA - European Renal Association
@ERAkidney
5/6 🧵 Conclusions 🛎️
A negative trial ❌ statistically, but an important step forward mechanistically in anti-GBM disease. #era26
ERA - European Renal Association
@ERAkidney
6/6 🧵 Signing off 👋on behalf of the Social Media team, Elsa Morgado @ElsaMorgado10
#era26 #challengeyourthinking -
ERA - European Renal Association
@ERAkidney
Network Medicine and Kidney Diseases
Prof. Julio Saez-Rodriguez
Head of Research, EMBL-EBI | Professor, Heidelberg University
#era26Post not available here, view on X
ERA - European Renal Association
@ERAkidney
5/
NEPTUNE OCEAN- glomerular disease atlas at single-cell resolution
🔅 Around 850K cells from FSGS, IgAN, MCD & proteinuric diseases mapped by nuclear transcriptomics.
ERA - European Renal Association
@ERAkidney
6/
From tissue to plasma- predicting disease risk non-invasively
🔅 Multicellular programs trained in KPMP projected onto plasma proteomics predicted AKI incidence
🔅Double hit profile carried the worst trajectory for both AKI and CKD
ERA - European Renal Association
@ERAkidney
7/
The road ahead for systems nephrology
🔅 Widen representation
🔅 Augment experimental design
🔅 Translate to care
ERA - European Renal Association
@ERAkidney
-
ERA - European Renal Association reposted
ERA - European Renal Association
@ERAkidney
3/MOTHeR HDx Study #era26
▪️Compares Theranova HDx with online HDF
▪️Multicenter, open-label RCT, HDx vs online HDF (1:1)
👉Adults on HD 3–24 months
🗓️Follow-up: 24 months
🎯Primary endpoint: mortality + CV events
🔗Protocol published in @CKJsocial
pubmed.ncbi.nlm.nih.gov/37915938/ -
ERA - European Renal Association
@ERAkidney
1/6 🧵 #era26 - High impact clinical trials in Nephrology. #challengeyourthinking
🪑: Mario Gennaro Cozzolino @MarioCozzolin19; Kaitlin Mayne
Effects of SGLT2 inhibitors on erythropoiesis and iron homeostasis: a systematic review and meta-analysis exploring how these agents may raise Hb/Hct beyond simple hemoconcentration.
💬 Speaker: Michele F. EisengaPost not available here, view on X
ERA - European Renal Association
@ERAkidney
5/6 🧵Take-home message 🧾
👉This meta-analysis supports that the hematologic effects of SGLT2 inhibitors are class-wide, dose/time responsive, and likely reflect coordinated erythropoietic and iron-regulatory pathways.
👉 A neat mechanistic layer to the cardiorenal story of SGLT2i. #era26 🚀
ERA - European Renal Association
@ERAkidney
🧵6/6 ✌️Signing off on behalf of the Social Media team, Elsa Morgado @ElsaMorgado10
#era26 #challengeyourthinking -
ERA - European Renal Association
@ERAkidney
1/7 🧵 #era26 - High impact clinical trials in Nephrology. #challengeyourthinking
🪑: Mario Gennaro Cozzolino @MarioCozzolin19; Kaitlin Mayne
Ravulizumab in IgA nephropathy: a prespecified interim analysis of the phase 3 I CAN trial. Promising complement-targeted data in IgAN.
💬: Jonathan Barratt @IgAN_JBarrattPost not available here, view on X
ERA - European Renal Association
@ERAkidney
6/7🧵 Take-home message🧾
🚀 A trial to watch closely. #era26
ERA - European Renal Association
@ERAkidney
🧵7/7 ✌️Signing off on behalf of the Social Media team, Elsa Morgado @ElsaMorgado10
#era26 #challengeyourthinking -
ERA - European Renal Association
@ERAkidney
🎉 Thanks for joining us at #era26!
📽️ The Congress may be over, but the webcasts are already available!
⚡ Next stop: #era27 Rotterdam. Get ready to feel the energy. 👉 www.era-online.org/events/rotterdam-2027/ -
ERA - European Renal Association
@ERAkidney
1/6 🧵 #era26 - High impact clinical trials in Nephrology. #challengeyourthinking
🪑 Chairs: Mario Gennaro Cozzolino @MarioCozzolin19, Kaitlin Mayne @KaitlinMayne
The CONCORDIA Study: All-Cause Mortality with HDx with Theranova Compared with Hemodiafiltration Using DOPPS as an External Real-World Comparator. Can expanded HD match HDF?
💬 Speaker: Roberto Pecoits-Filho @pecoitsfilhoPost not available here, view on X
ERA - European Renal Association
@ERAkidney
5/6 🧵 Take-home messages 🧾
👉The CONCORDIA study confirms that HDx therapy with Theranova dialyzers delivers comparable clinical survival outcomes to convective HDF in a real-world setting.
👉An excellent alternative that provides high-quality middle-molecule clearance using standard hemodialysis infrastructure. #era26
ERA - European Renal Association
@ERAkidney
6/6 🧵 Signing off✌️on behalf of the Social Media team, Elsa Morgado @ElsaMorgado10
#era26 #challengeyourthinking #nephrology #hdx #theranova -
ERA - European Renal Association
@ERAkidney
The time has come - closing lectures starting now in Hall 2 #era26
Session Chairs: Roser Torra 🇪🇸 and Dimitrios Goumenos 🇬🇷
Coverage by @juniornephron on behalf of the SoMe Team
ERA - European Renal Association
@ERAkidney
Final plenary lecture of #era26
📄From Science Fiction to Reality: The Xenotransplantation Revolution
📣 Leonardo Riella 🇺🇸
📍 70 years since the first successful kidney transplant ... how far have we come and what are the ongoing challenges
ERA - European Renal Association
@ERAkidney
⚠️ Growing transplant lists all over the world; different approaches exist to overcoming the shortage
Xenotransplantation is one option
‼️ First attempted in 1906
Now more plausible due to developments in CRISPR/Cas gene editing, and co-stimulation blockade
#era26
ERA - European Renal Association
@ERAkidney
📍 Amazing attendance at #era26
ERA - European Renal Association
@ERAkidney
#era26 has now concluded.
See you all in Rotterdam!Post not available here, view on X
ERA - European Renal Association
@ERAkidney
First human Xenotransplant:
✅ Immediate production of urine
✅ Normal ultrasound findings
✅ Stable electrolytes
✅ Good clearance
✅ No transmission of xeno-pathogens
⛔ Early TCMR
#era26
ERA - European Renal Association
@ERAkidney
📍Three further Xenotransplants: clinical results to come
📍Now approved for a clinical trial
#era26Post not available here, view on X
ERA - European Renal Association
@ERAkidney
📍 ERA funded sessions held in a local primary school to teach them about kidney health
📍 New Bee-Trail around Glasgow for the local community to learn about promoting biodiversity
#era26
ERA - European Renal Association
@ERAkidney
📍 Artwork competition for kids which have been displayed throughout the congress for voting by the delegates
📍 Winning artwork by Hayley and ImogenPost not available here, view on X
ERA - European Renal Association
@ERAkidney
📍AI cannot replace good judgement
⚠️ Clinicians remain accountable
#era26
ERA - European Renal Association
@ERAkidney
‼️ The right clinical question is always more powerful than an algorithm
💡 Our patients do not only need perfect algorithms, they need thoughtful doctors
"Critical thinking is what will keep medicine human" -
ERA - European Renal Association
@ERAkidney
The Strong Kidneys Committee Workshop opened with introductory remarks from Rasha Darwish and Charles J. Ferro, followed by Michel Jadoul, who presented a European perspective from EKHA on the WHO resolution on CKD and its implications for kidney health policy and advocacy. #era26 #kidneyhealth #ckd
ERA - European Renal Association
@ERAkidney
Next, Beatriz Fernández shared the Spanish experience in CKD care, highlighting a structured pathway built around early detection, accurate diagnosis, risk-based referral, patient and caregiver engagement, and coordinated care. The approach focuses on screening the right people, confirming CKD appropriately, protecting kidney health, and measuring outcomes through a clear implementation roadmap. #era26 #ckd #kidneyhealth
ERA - European Renal Association
@ERAkidney
Rumen Filev presented the Bulgarian experience, highlighting the work of the Strong Kidneys Task Force. Through the ABCDE campaign, multidisciplinary engagement, social media outreach, and educational initiatives including KINETIC, Bulgaria is building momentum to raise CKD awareness, improve diagnosis, and strengthen kidney health efforts nationwide. #era26 #ckd #kidneyhealth
ERA - European Renal Association
@ERAkidney
Closing the workshop, Charles Ferro reviewed the progress of the Strong Kidneys Taskforce and the “Protect Your Kidneys, Protect Your Future” campaign. With CKD affecting an estimated 850 million people worldwide, including 100 million in Europe, and many remaining undiagnosed, he emphasized the importance of the ABCDE framework and awareness initiatives across Europe and beyond, supported by growing engagement through social media campaigns. The session also featured an overview by Rasha Darwish of ongoing progress and kidney health initiatives across Africa, before the closing remarks. #era26 #kidneyhealth
-
ERA - European Renal Association
@ERAkidney
🔥Last presentation in high impact clinical trials in Nephrology #era26
⏩Efficacy and Safety of SGLT2 Inhibitors in Alport Syndrome: A Multicenter Prospective GLIFAS Study
🎙️Presented by Domenico Santoro
🧬Alport syndrome results from COL4A3–5 variants affecting GBM collagenPost not available here, view on X
ERA - European Renal Association
@ERAkidney
7/ #era26
🔷Overall kidney function remained stable, with no major sex-related differences
🔷 Women appeared to derive greater proteinuria benefit, whereas eGFR trajectories were similar between sexes
ERA - European Renal Association
@ERAkidney
8/ Findings support safety and potential efficacy, but remain observational and hypothesis-generating
#era26
🧵 by @CristinaDeReins -
ERA - European Renal Association
@ERAkidney
Be the leader you want to be: developing and optimising your personal brand 🎖️
🗣️ Leasil Burrow @Leasil
If you don’t write your own story it will be written by someone else.
4 aspects of a strong personal brand:
➡️ Clarity (most important and foundational)
➡️ Consistency
➡️ Relevance
➡️ Visibility
Know where you are heading! We are all an unfinished masterpiece
⭐️ Whatever happens, we are still us: the personal brand doesn’t change ⭐️
Fitting in the context and standing out shouldn’t be in contradiction
✍️ @FedericaNeveVig on behalf of SoMe team #era26 -
ERA - European Renal Association
@ERAkidney
🧵 1/5
⚖️ ETHICS Committee Workshop: Between a Rock and a Kidney Conundrum
🎤 Lecture 3: “Nothing About Me, Without Me” -When, Where and How?
👤 Aditya Pawar & Željka Večerić-Haler
💡 How much should patients be involved in major kidney care decisions? When should they participate, where should these discussions take place, and how can we ensure their voices are truly heard?
Follow this thread for key insights from the discussion.
📍 #era26Post not available here, view on X
ERA - European Renal Association
@ERAkidney
🧵 4/5
💡 Key message:
🔹 Patients want a stronger voice.
🔹 Transparency builds trust.
🔹 Participation requires fairness and support.
⚖️ Better decisions come from partnership, not paternalism.
📍 #era26
ERA - European Renal Association
@ERAkidney
🧵 5/5
This thread is brought to you by @Gawad_Nephro on behalf of SoMe.
📍 #era26 -
ERA - European Renal Association
@ERAkidney
🔥High impact clinical trials in Nephrology #era26
⏩MOTheR HDx Study: A MOPR Study to Explore Morbidity and Mortality in Patients Dialyzed with Theranova HDx Compared with OL-HDF
🎙️Presented by @DePsequera
The evolution of dialysis during the last decades gets us nowadays to hemodiafiltration and to medium cut off membranes discussions
ERA - European Renal Association
@ERAkidney
2/ #era26
🔷Survival benefit with online HDF appears volume-dependent
🔷Prior trials (ESHOL, CONVINCE) suggested lower mortality when convection volumes exceeded ~23 L/session
🔷Whether expanded hemodialysis (HDx, Theranova) can match OL-HDF remains uncertain
ERA - European Renal Association
@ERAkidney
3/MOTHeR HDx Study #era26
▪️Compares Theranova HDx with online HDF
▪️Multicenter, open-label RCT, HDx vs online HDF (1:1)
👉Adults on HD 3–24 months
🗓️Follow-up: 24 months
🎯Primary endpoint: mortality + CV events
🔗Protocol published in @CKJsocial
pubmed.ncbi.nlm.nih.gov/37915938/
ERA - European Renal Association
@ERAkidney
4/ #era26
Population
▪️533 treated patients
▪️Mean age 66 years
▪️67% male
▪️Mean dialysis vintage: 15 months
▪️Charlson index: ~4
Baseline
▪️Groups well balanced
▪️Similar medications and dialysis prescriptions
▪️HDF substitution volume: 25.8 L5:
📍Labs largely comparable
ERA - European Renal Association
@ERAkidney
5/ 🧪Laboratory trends #era26
✨Similar biochemical profiles over 24 months
👉Prealbumin, beta2-microglobulin and ferritin changed over time
👉No significant group-by-time interaction
ERA - European Renal Association
@ERAkidney
6/ Safety #era26
⚠️Serious adverse events similar:
HDx: 36.6%
OL-HDF: 38.7%
⚠️No differences in infections, cardiac or GI events
ERA - European Renal Association
@ERAkidney
7/ Primary endpoint #era26
📍Composite event:
🔷HDx: 23.3%
🔷OL-HDF: 24.7%
HR 0.87, 95% CI 0.63–1.19
📍Noninferiority met (p=0.011)
ERA - European Renal Association
@ERAkidney
8/ Before conclusion #era26
📍Noninferiority margin (IRR upper limit 1.25) was relatively permissive; up to 25% more events would still be considered acceptable
📍The strategy assumes OL-HDF itself improves survival, which remains debated despite CONVINCE.
📍Only 533 patients were analyzed versus 700 planned, reducing precision
📍on the positive side: HR 0.87 (95% CI 0.63–1.19) favored HDx and no safety signal emerged
cc:@hswapnil
ERA - European Renal Association
@ERAkidney
👇Conclusion
✍️Signing off, on behalf of #era26 social media team @CristinaDeReins -
ERA - European Renal Association
@ERAkidney
👏 At #era26, we challenged our thinking in nephrology, and the journey is now almost complete.
🤝 Our sincere thanks to all the Sponsors who made this event possible! -
ERA - European Renal Association
@ERAkidney
🧵 1/5
⚖️ ETHICS Committee Workshop: Between a Rock and a Kidney Conundrum
🎤 Lecture 1: Approaching “Disruption” and “Non-Adherence”
👤 Simon Sawhney & Gulcin Kantarci
💡 The session challenges us to move beyond labels such as “non-adherent” and “difficult patient” and instead explore the underlying barriers, circumstances, and values influencing patient behavior.
🤝 Ethical kidney care starts with understanding before judging.
📍 #era26Post not available here, view on X
ERA - European Renal Association
@ERAkidney
🧵 4/5
🚧 Discussion shifted to the real-world barriers that complicate ethical decision-making in nephrology.
⚠️ Ethical dilemmas often arise not only from medical uncertainty, but also from gaps in communication, differences in values, limited health literacy, and system-level constraints.
💡 Recognizing these barriers is the first step toward meaningful shared decision-making and truly patient-centered kidney care.
❓In your practice, what do you think is the biggest barrier to ethical and shared decision-making in nephrology?
📍 #era26
ERA - European Renal Association
@ERAkidney
🧵 5/5
This thread is brought to you by @Gawad_Nephro on behalf of SoMe.
📍 #era26 -
ERA - European Renal Association
@ERAkidney
🔥Coming next in high impact clinical trials in Nephrology #era26
⏩Efficacy and safety of B-cell directed therapies in IgA nephropathy: A collaborative meta-analysis
🎙️Presented by @brendonneuen
📍B-cell directed therapies are a promising therapeutic strategy in IgAN
📍Effects on proteinuria, GFR, and safety remain incompletely characterised
ERA - European Renal Association
@ERAkidney
2/ 🔷Systematic review and meta-analysis of placebo-controlled RCTs of B-cell–targeted therapies in biopsy-proven IgAN
🔷Used phase 3 doses (or equivalent) for each agent
🔷Assessed UPCR at ~9 months and annualized eGFR slope
#era26Post not available here, view on X
ERA - European Renal Association
@ERAkidney
8/ #era26
💪Strengths
🔷Large dataset with consistent effects.
🔷Minimal heterogeneity.
🔷Similar benefits across subgroups.
🛑Limitations
▪️Mostly short-term follow-up.
eGFR slope data cannot separate acute from chronic effects
▪️Incomplete outcome reporting across studies
ERA - European Renal Association
@ERAkidney
9/ ✨APRIL/B-cell-directed therapies consistently halve proteinuria, improve eGFR slope and hematuria remission, and appear safe, but confirmation with longer-term hard kidney outcomes remains needed
✍️ Signing off, on behalf of #era26 social media team @CristinaDeReins -
ERA - European Renal Association
@ERAkidney
Sustainable Nephrology Committee Worksop
Practical tips for a greener prescription
Speaker: Susi Knoller
🟢Why are climate issues relevant to Nephrology - climate changes, natural disasters and pollution all cause AKI, CKD and interruption of dialysis
🟢 Dialysis has v high water consumption - however minimal added benefit of high dialysate flow- can reduce and save money and water
🟢 HDF uses more water and can reduce mortality.. This can still be optimised to use less water
🟢 Low flow dialysis systems like nxstage use less water
#era26Post not available here, view on X
ERA - European Renal Association
@ERAkidney
Next up: Patient perspectives on Sustainable Kidney Care
Speaker: Frances Mortimer
🟢 Introduced KitNewCare project
🟢 As part of this project 3 patient focus groups were set up to explore the acceptability of proposed sustainable changes over 4 let areas
🟢 Across all domains changes were acceptable, provided they were safe
#era26
ERA - European Renal Association
@ERAkidney
Now Anna Julie Peired is leading an interactive session on Constructing a Green Dialysis Unit: An Interactive Evidence-Based Exercise
#era26
This session was covered by @Sarah_Gleeson_ on behalf of the ERA social media team 😁 -
ERA - European Renal Association
@ERAkidney
CKM Syndrome: "The Kidney in the Middle" | #era26
Adeera Levin at #era26 on KDIGO CKM Commentary: CKD is not just a kidney problem. It sits at the center of Cardio-Kidney-Metabolic syndrome, driving CVD risk and mortality.
CVD Burden in CKD is Massive
Prevalence climbs with CKD stage: No CKD 37.5% CVD prevalence → G2 63.4% → G3 66.6% → G4-G5 75.3%
Mortality skyrockets: Annual mortality risk highest in lowest eGFR + highest albuminuria. CKD patients have far higher CV death than general population, especially young patients with dialysis
KDIGO Risk Heatmaps: Predict 10 Outcomes
eGFR + uACR = risk stratification: Heatmaps from 27.5 million people show risk for 6 CV outcomes, 2 kidney-specific, 2 general outcomes by age, eGFR, albuminuria
Red zones = high risk: Lower eGFR G3b-G5 + higher albuminuria A2-A3 = red/orange. Predicts CV mortality, heart failure, stroke, MI, hospitalization, kidney failure replacement therapy
KDIGO Guidelines Address CKM Components
CKD definition is CKM entry: KDIGO defines CKD by kidney structure/function/urine abnormalities >3 months, staged by GFR + albuminuria
Guidelines cover CKM: KDIGO Clinical Practice Guidelines directly address CKD evaluation, blood pressure, diabetes management, lipid management. Upcoming guideline on heart failure in CKD
Overarching themes: Early detection/intervention + comprehensive personalized management + multidisciplinary care
Why Nephrologists Matter in CKM
Kidney role: Initiates, amplifies, and modifies severity/temporality of CVD/metabolic processes
Nephrologist role: Initiate diagnostics + therapies, amplify treatment based on risk, modify patient outcomes
Lifespan approach: KDIGO guidelines consider fetal-maternal health, sex, gender, regional/cultural differences, age for outcomes + applicability
Takeaway: CKD = CKM Stage 1+. Higher creatinine + albuminuria = higher CV risk and mortality. KDIGO risk heatmaps guide who needs aggressive prevention. Message: detect early, stage by eGFR + albuminuria, manage comprehensively with nephrology + cardiology together.
Presentation: Adeera Levin | Tweet: @eroldemir83 on behalf of SoMe Team -
ERA - European Renal Association
@ERAkidney
🔥Coming next in high impact clinical trials in Nephrology #era26 Significant Proteinuria Reduction with the Oral Factor B Inhibitor MY008211A in IgA Nephropathy: 12-Week Interim Results from a Phase 2 Trial
🎙️Presented by Ming Cheng
💊MY008211A is an oral complement Factor B (CFB) inhibitor 🔷Indication: IgANPost not available here, view on X
ERA - European Renal Association
@ERAkidney
6/ #era26
⚠️TEAEs were similar between MY008211A and placebo (~81%)
⚠️Grade ≥3 TRAEs were uncommon (6.3% vs 12.5%)
❇️No treatment discontinuations, encapsulated infections, or deaths.
ERA - European Renal Association
@ERAkidney
7/ ✨Conclusion
✍️ Signing off, on behalf of #era26, @CristinaDeReins -
ERA - European Renal Association
@ERAkidney
KDIGO 2026: New Paradigm for Diabetes + CKD - Prevent, Don’t Just Treat | #era26
Forget single-drug thinking. KDIGO 2026 guideline shifts to comprehensive, personalized, early combination therapy for diabetic CKD. Katherine R Tuttle broke it down.
2026 KDIGO Guideline Paradigm
3 principles: Personalized, accelerated, iterative therapy
4 pillars: 1) Lifestyle: diet, exercise, weight, smoking cessation 2) Foundational pharmacotherapy: SGLT2 inhibitor, statin, RAS blockade 3) Additional risk-based: nsMRA, GLP-1 RA, antiplatelet 4) Treatment targets: BP, lipids, glycemic control
Risk Stratification: Know Your Zone
KDIGO heat map: Risk by eGFR G1-G5 + albuminuria A1-A3. Red = high risk G3b-G5 + A2-A3 → "Treat and refer"
Goal: Move patients from red to yellow/green zones early with multifactorial intervention
2026 nsMRA Update - Finerenone
New 1A recommendation: Add nonsteroidal mineralocorticoid receptor antagonist with proven kidney/CV benefit for T2D + eGFR ≥25 milliliters per minute per 1.73 square meters + normal potassium + albuminuria ≥30 milligrams per gram while on max RAS inhibitor
Combo strategy: For persistent albuminuria on RASi, SGLT2i + nsMRA can be initiated simultaneously to mitigate hyperkalemia risk
Combination Therapy = Additive Protection
Kidney + CV outcomes: Adding to RAS blockade, each drug class helps. SGLT2i, GLP-1 RA, nsMRA. Triple combo SGLT2i + GLP-1 RA + nsMRA gives lowest HR for CKD progression 0.42, MACE 0.65, heart failure hospitalization 0.45
Finerenone + Empagliflozin: CONFIDENCE trial showed 52 percent albuminuria reduction at 180 days with combo vs 29 percent empagliflozin alone, 32 percent finerenone alone
Takeaway: KDIGO 2026 says "Yes, we CAN prevent CKD in diabetes". It’s not about one drug. It’s glycemic control + BP control + lifestyle + SGLT2i + GLP-1 RA + nsMRA + RAS blockade, started early and adjusted iteratively. Risk-based, not one-size-fits-all.
Presentation: Katherine R Tuttle | Tweet: @eroldemir83 on behalf of SoMe Team -
ERA - European Renal Association
@ERAkidney
📣 LAST DAY at #era26!
Read our Daily Congress Bulletin 👉 r.mail.era-online.org/mk/mr/sh/1t6AVsd2XFnIGIVzcmU66oI9M0… -
ERA - European Renal Association
@ERAkidney
🧵1- Diagnostics, Safety and Emerging Therapies in CKD
Chairs: Ewout Hoorn, Vianda S. Stel
🗣️Speaker: Jicheng Lv
Session 5: Efficacy and safety of HSK39297, a once-daily oral CFB inhibitor, in patients with primary IgA nephropathy: a double-blind phase II trial #era26Post not available here, view on X
ERA - European Renal Association
@ERAkidney
3/ Conclusion 👇🏻#era26
ERA - European Renal Association
@ERAkidney
4/#era26 Signing off, on behalf of ERA social media team, Rezzan Eren Sadioğlu @ErenRezzan
-
ERA - European Renal Association
@ERAkidney
🧵1- Diagnostics, Safety and Emerging Therapies in CKD
Chairs: Ewout Hoorn, Vianda S. Stel
🗣️Speaker: Kaisa Maki-Petaja
Session 4: AZD1613, human-specific monoclonal antibody against PAPP-A demonstrates favourable safety and tolerability profile in first-in-human Ph1 study #era26Post not available here, view on X
ERA - European Renal Association
@ERAkidney
3/ ℹ️ promising phase 1 data for cystic kidney disease 👇🏻#era26
ERA - European Renal Association
@ERAkidney
#era26 Signing off, on behalf of ERA social media team, Rezzan Eren Sadioğlu @ErenRezzan #era26
-
ERA - European Renal Association
@ERAkidney
🧵1- Diagnostics, Safety and Emerging Therapies in CKD
Chairs: Ewout Hoorn, Vianda S. Stel
🗣️Speaker: Alexandre Lahens
Session 3: Cystatin C based equations performances in patients without creatinine tubular secretionPost not available here, view on X
ERA - European Renal Association
@ERAkidney
3/ Conclusion 👇🏻#era26
ERA - European Renal Association
@ERAkidney
#era26 Signing off, on behalf of ERA social media team, Rezzan Eren Sadioğlu @ErenRezzan 👋🏻
-
ERA - European Renal Association
@ERAkidney
🧵1- Diagnostics, Safety and Emerging Therapies in CKD
Chairs: Ewout Hoorn, Vianda S. Stel
🗣️Speaker: Margarita Kondyli
Session 2: Urine peptides enable non-invasive differential diagnosis of nodular diabetic nephropathy #era26
ERA - European Renal Association
@ERAkidney
2/ 🧪💊non-invasive proteomic analysis helps to distinguish nodular dianetic nephropathy from non-nodular ones #era26
ERA - European Renal Association
@ERAkidney
3/ #era26 Signing off, on behalf of ERA social media team, Rezzan Eren Sadioğlu @ErenRezzan
-
ERA - European Renal Association
@ERAkidney
🔥The WERA Survey: Unveiling Gender Balance in the ERA Community #era26 #wera 🔥Introduction to the WERA Survey 🎙️Presented by Lucia Del Vecchio
Starting with Methods
▪️Validated WERA survey on gender balance in nephrology
▪️Assessed equity, career progression, ▪️and work–life balance
▪️Developed through literature review, expert input, and pilot testing
▪️920 ERA members participatedPost not available here, view on X
ERA - European Renal Association
@ERAkidney
3/ 🔥Influence of gender and parenthood on scientific output and leadership positions among european nephrologists: results from the Women of ERA survey #era26 🎙️@anagarcp
ERA - European Renal Association
@ERAkidney
4/ 📍Participants #era26
▪️920 respondents; 67% women
▪️Broad representation across Europe
📍Gender by age
▪️Women predominated at younger ages (73–78%)
▪️Gender gap narrowed with age
▪️Men became the majority after age 65 (60%)Post not available here, view on X
ERA - European Renal Association
@ERAkidney
8/ #era26
🧑🧑🧒🧒Parenthood was associated with greater leadership and academic advancement in men than women
📍Gender disparities persisted despite similar professional engagement
📍Factors beyond productivity likely contribute to the leadership gap
ERA - European Renal Association
@ERAkidney
Signing off, on behalf of #era26 social media team, @CristinaDeReins
-
ERA - European Renal Association
@ERAkidney
🧵1- Diagnostics, Safety and Emerging Therapies in CKD
Chairs: Ewout Hoorn, Vianda S. Stel
🗣️Speaker :Jennifer Lees
💉Session 1: Kidney-related adverse events associated with intravitreal VEGF-inhibitor use in England: a national cohort studyPost not available here, view on X
ERA - European Renal Association
@ERAkidney
🧵4/ We can reasonably continue to give intravitreal anti-VEGF with weighing the risks
#era26
ERA - European Renal Association
@ERAkidney
5/ #era26 Signing off, on behalf of ERA social media team, Rezzan Eren Sadioğlu @ErenRezzan
-
ERA - European Renal Association
@ERAkidney
Kidney Genetics ScoreCard
🗣️ Prof. Katalin Susztak, MD PhD, University of Pennsylvania
#era26Post not available here, view on X
ERA - European Renal Association
@ERAkidney
7/
The Kidney Disease Genetics ScoreCard- genes to drugs:
🔅 Integrates coding variants, gene function, single cell multiome, regulatory variants & target evidence
🔅 Future: from GWAS variant to cell type to mechanism and finally into clinical trial
ERA - European Renal Association
@ERAkidney
✍🏻off @drvt87 for team SoMe
-
ERA - European Renal Association
@ERAkidney
From Genes to Outcomes: The Role of Diagnostic Variants and Polygenic Risk in CKD Progression
🗣️ Dr. Matthias Wuttke, University of Freiburg, Germany
#era26Post not available here, view on X
ERA - European Renal Association
@ERAkidney
4/
How many CKD patients carry a diagnostic variant?
🔅 VarSome ACMG flagged 15,727 variants; after manual curation → 721 diagnostic variants in 676 participants
🔅 Top genes: PKD1, COL4A5, COL4A3, PKD2, COL4A4, IFT140, UMOD
ERA - European Renal Association
@ERAkidney
5/
Gene-by-gene: how fast does eGFR fall?
🔅 PKD1 carriers: fastest decline (~3.8 ml/min/yr, median age 51)
🔅 COL4A hom/hemi: ~3.2 ml/min/yr (age 49)
🔅 UMOD variants: ~3.1 ml/min/yr (age 48)Post not available here, view on X
ERA - European Renal Association
@ERAkidney
7/
Take-home:
🔅 ~1 in 12 CKD patients carries a diagnostic monogenic variant
🔅 PGS refines risk beyond the single variant-both matter
🔅 Integrating rare variants + PGS is the future of precision nephrology
ERA - European Renal Association
@ERAkidney
-
ERA - European Renal Association
@ERAkidney
🔥 @pecoitsfilho inviting all #era26 participant to Hall 2 for high impact clinical trials
📍The CONCORDIA study
🗓️Happening in just few hours, 8:30 am (June 6)
💬Interview by: @ElsaMorgado10 @CristinaDeReins
⚙️Editing: @eristark42This media couldn't be displayed. See it on the original post. -
ERA - European Renal Association
@ERAkidney
🔥During #era26 late-breaking clinical trials, @KatherineTuttl8 added a clinical perspective to all FIND-CKD discussions
#ckd is a public health crisis, being projected to become the 5th leading cause of death by 2040 (now 9th)Post not available here, view on X
ERA - European Renal Association
@ERAkidney
7/
#era26
Now we can add finerenone to the pantheon of non-DM CKD treatment
🔹As the author mentions, we need to account for the etiology either
ERA - European Renal Association
@ERAkidney
8/ ✨Take-home message
✍️Signing off, on behalf of #era26 social media team, @CristinaDeReins -
ERA - European Renal Association
@ERAkidney
🔥During #era26 Late-Breaking Clinical Trials 2, @AgarwalRajivMD presented efficacy and safety of finerenone in patients with chronic kidney disease: a pooled individual participant data analysis (INFINITY)♾
Finerenone trials included a broad CKD population encompassing a range of disease aetiologies and levels of glycemia, eGFR & albuminuriaPost not available here, view on X
ERA - European Renal Association
@ERAkidney
3/ ♾ INFINITY #era26
📌Less kidney failure with finerenone HR0.85 (95% Cl 0.74- 0.99)
📌 Finerenone reduced kidney failure, HF events, and mortality
📌Benefits were strongest for kidney composites and HF hospitalization
ERA - European Renal Association
@ERAkidney
4/ ♾I NFINITY- HbA1c subgroup analysis #era26
✳️Kidney outcome:
🔹Benefit was consistent across baseline HbA1c levels
🔹No interaction with glycemic control (p=0.51)
✳️CV outcome:
🔹Benefit was consistent across baseline HbA1c levels
🔹No interaction with glycemic control (p=0.47)Post not available here, view on X
ERA - European Renal Association
@ERAkidney
👏#era26 simultaneous publication @TheLancet
#infinity #finerenone
www.thelancet.com/journals/lancet/article/PIIS0140-6736(2…
ERA - European Renal Association
@ERAkidney
Signing off, on behalf of #era26 social media team @CristinaDeReins
-
ERA - European Renal Association reposted
ERA - European Renal Association
@ERAkidney
🔥Next into Emerging Trial Evidence in Hypertension, CKD, and Transplantation
⏩ Reductions in albuminuria in patients with hypertensive renal disease after radiofrequency renal denervation: results from Global SYMPLICITY Registry 🎙️Presented by @markus_schlaich
#era26
🎯 Current analysis examines whether renal denervation (RDN) reduces albuminuria -
ERA - European Renal Association
@ERAkidney
🔥Late Breaking Clinical Trials 2 #era26
⏩ Efficacy, safety and pharmacokinetics/pharmacodynamics of crovalimab for atypical haemolytic uraemic syndrome (aHUS): Phase III COMMUTE-a trial in adults/ adolescents
🎙️Presented by @DrBradleyDixon
💊 Crovalimab: long-acting SC C5 inhibitor with home-administration potentialPost not available here, view on X
ERA - European Renal Association
@ERAkidney
7/ #era26
🎯Crovalimab met its primary endpoint, restored/maintained TMA control, and enabled dialysis independence with durable complement blockade and good tolerability
ERA - European Renal Association
@ERAkidney
Signing of, on behalf of #era26 social media team, @CristinaDeReins
-
ERA - European Renal Association reposted
Izabela Zakrocka
@IzabelaZakrocka
The best strong kidneys dance ever! @beaff26 @torra_roser #era26 @ERAkidney ✨🥳
-
ERA - European Renal Association
@ERAkidney
🧵1/8
Obesity in CKD - part I/III
This #era26 symposium challenged us to think beyond weight loss &BMI ⚖️, and also to reflect on the impact of the increasing 🌍 consumption of Ultraprocessed Foods (UPF)🍔🍟🥤.
#challengeyourthinking #ckd #obesity
🪑 Ziad Massy @MassyZiad
🪑 Inga Arune Bumblyte
ERA - European Renal Association
@ERAkidney
🧵2/8 Single or Multiple GLP-1 RAs for Chronic Kidney Disease: Update from Recent Trials
🎤 Hiddo J.L. Heerspink @HeerspinkHiddo
👉 The emerging question is no longer whether incretin-based therapies work in CKD, but whether dual and triple agonists can deliver even greater kidney protection. 🚀🩺 #era26Post not available here, view on X
ERA - European Renal Association
@ERAkidney
🧵7/8 Authors conclusion’s 📝 #era26
ERA - European Renal Association
@ERAkidney
🧵8/8 👋Signing off on behalf of the Social Media team, Elsa Morgado @ElsaMorgado10
#era26 #challengeyourthinking #ckd #obesity #gip #glp1 -
ERA - European Renal Association
@ERAkidney
Failing Allograft: A Rational Approach to Immunosuppression and Graftectomy
🗣️ Prof. Olivier Thaunat, Edouard Herriot Hospital, Lyon, France
#era26Post not available here, view on X
ERA - European Renal Association
@ERAkidney
7/
Practical algorithm for eGFR <20 ml/min: the take-home
🔅 Continue IS; reduce MMF if toxic; CNI target 4–6 (low risk) / 5–7 (high risk)
🔅 Pre-emptive LD retransplant → keep IS
🔅 Retransplant candidate on dialysis → stop MMF, CNI target 3–5
ERA - European Renal Association
@ERAkidney
-
ERA - European Renal Association
@ERAkidney
#era26 @ERAkidney
📝Symposium: Dialysis ➡️How to treat uremia beyond renal replacement therapy❓
Chair: Rukshana Shroff & Yuri Battaglia
🧵1/
1️⃣The case for inflammation: what to target?
🗣️Elke Schäffner
🔷Uremia is more than toxin retentition:
➡️Gut dysbiosis!
➡️Sarcopenia/cachexia
🔷Kidney-gut Inflammatory pathway➡️
📍Barrier Disfunction ➡️Microbial translocation
Muscle kidney heart inf pathway:
🔷Exercise: skeletal muscle is highly adaptive!
🔷Aerobic & resistance ➡️but available data is limited
📍Low protein diet: beneficial but be careful in cachexia*️⃣
ERA - European Renal Association
@ERAkidney
#era26 🧵2/
2️⃣The case for sodium, from an old to a new perspective
🗣️Laura Labriola
🔷How could we optimize fluid balance in HD patients?
📍Low salt diet
📍Dry weight adjustment!➡️High dose diuretics if RKF
📍Prescription of dialysate sodium??
➡️loss by convection = 78%
➡️loss by diffusion = 22%
🔷Less sodium in dialysate -> 134-138
One study: 135 mM > hypotension OR 3.6! ➡️ Anothers studies: no effect in hypotension)
🔷D-Na: 135-> 140 raise blood pressure
🔷High dialysate sodium> not harmful❗️
🔷Lower D-Na higher mortality HR 1.57❗️
📍What to do? Lower D-Na is not support for improving fluid control
ERA - European Renal Association
@ERAkidney
#era26 🧵3/
3️⃣ The case for uremic toxins, finally ready for primetime?
🗣️Björn Meijers
🔷Uremia is accumulation AND depletion
🔷Prebiotics➡️Could have a beneficial effect❗️
🔷Targeting depletion: n-3 fatty acids ➡️ less serious cardiovascular effects
🔷The future: targeting PAG (Phenylacetylglutamine) and IS (indoxyl sulfate)
Signing off, on behalf of #era social media team, Francisco Valga @Nefrogeek -
ERA - European Renal Association
@ERAkidney
1️⃣
Data science at #era26 FC22: Sheng‑Han Yueh and the Renal Research Institute team test whether high‑frequency HD machine data, compressed via autoencoders, can improve 6‑month mortality prediction in in‑centre HD. #dialysis @RR_InstitutePost not available here, view on X
ERA - European Renal Association
@ERAkidney
7️⃣
Conclusion: high‑frequency HD machine data, compressed via deep learning, add incremental prognostic signal to traditional variables for 6‑month mortality risk stratification in in‑centre HD – opening doors to real‑time risk dashboards and targeted interventions.
ERA - European Renal Association
@ERAkidney
8️⃣
Signing off @NaveenNephro on behalf of the @ERAkidney Social Media team.
Stay tuned for more live coverage and insights from #era26. -
ERA - European Renal Association
@ERAkidney
A look into future KRT at #era26 FC22: Tadeo Alcerreca Valdez and colleagues develop ultrathin silicon‑based nanomembranes aiming toward an implantable, heart‑driven hemodialyzer with dramatically higher permeability. #dialysis
Post not available here, view on X
ERA - European Renal Association
@ERAkidney
Authors conclude that this scalable SiN nanomembrane platform can withstand physiological pressures while delivering exceptional permeability, paving the way for implantable hemodialyzers coupled to dialysate regeneration systems
ERA - European Renal Association
@ERAkidney
Signing off @NaveenNephro on behalf of the @ERAkidney Social Media team.
Keep following #era26 for more on next‑generation dialysis technologies. -
ERA - European Renal Association
@ERAkidney
Mechanistic science at #era26 FC22: Hiroto Saito (Kitasato University) evaluates whether nitric‑oxide–supplemented dialysate offers consistent anticoagulant effects across different HD membrane materials in a rat model. #dialysis
Post not available here, view on X
ERA - European Renal Association
@ERAkidney
Conclusion: NO‑supplemented dialysate exerts a consistent anticoagulant effect independent of whether the membrane is PES or CTA, with stable blood pressure throughout – supporting NO‑based regional anticoagulation concepts for HD
ERA - European Renal Association
@ERAkidney
Signing off @NaveenNephro on behalf of the @ERAkidney Social Media team.
More innovation threads from #era26 coming soon -
ERA - European Renal Association
@ERAkidney
From #era26 FC22, Partha Das and the DaVita International team present a large matched multinational cohort from Latin America and the Middle East: does online HDF reduce mortality and hospitalisation compared with HD? #erakidney #dialysis
Post not available here, view on X
ERA - European Renal Association
@ERAkidney
Key outcomes:
All‑cause mortality: odds ratio 0.65 (95% CI 0.55–0.77), ≈35% relative risk reduction with HDF.
All‑cause hospitalisation: odds ratio 0.75 (95% CI 0.69–0.82), ≈24% risk reduction
ERA - European Renal Association
@ERAkidney
Country‑level signals (matched cohorts): HDF shows consistent mortality reductions in Ecuador, Colombia and Saudi Arabia, mirrored by lower hospitalisation rates across all three settings.
Post not available here, view on X
ERA - European Renal Association
@ERAkidney
Authors note limitations of observational design and heterogeneity of health systems, but crucially, the mortality advantage reported in European RCTs and meta‑analyses appears reproducible in real‑world LATAM/Middle East practice
ERA - European Renal Association
@ERAkidney
Signing off @NaveenNephro on behalf of the @ERAkidney Social Media team. Follow #era26 for more on HDF, membranes and beyond.
-
ERA - European Renal Association
@ERAkidney
🧵1/ More Than Numbers: Living, Feeling and Treating CKD
Chairs: Vladimir Tesar, Amarylis Van Craenenbroeck
🫀Session 5: Dose-exposure-response of finerenone on serum potassium and cardiovascular outcomes among patients with heart failure: Insights from FINEARTS-HF
🗣️ Speaker: Finnian R. Mc Causland
#era26Post not available here, view on X
ERA - European Renal Association
@ERAkidney
3/ When patients are able to get the higher⬆️ dose of finerenone CV beneficial effects ⬆️#era26
ERA - European Renal Association
@ERAkidney
4/ 🙋🏻♀️ #era26 Signing off, on behalf of ERA social media team, Rezzan Eren Sadioğlu @ErenRezzan
-
ERA - European Renal Association
@ERAkidney
Live from #era26 FC22 “Filters, Flows, Membranes, Modalities and more” – spotlight on Giuseppe Di Chiaro (Modena, Italy) asking: who really reaches high‑volume post‑dilution HDF targets in routine care, and why? #nephpearls #dialysis
Post not available here, view on X
ERA - European Renal Association
@ERAkidney
Take‑home: in routine practice, high‑volume post‑dilution HDF is often under‑delivered relative to guideline targets; optimising Qb and tailoring targets to anthropometrics is central to closing that gap.
ERA - European Renal Association
@ERAkidney
Signing off @NaveenNephro on behalf of the @ERAkidney Social Media team. Stay tuned for further updates from #era26.
-
ERA - European Renal Association
@ERAkidney
🧵 Symposium: Non-pharmacological approaches to cardiovascular complications in CKD #era26
🎙️Chaired by Jonathan Gabriel Fox & Milica Bozic
🫀Cardiovascular disease (#cvd) remains the leading cause of morbidity and mortality across the #ckd spectrum.
🟢Beyond💊: exercise, diet and the microbiome as CV therapies in CKD
Today’s speakers will discuss:
👟Exercise training and cardiovascular disease in severe CKD — Naomi Clyne
🧂 Sodium and potassium: the yin and yang of hypertensive vascular disease — Johannes Stegbauer
🦠 The gut microbiome and cardiovascular burden in CKD — Laetitia Koppe
Follow this thread for key insights 👇
ERA - European Renal Association
@ERAkidney
1️⃣ Naomi Clyne – The role of exercise training on cardiovascular risk factors and heart disease in severe #era26
➡️ Key messages:
🔹Exercise is far more than physical activity: skeletal muscle acts as an endocrine organ, releasing myokines with systemic anti-inflammatory and cardiometabolic effects.
🔹Physical inactivity is a major CV risk factor across all #ckd stages, while even modest increases in activity are associated with improved outcomes.
🔹Exercise should be viewed as a therapeutic intervention, adaptable to each patient’s functional capacity.
📊 Key data:
🔹 #cvd accounts for 58% of deaths in CKD stage 5 and KRT patients.
🔹 As little as 15 minutes/day (90 min/week) of physical activity is associated with 🔽 mortality risk (HR 0.87).
🔹 In the EXCITE trial, 6 months of home-based exercise improved hospitalization-free survival in dialysis patients.
🔹 In the DiaTT trial, 12 months of intradialytic exercise reduced hospital days from 12.8 to 10.9 days/patient (p=0.036).
🔹 In RENEXC, resistance training reduced albuminuria from 98 to 64 g/mol after 12 months (p<0.001).
💡 Take-home messages:
🔹Exercise is medicine. Even small doses can improve outcomes, reduce hospitalizations and potentially slow disease progression in CKD patientPost not available here, view on X
ERA - European Renal Association
@ERAkidney
3️⃣ Laetitia Koppe – Revitalizing the gut microbiome in CKD: can we reduce cardiovascular burden? #era26
➡️ Key messages:
🔹Kidney disease and #gut health are closely interconnected.
🔹#ckd promotes intestinal dysbiosis, favoring bacteria that generate uremic toxins linked to vascular damage and disease progression.
🔹Specific microbial pathways convert dietary substrates into toxins such as indoxyl sulfate, p-cresol and TMAO, which contribute to cardiovascular risk.
🔹Targeting the gut microbiome is emerging as a promising therapeutic strategy in CKD.
📊 Key data:
🔹 Elevated TMAO levels are associated with a 2.24-fold higher risk of incident CKD.
🔹 CKD patients exhibit reduced microbial diversity, with expansion of Enterococcaceae and loss of beneficial Lactobacillaceae.
🔹 Plant-based low-protein diets reduce circulating uremic toxins and toxin-producing bacterial species.
🔹 SGLT2 inhibitors may exert off-target microbiome effects, including reductions in p-cresol production.
💡 Take-home messages:
🔹The gut microbiome represents a potentially modifiable cardiovascular risk factor in CKD.
🔹Dietary interventions, microbiome-targeted therapies and existing drugs may help reduce the burden of uremic toxins.
ERA - European Renal Association
@ERAkidney
🔚 Symposium take-home messages:
Cardiovascular prevention in #ckd extends far beyond pharmacological treatment.
✅ Exercise acts as a powerful cardioprotective intervention.
✅ Potassium may counterbalance the vascular toxicity of excess sodium more effectively than salt restriction alone.
✅ The gut microbiome is emerging as a key driver of cardiovascular risk and a promising therapeutic target.
The future of #cardiorenal care will likely combine lifestyle, nutrition and microbiome-based strategies alongside conventional therapies.
@jbroseta on behalf of ERA SoMe Team
#era26 #ckd #cardiorenal #nephrology -
ERA - European Renal Association
@ERAkidney
The session “Genome Games: Rare Variants, Risk Scores & Cellular Signals” opened with Floriana Secondulfo presenting diagnostic challenges and poor acidosis control in proximal renal tubular acidosis. The study delineates a distinct clinical profile for SLC4A4-associated pRTA, highlighting important considerations for diagnosis and disease management. #era26 #nephrology #kidneyresearch
ERA - European Renal Association
@ERAkidney
Next, Matthew Lanktree presented data on combining polygenic risk scores across 16 kidney and cardiometabolic traits to improve CKD prediction. Multi-trait PRSs showed stronger associations with CKD than PRSs based on CKD or eGFR alone, highlighting the value of integrating genetic risk across related conditions. #era26 #ckd #genomics
Post not available here, view on X
ERA - European Renal Association
@ERAkidney
Next, Gabriel Doctor presented a mixed-ancestry, multi-cohort genome-wide association study of 1,723 patients with idiopathic nephrotic syndrome. Leveraging a large and ancestrally diverse INS population, the study enabled new locus discovery and advances in understanding the genetic architecture of the disease. #era26 #kidneyresearch #genomics
ERA - European Renal Association
@ERAkidney
Closing the session, Andrew Kassianos presented data showing that ferroptosis-associated microRNAs may help predict progression from AKI to CKD, highlighting their potential as biomarkers for risk stratification and disease monitoring. #era26 #aki #ckd #kidneyresearch
-
ERA - European Renal Association
@ERAkidney
Happening in Clyde now at #era26
Prediction, precision and inclusion in ANCA vasculitis: open your mind to new possibilities
Gender disparity and sex disaggregated outcomes in ANCA vasculitis: should we rethink?
🗣️Vanja IvkovicPost not available here, view on X
ERA - European Renal Association
@ERAkidney
#era26
To conclude, sex-differences seem to exist, and we must keep an eye on our own practices to fix them.
If willing to help, check out the CRESCENDO study:
academic.oup.com/ckj/advance-article/doi/10.1093/ckj/sfag…
ERA - European Renal Association
@ERAkidney
On behalf of the SoMe team, and happy Friday:
#era26
@DrBarbaTeba and @CristinaDeReins -
ERA - European Renal Association
@ERAkidney
📌Don't miss Leonardo Riella’s Plenary Lecture at #era26, “From Science Fiction to Reality: The Xenotransplantation Revolution” happening:
📅 TOMORROW, 10:45 - 12:00 (BST)
Discover our Scientific Programme 👉 www.era-online.org/events/glasgow-2026/scientific-programme/ -
ERA - European Renal Association
@ERAkidney
Are We Still Using 'Too Much' CNI? No | #era26
Calcineurin inhibitor-based triple therapy remains the standard for kidney transplant immunosuppression.
CNI Triple Therapy: The Proven Standard
Low rejection rates: CNI-based triple therapy has been the standard therapy for years with low incidence of rejection
Toxicity managed: CNI renal and extrarenal toxicity impacts long-term graft function, but induction therapy and low-dose tacrolimus reduced the problem
Switching has consequences: If CNI is replaced by mammalian target of rapamycin inhibitor or belatacept, increased rejection and de novo donor specific antibodies are associated
The Belatacept Dilemma: Metabolic Benefits vs Rejection Risk
BENEFIT study findings: Belatacept-based regimen has better metabolic profile, less donor specific antibodies, better patient and graft survival and graft function. But early rejection risk is higher, especially early posttransplant
Patient selection matters: Not all patients respond equally. CD28 high CD4 T cells pretransplant are higher in rejecting patients. CD28 null CD4 T cells are higher in stable patients. Memory T cell increase may drive rejection risk
Practical barriers: Belatacept requires intravenous infusion, so needs time and space to administer. Best induction and maintenance strategies are yet to be established. Only approved for Epstein Barr virus positive patients
mTOR Inhibitor Switch: Worse Long-term Outcomes
Meta-analysis data: Meta-analysis of randomized controlled trials shows switch to mammalian target of rapamycin inhibitor beyond 3 months is associated with reduced graft survival. High quality evidence
mTORi trade-off: mTOR inhibitor-based regimens showed better early estimated glomerular filtration rate but increased risk of rejection, donor specific antibodies, and graft loss in the long term
Low-Dose CNI Also Failed
Very low tacrolimus unsuccessful: Study in stable steroid-free kidney transplant recipients randomized to standard 7 to 12 micrograms per liter vs very low greater than 3 micrograms per liter. Very low tacrolimus was unsuccessful to prevent rejection, especially when steroid-free
Target level: Tacrolimus greater than 7 micrograms per liter in the first year is needed even in low risk patients to prevent rejection
Takeaway: No, we are not using too much CNI. CNI-based triple therapy gives the lowest rejection rates. Alternatives like belatacept improve metabolism and graft function but carry higher early rejection risk and need Epstein Barr virus positivity. mTOR inhibitor switch improves early estimated glomerular filtration rate but harms long-term graft survival. Best approach: use induction and low-dose CNI to reduce toxicity while keeping rejection control.
Presentation: İlaria Gandolfini | Tweet: @eroldemir83 on behalf of SoMe Team -
ERA - European Renal Association
@ERAkidney
Happening in Clyde now at #era26
Prediction, precision and inclusion in ANCA vasculitis: open your mind to new possibilities
Should steroids take a back seat in 2025: real world use of avacopan
🗣️Lorraine Harper
ERA - European Renal Association
@ERAkidney
Higher rates of infecton in ANCA patients compared with control, no differences among RTX of CFC treatments.
#era26
ERA - European Renal Association
@ERAkidney
⬇️steroids ⬇️infections without compromising efficacy
In the ADVOCATE trial, avacopan was presented as a solution, however, it is currently under FDA/EMA investigation regarding data integrity
#era26Post not available here, view on X
ERA - European Renal Association
@ERAkidney
Other complement blocking agents:
☣️Iptacopan
☣️Pegcetacoplan
☣️Eculizumab
☣️Vilobelimab
#era26
Although concerns are rising on avacopan, complement inhibition appears to work
ERA - European Renal Association
@ERAkidney
on behalf of the SoMe team
@DrBarbaTeba and @CristinaDeReins -
ERA - European Renal Association
@ERAkidney
✅️A roadmap towarda precision medicine in genetic disease in Europe! #era26
❗️A bigger picture of genetic disease!Post not available here, view on X
ERA - European Renal Association
@ERAkidney
⚠️Employing AI to reduce diagnosis delay in rare disease!
↔️Genotype-phenotype correlation in individuals with nephronophtisis!
ERA - European Renal Association
@ERAkidney
❗️New development and challenges in genetic testing!
⬆️One systematic review with more than60 studies in patients with CKD!
❓️CKDx - CKD with unexplained etiology! by ERA social media team @AgavriloaeiB -
ERA - European Renal Association
@ERAkidney
Are We Still Using 'Too Much' CNI? Yes | #era26
90-95 percent of kidney transplant patients get calcineurin inhibitor at discharge. 80-90 percent stay on it long term. But Luuk Hilbrands at #era26 says fear of rejection is driving overuse, threatening long-term graft survival.
Why CNIs Are Overused: Status Quo Bias
Success became habit: CNIs drastically reduced acute rejection when introduced and became the default backbone of immunosuppression. Clinicians continue using them out of habit even when alternatives exist
Fear-driven prescription: Acute rejection is visible and immediate, so clinicians increase CNI. Chronic kidney disease and cancer from CNI are delayed and multifactorial, so less attributed. This "fear nudges" doctors to continue CNI when alternatives may be better
Nephrotoxicity is the Achilles heel: CNI causes acute kidney injury, thrombotic microangiopathy, and interstitial fibrosis with tubular atrophy leading to progressive chronic kidney disease
The Cost of CNI Overuse
Metabolic + other toxicity: Hypertension more with cyclosporine than tacrolimus. Diabetes mellitus more with tacrolimus than cyclosporine. Plus hyperlipidemia, neurotoxicity-tremor, diarrhea, infections, malignancies
Long-term graft loss: Indisputable nephrotoxic effects of CNIs threaten long-term graft survival despite good early outcomes
Alternatives Exist - Data Supports Conversion
Belatacept conversion trial: Budde et al J Am Soc Nephrol 2021. 446 patients 6-60 months posttransplant converted to belatacept vs continued CNI. At 24 months: patient and graft survival 98 percent vs 97 percent. Renal function 55.5 vs 48.5 milliliters per minute per 1.73 square meters favoring belatacept. Biopsy proven acute rejection 8 percent vs 4 percent. De novo donor specific antibodies 1 percent vs 7 percent
Less new-onset diabetes: Pooled BENEFIT data shows 5 percent new-onset diabetes with belatacept intensive or less intensive vs 10 percent with cyclosporine. Vanrenterghem et al Transplantation 2011
Long-term graft survival: Vincenti et al NEJM 2016. 7-year data shows belatacept vs cyclosporine hazard ratio for death or graft loss 0.57, p equals 0.02. Beneficial long-term graft survival with belatacept
mTOR substitution: CNI substitution by belatacept or mammalian target of rapamycin inhibitor is viable. CNI minimization or withdrawal from triple to double therapy: mycophenolate mofetil or azathioprine plus prednisone, mycophenolate mofetil or azathioprine plus mammalian target of rapamycin inhibitor, mammalian target of rapamycin inhibitor plus prednisone
The Trade-off: More Early Rejection, Better Long-term
Higher early acute rejection: BENEFIT trial shows acute rejection less than 1 year: belatacept more intensive 22 percent, belatacept less intensive 17 percent, cyclosporine 7 percent. Kaufman et al shows more biopsy proven acute rejection with alemtuzumab or rATG plus belatacept vs rATG plus tacrolimus
But grafts last longer: Despite higher early rejection, long-term graft survival is better with belatacept. 2-year conversion data shows improved estimated glomerular filtration rate with no graft survival penalty
Takeaway: Yes, we still use too much CNI. Status quo bias keeps 90 percent of patients on nephrotoxic drugs long term. Conversion to belatacept 6-60 months posttransplant improves renal function, reduces diabetes and donor specific antibodies, and improves 7-year graft survival despite higher early acute rejection. CNI substitution or minimization is possible. Time to move beyond "fear-driven prescription".
Presentation: Luuk Hilbrands | Tweet: @eroldemir83 on behalf of SoMe Team -
ERA - European Renal Association
@ERAkidney
Happening in Clyde now at #era26
Prediction, precision and inclusion in ANCA vasculitis: open your mind to new possibilities
Recovery, frailty and ANCA vasculits: a predictive and precise approach
By @BrixSilkePost not available here, view on X
ERA - European Renal Association
@ERAkidney
Personalized management
☣️Address patient fitness and capability to recover
☣️RTX vs CFC: choose according to patient's phenotype
☣️Consider plasma exchange after addressing said infection risk
☣️Focus on reducing immunosupression in the future for your patient
#era26
ERA - European Renal Association
@ERAkidney
On behalf on the SoMe team, yours truly
#era26
@DrBarbaTeba and @CristinaDeReins -
ERA - European Renal Association
@ERAkidney
❗️From ERA science Barcelona with information here in Glasgow!
#era26Post not available here, view on X
ERA - European Renal Association
@ERAkidney
❗️Uromodulin is important in ADTKD!
⬆️Most common monogenic kidney disease after collagen IV and ADPKD!
ERA - European Renal Association
@ERAkidney
⚠️Urinary extracellular vesicel MMP can predict the progression in ADPKD! By ERA social media team @AgavriloaeiB
-
ERA - European Renal Association
@ERAkidney
🧵1/ More Than Numbers: Living, Feeling and Treating CKD
Chairs: Vladimir Tesar, Amarylis Van Craenenbroeck
🫀Session 4: Mineralocorticoid receptor antagonist initiation in cardiorenal patients: hyperkalaemia and discontinuation by kidney function in the CaRe study
🗣️ Speaker: Roberto Pecoits-Filho @pecoitsfilho
#era26Post not available here, view on X
ERA - European Renal Association
@ERAkidney
3/⚪️ Half of the patients of CKD 4 experienced severe hyperkalemia.
⚪️Over 2 years, more than half of the patients discontinued MRA therapy.
ERA - European Renal Association
@ERAkidney
4/ conclusion #era26
ERA - European Renal Association
@ERAkidney
#era26 Signing off, on behalf of ERA social media team, Rezzan Eren Sadioğlu @ErenRezzan 🙋🏻♀️
-
ERA - European Renal Association
@ERAkidney
#era26 @ERAkidney
📝 Symposium: AKI & Critical Care Nephrology
Chair: Serhan Tuglular & Anna Faivre
3️⃣ Beyond Repair: Regenerating the Injured Kidney with Stem Cells and Extracellular Vesicles
🗣️: Cristina Grange
🧵1/ Stem cell therapy
📍Extracellular vesicles (EV) in AKIPost not available here, view on X
ERA - European Renal Association
@ERAkidney
#era26 🧵3/
🔷hTERT-based inmortalization strategy
🔷EV engineering -> RBC easily extracted❗️ and can be obtained in high amounts and could be engineered with klotho❗️
🔷Hybrid co-formulation
🔷Alternative EV sources: in study
ERA - European Renal Association
@ERAkidney
#era26 🧵4/ klotho RBC could improve fibrosis📍but there are still many challenges
Signing off, on behalf of #era social media team, Francisco Valga @Nefrogeek -
ERA - European Renal Association
@ERAkidney
Dialysis Goes Mobile 🚙: Home Therapies, Wearables & Freedom.
Free lectures session.
Moderators: Christian Combe and Ana Carina da Costa Ferreira
1/5
🎤 Sundar Ramaswamy
Improving Confidence in Home Hemodialysis Through Conversational AI-Driven Knowledge Access
Promising results from the development of a tool with the use of AI 🤖 to give answers to teams and patients about home hemodialysis.Post not available here, view on X
ERA - European Renal Association
@ERAkidney
3/5
🎤 Alishba Khan
“Sugar in the Bag” — What Do Peritoneal Dialysis Patients Know About Glucose Exposure?
Glucose load 🍬 and glucotoxicity are important issues in PD… but how much patients know about it?
The experience of a survey in 92 patients in two centers show low awareness about the problem and the need for educational interventions.
ERA - European Renal Association
@ERAkidney
4/5
🎤 Chun Kau Gordon Chan
Graded Association between Gastric Acid Suppressants and Fracture Risk in Peritoneal Dialysis Patients: A Territory-Wide Cohort Study
Patients with CKD face a 4-5x risk of fracture 🦴. In this study on 18,000 patients over 14 yrs on Hong Kong database, the use of PPI in PD patients shows higher risk of fracture. This suggest the need for a deprescribing attitude.
ERA - European Renal Association
@ERAkidney
✍️ @FedericaNeveVig on behalf of SoMe team #era26
-
ERA - European Renal Association
@ERAkidney
🧵1/ More Than Numbers: Living, Feeling and Treating CKD
Chairs: Vladimir Tesar, Amarylis Van Craenenbroeck
😮💨Session 3: Gastrointestinal Myopathy in Chronic Kidney Disease: A Novel Manifestation of Uremic Myopathy with Direct Structural Evidence
🗣️ Speaker: Ye Xiaoshuang
#era26Post not available here, view on X
ERA - European Renal Association
@ERAkidney
4/ This study is first description of CKD- related gastrointestinal myopathy 🧪💉🐁
ERA - European Renal Association
@ERAkidney
#era26 Signing off, on behalf of ERA social media team, Rezzan Eren Sadioğlu @ErenRezzan
-
ERA - European Renal Association
@ERAkidney
Dialysis Goes Mobile 🚙: Home Therapies, Wearables & Freedom.
Free lectures session.
Moderators: Christian Combe and Ana Carina da Costa Ferreira
🎤 Quing Xu - winner of prize for the best free lecture 🏆
A Novel Peritoneal Dialysis Fluid Based on Succinylated Gelatin and Citrate: A Preliminary Investigation of Efficacy, Safety, and Biocompatibility
A proposal of a promising new PD fluid 💦with good biocompatibility, good ultrafiltration performance and dialysate efficacy and lower peritoneal thickness and collagen (in vitro and animal model 🐁)
✍️ @FedericaNeveVig on behalf of SoMe team #era26 -
ERA - European Renal Association
@ERAkidney
🧵 Free Communications 18: Bones, Hearts & Metabolism: Dialysis Complications Unpacked #era26
Chaired by Jovana Kusic Milicevic and Pieter Evenepoel.
Today’s session explores key complications in hemodialysis:
🩸 Bleeding risk and anticoagulation
🦴 Osteoporosis and fractures
❤️ Cardiovascular risk prediction
🏃 Exercise-based cardioprotection
Follow this thread for the key findings 👇Post not available here, view on X
ERA - European Renal Association
@ERAkidney
5️⃣ Matthieu Josse – Biphasic cardioprotection by pre-dialysis exercise in HD patients
#era26 #hemodialysis #cardionephrology #exercise
➡️ Key messages:
🔹 HD induces transient myocardial dysfunction (“myocardial stunning”), characterized by regional wall motion abnormalities (RWMA) and worsening global longitudinal strain (GLS).
🔹 Acute exercise performed immediately before dialysis may protect the myocardium against this dialysis-induced injury.
🔹 The proposed mechanism is ischemic preconditioning, whereby a brief exercise stimulus triggers protective pathways that persist beyond the exercise session itself.
📊 Study design:
🔹 Randomized crossover study
🔹 27 maintenance hemodialysis patients
🔹 Exercise performed 30 minutes before dialysis
🔹 Cardiac function assessed using:
▪️ Regional wall motion abnormalities (RWMA)
▪️ Global longitudinal strain (GLS)
🔹 Effects evaluated during:
▪️ First window of protection (FWOP)
▪️ Second window of protection (SWOP)
📊 Key findings:
Compared with control sessions, pre-dialysis exercise resulted in:
✅ Fewer regional wall motion abnormalities
🔹 FWOP: significant reduction (p<0.001)
🔹 SWOP: significant reduction (p=0.02)
✅ Better preservation of myocardial function
🔹 GLS improved by ~1.5% in both protection windows (p<0.001)
Importantly:
🔹 No significant differences in UF volume, UF rate or dialysis duration
🔹 No meaningful differences in blood pressure, cardiac output or blood volume changes
This suggests the cardioprotective effect was not explained by hemodynamic changes.
💡 Take-home messages:
🔹 A brief session of exercise before dialysis reduced dialysis-induced myocardial dysfunction, with benefits observed not only during the immediate dialysis session but also during the subsequent treatment.
🔹 These findings support the hypothesis that exercise-induced preconditioning may offer a simple, low-cost and non-pharmacological strategy to reduce cardiac injury in hemodialysis patients.
ERA - European Renal Association
@ERAkidney
🔚 FC18 take-home messages:
Dialysis complications extend far beyond kidney replacement itself and remain major determinants of outcomes in patients with kidney failure.
🩸 In patients initiating oral anticoagulation, PPI were associated with a substantially lower risk of UGIB, supporting targeted gastroprotection in selected high-risk hemodialysis patients.
🦴 The TRINITY study provided the first randomized evidence that romosozumab significantly increases bone mineral density in HD patients with osteoporosis, with encouraging signals suggesting a potential reduction in fracture burden.
❤️ Novel approaches to cardiovascular risk assessment continue to emerge. Circulating Humanin improved the performance of several CV risk prediction models, highlighting the potential role of biomarkers in refining risk stratification in HD populations.
🏃 Exercise may be medicine in dialysis care. A brief session of pre-dialysis exercise reduced dialysis-induced myocardial dysfunction, with cardioprotective effects extending beyond the immediate treatment session. These findings support exercise-induced preconditioning as a promising, low-cost, non-pharmacological strategy to protect the heart during hemodialysis.
💡 Overall message: Improving outcomes in dialysis requires moving beyond adequacy metrics alone and addressing bleeding risk, bone health, cardiovascular vulnerability and cardiac protection through innovative, patient-centred approaches.
@jbroseta on behalf of the ERA SoMe Team
#era26 #dialysis #hemodialysis #ckd #cardionephrology #bonehealth #exercisemedicine -
ERA - European Renal Association
@ERAkidney
🧵1/ More Than Numbers: Living, Feeling and Treating CKD
Chairs: Vladimir Tesar, Amarylis Van Craenenbroeck
🫥Session2: Depressive symptoms in chronic kidney disease: the hidden role of uremic toxins
🗣️ Speaker: Helene Levassort
#era26
ERA - European Renal Association
@ERAkidney
2/ 🫥Uremic toxins and depressive symptoms were measured in CKD patients.
🫥CESD scores increased over time in the kohort thorough 5 years.
🫥Certain toxins especially increased PAG levels were associated with increased CESD scores. #era26
ERA - European Renal Association
@ERAkidney
3/ #era26 Signing off, on behalf of ERA social media team, Rezzan Eren Sadioğlu @ErenRezzan
-
ERA - European Renal Association
@ERAkidney
Starting now in the Forth Room #era26
Come listen to the highest scoring abstracts in the kidney transplantation theme
“After the Graft: Outcomes, Inequities and Immunosuppression”
Session Chairs: Arzu Velioglu 🇹🇷 & Adnan Sharif 🇬🇧
Coverage by @juniornephron on behalf of the SoMe Team
ERA - European Renal Association
@ERAkidney
📃Temporal trends in comorbidities and causes of death in kidney transplant recipients from four European countries: an ERA Registry study
📣Brittany Boerstra 🇳🇱
#era2
ERA - European Renal Association
@ERAkidney
📌 Increasing rates of diabetes and cardiovascular disease seen
📌 Due predominantly to temporal increases in age of recipients
#era26
ERA - European Renal Association
@ERAkidney
📌 Higher crude 5-year mortality
📌 Lower adjusted 5-year mortality
📌 Improvements in treatment is in part masked by an increase in higher risk donors
#era26
ERA - European Renal Association
@ERAkidney
📃Inequalities in listing and re-transplantation post-kidney transplant failure in the UK: Failing Kidney Transplant Outcomes Registry Analysis (FAKTOR)
📣Samuel Westaway 🇬🇧
#era26
ERA - European Renal Association
@ERAkidney
📌 50% relisted within 2 years of failure
📌 ~20% retransplanted within 2 years failure
#era26
ERA - European Renal Association
@ERAkidney
Factors associated with increased relisting
📌 Male
📌 Lower socioeconomic deprivation
📌 Managed at a transplant centre
Factors associated with increased retransplantation
📌 Lower socioeconomic deprivation
📌 White ethnicity
#era26
ERA - European Renal Association
@ERAkidney
📃Evolution of donor-specific HLA antibodies after belatacept conversion in kidney transplant recipients: a single-center study
📣Ömer Ege Ömeroglu 🇩🇪
#era26
ERA - European Renal Association
@ERAkidney
📌 Belatacept has previously been associated with improved graft function and better adherence
📌 Majority of patients had stable or improved immunological profiles
#era26
ERA - European Renal Association
@ERAkidney
📌 Low rates of dnDSA and AMR following belatacept conversion
📌 Promising future treatment strategy in KTRs
#era26Post not available here, view on X
ERA - European Renal Association
@ERAkidney
📌 > 3000 patients starting dialysis after transplant failure
📌 ~ 75% on at least one immunosupressive drug
#era26
ERA - European Renal Association
@ERAkidney
📌 No significant mortality associated with ongoing immunosuppression usage
📌 Lower mortality associated with early calcineurin or mTOR usage
#era26Post not available here, view on X
ERA - European Renal Association
@ERAkidney
📌 Phase III trial
- Cohort A: CKD IIIb/IV/V or
- Cohort B: ESKD on HD
📌 Stable oxalate levels on treatment in both cohorts
#era26
ERA - European Renal Association
@ERAkidney
📌 6 patients received kidney transplant on lumasiran
📌 No reported oxalate nephropathy post-transplant
#era26 -
ERA - European Renal Association
@ERAkidney
🧵1/ More Than Numbers: Living, Feeling and Treating CKD
Chairs: Vladimir Tesar, Amarylis Van Craenenbroeck
👟💪Session 1: Health-related quality of life after 12 months of self-administered exercise in patients with CKD 3-5 – a substudy of RENEXC
🗣️ Speaker: Philippa Svensson
#era26Post not available here, view on X
ERA - European Renal Association
@ERAkidney
3/ conclusion:
⚪️0-4-8-12 months HRQOL was recorded
⚪️ balance+ aerobic exercise group had
HRQOL improved
ERA - European Renal Association
@ERAkidney
#era26
Signing off, on behalf of ERA social media team, Rezzan Eren Sadioğlu @ErenRezzan -
ERA - European Renal Association
@ERAkidney
1 / Cardiovascular complications in CKD patients: Severe arrythmia and sudden cardiac death in dialysis patients: how to prevent? - Simonetta Genovesi 🇮🇹
#era26
ERA - European Renal Association
@ERAkidney
2/ intra-dialysis sudden cardiac arrest
📍Associated with first dialysis session of the week and hypokalaemia
#era26Post not available here, view on X
ERA - European Renal Association
@ERAkidney
4/ Peritoneal dialysis
High troponin and BNP associated with sudden cardiac death
#era26
ERA - European Renal Association
@ERAkidney
5/ what can we do about sudden cardiac death?
-
ERA - European Renal Association reposted
Arunkumar
@Arunkr_Dr
📊 #turing results #era26
✅ Ritux delayed relapse
✅ 3 × 1 g doses over 26 wks maintained remission for >2.8 years
✅ Higher CR rates in FSGS (21/30 vs 11/26; p=0.037)
✅ Faster prednisolone taper feasible
Another important step toward steroid-sparing Rx in podocytopathies -
ERA - European Renal Association
@ERAkidney
1/ Cardiovascular complications in CKD patients: Global assessment of cardiovascular risk prediction tools in CKD - José Manuel Valdivielso 🇪🇸
High prevalence of CV disease in CKD
#era26
ERA - European Renal Association
@ERAkidney
2/ risk assessment scores:
Framingham - underestimates CV risk in CKD
And Score2, Q risk, Prevent, PCE…
Specific CKD CV risk factors must be considered
CV disease increases with:
📍 Reduced eGFR
📍 Increased proteinuria
#era26
ERA - European Renal Association
@ERAkidney
3/ ✅ Recommended lipid-lowering treatment reflecting high CV risk
Atherosclerosis assessment in CKD
📍Coronary artery calcium score to detect subclinical disease - not available everywhere
📍 US imaging an alternative to look for the presence of plaque and linked to incidence of cardiovascular events
#era26 -
ERA - European Renal Association
@ERAkidney
1/ Chia‑Te Liao presents a translational EV story at #era26 FC16: fresh‑thawed platelet lysate–derived extracellular vesicles (FTPL‑EVs) as a scalable, cell‑free therapy for renal ischaemia–reperfusion injury
Post not available here, view on X
ERA - European Renal Association
@ERAkidney
6/ In a bilateral IRI model, FTPL‑EVs reduced tubular injury scores, KIM‑1 expression, necrosis and improved BUN/creatinine—outperforming AF‑MSC‑EVs under identical conditions, supporting further development as an off‑the‑shelf renoprotective therapy.
ERA - European Renal Association
@ERAkidney
7/ Signing off @NaveenNephro on behalf of the @ERAkidney Social Media team. Stay tuned for further updates.
-
ERA - European Renal Association
@ERAkidney
1/ Jing Liu closes #era26 FC16 with a macrophage‑centred view of IRI‑AKI: macrophage‑derived FABP4 as a driver of inflammatory injury and a potential therapeutic target.
Post not available here, view on X
ERA - European Renal Association
@ERAkidney
3/ Pharmacologic FABP4 inhibition and global Fabp4 knockout both attenuated IRI‑AKI, lowering BUN/creatinine, KIM‑1/NGAL expression and histological injury, supporting a pathogenic role.
ERA - European Renal Association
@ERAkidney
4/ Conditional knockouts revealed cellular specificity: myeloid FABP4 deletion (Lyz2‑Cre Fabp4^fl/fl) markedly protected against IRI‑AKI, whereas tubular FABP4 deletion (Cdh16‑Cre Fabp4^fl/fl) did not confer significant renoprotection.
Post not available here, view on X
ERA - European Renal Association
@ERAkidney
6/ Conditioned media from FABP4‑deficient macrophages reduced IL‑6, KIM‑1, NGAL and pro‑apoptotic signalling in hypoxia–reoxygenation–injured tubular cells, indicating that macrophage FABP4 modulates paracrine injury to TECs.
ERA - European Renal Association
@ERAkidney
7/ Signing off @NaveenNephro on behalf of the @ERAkidney Social Media team. Stay tuned for further updates.
-
ERA - European Renal Association
@ERAkidney
1/ Cardiovascular complications in CKD patients: Latest data on cardiorenal effects of ns-MRAs in CKD patients - Pantelis Sarafidis 🇬🇷
⚠️Increasing global burden of CKD
⚠️Cardiovascular disease significant morbidity and mortality in CKD
#era26Post not available here, view on X
ERA - European Renal Association
@ERAkidney
3/ non-steroidal MRA: Finerenone
Key studies:
📍FIDELIO-DKD
📍FIGARO-DKD
📍FINE-ONE (in T1DM)
⭐️Fewer episodes of hyperkalaemia
⭐️Reduction in proteinuria
#era26
ERA - European Renal Association
@ERAkidney
4/ FIND-CKD | INFINITY
Optimised RASi -> Finerenone
Non-diabetic CKD (mostly HTN and Chronic GN)
Benefits:
✅ Reduction in eGFR loss
✅ Reduction in kidney failure
✅ Reduction in adverse cardiovascular outcomes
✅ Positive safety outcomes
#era26 -
ERA - European Renal Association
@ERAkidney
1/ Ning Li takes us deep into intracellular complement at #era26 FC16: CD35‑loaded extracellular vesicles (CD35‑EVs) targeting monocyte “complosome” activation to protect against sepsis‑associated AKI and multi‑organ dysfunction.
Post not available here, view on X
ERA - European Renal Association
@ERAkidney
6/ Monocyte complosome activation enhanced glycolysis via mitochondrial C5aR1, boosted chemotaxis, organ infiltration and MPO‑mediated injury across kidney, lung, liver and heart—effects attenuated by monocyte C3 deletion or CD35‑EV therapy.
ERA - European Renal Association
@ERAkidney
7/ Signing off @NaveenNephro on behalf of the ERA Social Media team. Stay tuned for further updates.
-
ERA - European Renal Association
@ERAkidney
🧵 1/7
🩸 Symposium: Anemia in CKD
📖 Lecture 3: 🧬 Do We Really Need Alternatives to ESAs?
🎤 Prof. Lucia Del Vecchio
ESAs have transformed the management of CKD-related anemia, yet concerns regarding efficacy, safety, hyporesponsiveness, and treatment burden continue to drive the search for alternative therapies.
Follow this thread for key insights and take-home messages from this session.
📍 #era26Post not available here, view on X
ERA - European Renal Association
@ERAkidney
🧵 6/7
🎯 Prof. Lucia Del Vecchio concluded with a shift in perspective.
❌ The question is no longer: ESA or HIF-PHI?
✅ The real challenge is identifying which patient will benefit from which therapy, and when.
💡 New therapies are not replacing ESAs—they are expanding our ability to individualize treatment for patients who may be underserved by ESAs alone.
📍 #era26
ERA - European Renal Association
@ERAkidney
🧵 7/7
This thread is brought to you by @Gawad_Nephro on behalf of SoMe.
📍 #era26 -
ERA - European Renal Association
@ERAkidney
1/ From #era26 FC16 “Shock to the System”: Federica Genovese presents endotrophin (PRO‑C6), a collagen VI–derived fragment, as a biomarker linking AKI to long‑term kidney outcomes.
Post not available here, view on X
ERA - European Renal Association
@ERAkidney
6/ Take‑home: endotrophin appears to mark sustained fibrogenic activity after AKI and may enable earlier risk‑stratification to identify patients needing intensified nephroprotective follow‑up or trials of anti‑fibrotic strategies.
ERA - European Renal Association
@ERAkidney
7/ Signing off @NaveenNephro on behalf of the ERA Social Media team. Stay tuned for further updates
-
ERA - European Renal Association
@ERAkidney
Overcoming Barriers in Highly Sensitized Kidney Transplant Patients | #era26
HLA incompatible transplant requires different strategies than HLA compatible cases. Marta Crespo at #era26 mapped the pathways from crossmatch testing to desensitization and paired exchange.
Risk Assessment: Who Needs What Strategy
CDC crossmatch positive: If CDC crossmatch is positive, direct to paired kidney exchange programs immediately
Calculated panel reactive antibodies threshold: If calculated panel reactive antibodies greater than 85 percent, chance of deceased donor transplant drops sharply. Refer to special programs. Compatible transplant improves survival
Low mean fluorescence intensity donor specific antibodies: Kidney transplant with low mean fluorescence intensity donor specific antibodies or low positive B cell flow crossmatch is an underappreciated option. Schinstock et al 2017 showed acceptable death censored graft survival in donor specific antibody positive crossmatch negative patients vs donor specific antibody negative
Algorithms for Compatible vs Incompatible Transplant
HLA compatible algorithm: Start with detailed immunological chart of previous donors and HLA antibodies. Explore HLA related living donor first, then other living donors. If incompatible, evaluate donor specific antibodies and consider paired exchange. Deceased donor via special programs EUROTR, PATHI, Scandia TR
HLA incompatible algorithm: Same first steps, but if incompatible living donors found, decision point is desensitization or paired exchange with donor specific antibodies. For deceased donor, use special programs with almost compatible low donor specific antibodies plus desensitization
Eurotransplant acceptable mismatch: Kidney allocation based on proven acceptable antigens gives superior graft survival in highly sensitized patients. But 35 percent still do not find a compatible donor. EUROSTAM gives 27 percent of long-time waiting list sensitized patients a better chance in a different donor pool
Special Programs & Outcomes
PATHI program Spain: For calculated panel reactive antibodies 100 percent patients, PATHI with virtual crossmatch allocation showed 92.5 percent patient survival and 88.7 percent graft survival at 1 year. Main limitation: if greater than 24 months active in PATHI, centers must accept kidney transplant with low mean fluorescence intensity donor specific antibodies or accept with desensitization
Persistent donor specific antibodies matter: Redondo et al and Segev et al data show 10.6 percent had unknown preformed donor specific antibodies at transplant. Persistent preformed donor specific antibodies increase antibody mediated rejection rate and decrease survival. Mean fluorescence intensity greater than 5100 DQ donor specific antibodies are high risk
US access gap: US data 2016-2017 shows cumulative incidence of access to deceased donor transplant drops dramatically as calculated panel reactive antibodies increases from 80 percent to 100 percent
Takeaway: For sensitized patients, pathway depends on crossmatch and calculated panel reactive antibodies. CDC positive means paired exchange. High calculated panel reactive antibodies means special programs like PATHI or EUROTR. Low mean fluorescence intensity donor specific antibodies with negative CDC crossmatch can proceed without desensitization. Goal is best immunological donor with least risk.
Presentation: Marta Crespo | Tweet: @eroldemir83 on behalf of SoMe Team -
ERA - European Renal Association
@ERAkidney
🧵 1/7
🩸 Symposium: Anemia in CKD
📖 Lecture 2: 💊 SGLT2i and Anaemia – Real Benefit or Coincidence on Cardiorenal Outcomes?
🎤 Prof. Davide Bolignano
SGLT2 inhibitors consistently increase hemoglobin levels in patients with CKD and heart failure. Is this simply a hematological effect, or could it contribute to their remarkable cardiorenal benefits?
Follow this thread for key insights and take-home messages from this session.
📍 #era26
Send the first slide and I'll prepare 🧵 2/7.Post not available here, view on X
ERA - European Renal Association
@ERAkidney
🧵 4/7
🩸 The rise in hemoglobin observed with SGLT2 inhibitors appears to be more than simple hemoconcentration.
💊 Experimental and clinical data suggest that dapagliflozin may suppress hepcidin, improve iron availability, and stimulate erythropoiesis.
🧬 These findings support a biologically active role of SGLT2i in anemia correction, potentially contributing to their broader cardiorenal benefits.
📍 #era26
ERA - European Renal Association
@ERAkidney
🧵 5/7
💊 Could SGLT2 inhibitors act as indirect HIF enhancers?
🧬 Emerging mechanistic data suggest that SGLT2i may modulate hypoxia-signaling pathways, promoting erythropoietin synthesis while preserving cardiorenal protection.
🩸 This raises the intriguing possibility that part of the anemia-correcting effect of SGLT2i may share biological pathways with HIF-PH inhibitors, albeit through different mechanisms.
📍 #era26
ERA - European Renal Association
@ERAkidney
🧵 6/7
💊 The proposed link between SGLT2 inhibitors and anemia correction appears multifactorial.
🩸 Beyond hemoconcentration, SGLT2i may reduce inflammation and hepcidin levels, improve iron mobilization, enhance HIF-2α signaling, and stimulate erythropoietin production.
🧬 Together, these effects may promote erythropoiesis and help explain why improvements in hemoglobin are consistently observed across cardiorenal populations.
📍 #era26
ERA - European Renal Association
@ERAkidney
🧵 7/7
Thank you for following this thread.
Coverage by @Gawad_Nephro on behalf of the ERA SoMe Team.
📍 #era26 -
ERA - European Renal Association
@ERAkidney
🧵1/7
🩸 Anemia is one of the most common complications of CKD, with prevalence increasing progressively as kidney function declines.
🧲 Iron deficiency remains a major driver of anemia in CKD, influenced by inflammation, impaired absorption, blood loss, and ESA use.
✅ Correcting iron deficiency can improve hemoglobin response, reduce transfusion requirements, and enhance quality of life and functional capacity.
📍 #era26Post not available here, view on X
ERA - European Renal Association
@ERAkidney
🧵6/7
🔚 To conclude, iron therapy in CKD may offer benefits that extend beyond anemia correction.
🧲 In addition to improving hemoglobin levels, ESA responsiveness, and reducing transfusion requirements, iron repletion may enhance exercise capacity, alleviate symptoms, and improve quality of life.
🫀 Emerging evidence suggests that correcting functional or absolute iron deficiency may provide cardiovascular benefits in CKD patients at high cardiovascular risk, irrespective of hemoglobin levels.
📍 #era26
ERA - European Renal Association
@ERAkidney
🧵7/7
This thread was brought to you by @Gawad_Nephro on behalf of the ERA SoMe Team.
📍 #era26 -
ERA - European Renal Association
@ERAkidney
Friday afternoon fun at the #era26
Integrated care for dialysis patients: different perspectives?
🪑🪑: Sevcan Bakkaloglu, Christian Combe
What if we are restricted: cultural & limitation barriers
🗣️@RKazancioglu
@drbarbateba bringing you the Scotish-afternoon tea☕️Post not available here, view on X
ERA - European Renal Association
@ERAkidney
Barriers might also present in different shapes:
🫘Manpower shortage, with a focus on healthcare providers
🫘Natural disasters
🫘War zones
ERA - European Renal Association
@ERAkidney
Support alternatives to hemodialysis: PD, shorten the dialysis sessions and overview their nutritional status.
Strategic pans need to adapt high-income country guidelines to local realities -
ERA - European Renal Association
@ERAkidney
Storytelling: your Secret Weapon
🗣️ Andrew McFarlan from @PinkElephantCom
Everybody loves a good story!
📖 Storytelling may represent a useful tool for nephrologist, to better communicate with patients 👥 and with the scientific community 🧑🎓
ERA - European Renal Association
@ERAkidney
Here are some “golden rules” to properly approach storytelling:
➡️ Keep it simple and focused
➡️ Get to the point: balance detail and succinctness
➡️ Turn dry data into imagery: use evocative images
➡️ Remove unnecessary negativity
➡️ Weave in personal anecdotes and case studies to build trust and engagement
➡️ Use proper tone, voice and body language
To be memorable: start with a story 📖… finish with a punchline 🥊
✍️ @FedericaNeveVig on behalf of SoMe team #era26 -
ERA - European Renal Association
@ERAkidney
New session
Can the use of complement inhibition be expanded in glomerular disease
#era26
First presentation by Complement activation as a primary driver of disease
Marina Vivarelli (Rome, Italy)Post not available here, view on X
ERA - European Renal Association
@ERAkidney
3/1🌸 glycemic mechanism of injury and complement involvement in DKD
ERA - European Renal Association
@ERAkidney
4/1🌸 DKD disease progression predictors
ERA - European Renal Association
@ERAkidney
5/1🌸Conclusions
ERA - European Renal Association
@ERAkidney
2/1 second presentation. Complement activation as a secondary drive for injury
ERA - European Renal Association
@ERAkidney
2/1 Second Complement activation as a secondary drive for injury
ERA - European Renal Association
@ERAkidney
3/2🌸mechanism of complement activation role and role of complements in IgA nephropathy
ERA - European Renal Association
@ERAkidney
4/2🌸Can you differentiate between the different complement activation pathways???
-
ERA - European Renal Association
@ERAkidney
1/ EASD/ERA Joint session: Diabetes Management in ESKD (PD and HD) and Opportunities of New Diabetes Technologies in this Cohort - Janaka Karalliedde 🇬🇧
#era26Post not available here, view on X
ERA - European Renal Association
@ERAkidney
4/ Management of DM in ESKD
#era26
ERA - European Renal Association
@ERAkidney
5/ Automated Insulin Delivery to improve glycaemic control #era26
✅increase time in range
✅better control with fewer spikes and troughs
✅other benefits including thirst and fluid balance -
ERA - European Renal Association reposted
Brian Rifkin, MD
@brian_rifkin
#nephjc made it into #era26 👏
@CristinaDeReins
www.nephjc.com/news/nephjc-shorts-mcd-fsgs -
ERA - European Renal Association reposted
Milagros Flores
@dra_miliflores
Otro análisis #findckd
📍903 pacientes
📍80% con biopsia renal
🔹Resultados?📉TFGe slope total
🎯¿cuál se benefició más?
IgAN ➡️ HR 0.82
FSGS ➡️ HR 0.60
Membranosa ➡️ HR 0.77
Entonces, podría finerenona convertirse en el siguiente pilar de las GN!? #era26 -
ERA - European Renal Association reposted
NEJM
@NEJM
Presented at #era26:
In this 104-week trial involving patients with primary membranous nephropathy, the type II anti-CD20 antibody obinutuzumab was superior to the calcineurin inhibitor tacrolimus in inducing complete remission. Full phase 3 MAJESTY trial results: www.nejm.org/doi/full/10.1056/NEJMoa2602678
@ERAkidney -
ERA - European Renal Association reposted
Arunkumar
@Arunkr_Dr
🔥 INFINITY pooled analysis (FIDELIODKD + FIGARODKD + FINDCKD)
Finerenone: ✅ Kidney outcome HR 0.76 ✅ HF hospitalization HR 0.78 ✅ CV death HR 0.82 ✅ All-cause mortality HR 0.88
One of the strongest cardiorenal datasets yet for CKD across diabetic + non-DM populations #era26 -
ERA - European Renal Association reposted
Carlo Alfieri
@carlo_alfieri
Proud to present two studies today at #era26:
🧬 Transcriptionally Reprogrammed CD4⁺ and CD8⁺ T Cells in Post-Transplant Cancer
💊 Roxadustat vs Darbepoetin Alfa in Post-Kidney Transplant Anemia
#kidneytransplant #nephrology #transplantresearch #cancerresearch @ERAkidney -
ERA - European Renal Association reposted
Sarah Gleeson
@Sarah_Gleeson_
Team Imperial at #era26 (or 90% of us!)
-
ERA - European Renal Association
@ERAkidney
Cardiovascular Screening in Kidney Transplant Candidates: Less is More | #era26
Cardiovascular disease is the most common cause of death after kidney transplantation, especially in the first 3 months. But extensive screening does not improve outcomes and can delay transplant.
Why Screening Philosophy Matters
Balance benefit vs harm: WHO screening criteria demand important health problem, recognizable early stage, suitable test, effective treatment, cost-effective strategy. Goal is to enable transplantation while avoiding harm
Do not over-screen: Do not over-screen and unnecessarily deny access to kidney transplantation. Do not expose patients with unacceptably high cardiovascular risk to major surgery
Presume fitness: Initial assessment should presume fitness for transplantation to widen access to the best renal replacement therapy
What KDIGO 2020 + AHA 2022 Say
KDIGO 2020: Recommends non-invasive coronary artery disease screening in asymptomatic candidates at high risk for coronary artery disease such as diabetes, previous coronary artery disease, or poor functional capacity. Presence of coronary artery disease alone should not automatically exclude candidates. Does not recommend routine coronary revascularization solely to reduce perioperative cardiac events
AHA 2022: Recommends ischemia screening of asymptomatic patients with 3 or more risk factors: diabetes, history of atherosclerotic cardiovascular disease, age greater than 60 years, dialysis duration greater than 5 years, silent ischemia on electrocardiography
Core tests: History, physical examination, symptoms, risk factors plus 12-lead electrocardiogram and resting echocardiography are essential first steps
ISCHEMIA-CKD Changed the Game
Trial design: 777 patients with advanced chronic kidney disease and moderate-to-severe ischemia randomized to invasive strategy vs conservative medical therapy. Bangalore et al, New England Journal of Medicine 2020
No benefit, more harm: Invasive strategy did not reduce mortality, myocardial infarction, or heart failure. Higher stroke risk hazard ratio 3.76 and higher risk of early dialysis initiation hazard ratio 1.48
Waitlist sub-study: 194 kidney transplant waitlisted participants analyzed. Invasive strategy was not associated with improved outcomes. Herzog et al, Journal of the American College of Cardiology 2021
Which Test to Choose?
Stress echocardiography: Combines structural and ischemic evaluation in one test, no radiation, prognostic value for major adverse cardiovascular events and overall survival. Preferred vs myocardial perfusion scan for similar sensitivity
CT coronary angiography: Non-invasive anatomical assessment. Normal result provides reassurance but contrast-related risk and false positives with vascular calcification are concerns
Invasive coronary angiography: Gold standard for coronary anatomy but carries vascular and contrast-related risks. Reserve for identifying revascularization indications when non-invasive tests are inconclusive
Takeaway: Early cardiovascular deaths post-transplant remain high, with 2.6 percent first-year major adverse cardiovascular events in UK data. But routine prophylactic revascularization is not supported. Start with functional status, electrocardiogram, and echocardiogram. Use non-invasive testing for intermediate or high risk. Invasive angiography and revascularization only for selected cases. Case-by-case decisions preserve transplant access.
Presentation: Arzu Velioglu | Tweet: @eroldemir83 on behalf of SoMe Team -
ERA - European Renal Association
@ERAkidney
Friday afternoon fun at the #era26
Integrated care for dialysis patients: different perspectives?
🪑🪑: Sevcan Bakkaloglu, Christian Combe
Conservative Approaches in Kidney Failure: Withholding or Stopping Dialysis
🗣️Bernard Paternostre
@drbarbateba bringing you the newsPost not available here, view on X
ERA - European Renal Association
@ERAkidney
We need to avoid "prognostic paralysis" and deliver active total care accordinf to the need of our patients, not their prognosis nor diagnoses
ERA - European Renal Association
@ERAkidney
Other useful tools:
PALLIA10: allows us to identify those patients that could benefit from a palliative care referral
Communicaton with these specialties will help us managing current and future problems with our patients -
ERA - European Renal Association
@ERAkidney
1/ EASD/ERA Joint session:
Post-Transplant Diabetes Mellitus (Risks, Recognition, and Management) - Rachel Hellemans 🇧🇪
Incidence 10 - 40 % in first 1 year
📍different screening practices
📍different immunosuppression
📍diagnose >45 days post transplant
#era26Post not available here, view on X
ERA - European Renal Association
@ERAkidney
5/ Management
Still some hesitancy on the use of newer drugs (SGLT2i or GLP-1 analogues) due to lack of data
Retrospective studies have shown positive findings for SGLT2i:
✅glycaemic control
✅cardiovascular outcomes
✅renal complications
✅lower mortality
#era26
ERA - European Renal Association
@ERAkidney
6/ Post Transplant GLP-1 analogues:
✅Lower Mortality
✅Reduction in weight
✅Major CV events
✅Lower HBA1C
✅Reduce albuminiria
📍use with caution and monitor drug levels
📍retrospective data
#era26 -
ERA - European Renal Association
@ERAkidney
Friday afternoon fun at the #era26
Integrated care for dialysis patients: different perspectives?
🪑🪑: Sevcan Bakkaloglu, Christian Combe
Integrated care for dialysis patients
🗣️Irma Tchokhonelidze
@drbarbateba bringing you the newsPost not available here, view on X
ERA - European Renal Association
@ERAkidney
Vascular access difficulties, frailty and patient education as the main barriers for the patints. Other options that should be explored:
🔎Hybrid dialysis (Japan perspective)
🔎Patient training, including psychosocial well-being
ERA - European Renal Association
@ERAkidney
At the same time, AI is embedded within our clinical practice:
🤖Real-time patient monitoring of the patients is possible and encouraged
🤖AI might offer new technologies with thelehealth capabilities (G.R.E.E.N.) -
ERA - European Renal Association
@ERAkidney
Preemptive Kidney Transplant: Costs, Timing & Equity | #era26
Preemptive kidney transplantation should be the first option, but donor availability, equity, and timing make the decision complex. Orsolya Cseprekal broke down the clinical evidence and decision-making at #era26.
Clinical Evidence on Preemptive Transplantation
Survival benefit: Preemptive transplantation vs non-preemptive transplantation shows better patient survival, independent of dialysis time and waiting list status
Cost impact: Average monthly healthcare costs over 3 years show a large upfront spike for transplantation, then costs drop and stay lower than dialysis long term. Transplantation is cost effective and provides more quality-adjusted life years
Not always net benefit: If listed preemptively but transplanted too early at estimated glomerular filtration rate 15 to 20 milliliters per minute per 1.73 square meters, annual costs are higher with no additional quality-adjusted life years gained when dialysis probability is below 45 percent
When to Refer? KDIGO 2024 + New Tools
KDIGO guideline: Consider planning for preemptive transplantation and/or dialysis access when estimated glomerular filtration rate is 15 to 20 milliliters per minute per 1.73 square meters or risk of kidney replacement therapy is greater than 40 percent over 2 years
eGFR alone insufficient: Estimated glomerular filtration rate alone is not appropriate to predict preemptive transplantation outcome. Risk assessment at time of transplantation is crucial to approach "preemptive in due course"
Uremic Burden Index: New parameter proposed: Uremic burden index equals delta estimated glomerular filtration rate multiplied by time on waiting list. Uremic burden index characterizes cumulative uremic exposure and distinguishes high-risk recipients. Validation needed
Donor Availability & Equity
Donor shortage: Preemptive transplantation in the context of donor availability and equity is a major challenge. Kidney exchange programs increase number of pairs and optimize age mismatch and Human Leukocyte Antigen mismatch
High-risk groups: In high-risk recipients with elderly deceased donors, 5-year graft loss risk greater than 30 percent even for living donor transplantation. Older donors and poorer Human Leukocyte Antigen-DR matching increase failure risk
Individual decision making: While preemptive transplantation remains optimal, success hinges on comprehensive risk assessment. Individual clinical decision making over strict algorithms is key, especially for patients over 75 years old
Takeaway: Preemptive transplantation saves lives and money long term vs dialysis, but timing matters. Transplanting too early adds surgical/immunosuppression risk and cost without survival benefit. Use KDIGO 15 to 20 as a trigger, then individualize with uremic burden index and donor/recipient risk factors. Equity in donor access remains the biggest barrier.
Presentation: Orsolya Cseprekal | Tweet: @eroldemir83 on behalf of SoMe Team -
ERA - European Renal Association
@ERAkidney
🎉 It’s a pleasure to announce and congratulate Rosanna Coppo, who has been awarded the ERA Honorary Membership.
👉 Rosanna Coppo is also the second woman in ERA’s history to receive this prestigious recognition, marking an important milestone for our Association. -
ERA - European Renal Association
@ERAkidney
Now at #era26
🪑🪑: @KateIsabelle24 , Z. Serhan Tuglular
☠️When science meets crime: the impact of forensic science
@ProfNNicDaeidPost not available here, view on X
ERA - European Renal Association
@ERAkidney
Overall, there is a high sense of uncertainty in forensic sciences:
Research is under-resourced and the system is set to fail unless significant change: how to solve it?
We do not have enough ground truth data for most evidence types: the transfer, persistence and background abundance of an object will allow us to answer the how and when something happened.
ERA - European Renal Association
@ERAkidney
Communication challenge; what I said vs what you heard ↪️ although your listener might be presented with brilliant information, many times it makes no sense to them. We need to ask the right questions.
ERA - European Renal Association
@ERAkidney
We need to dare and try new things and think outside the box!
On behalf of the SoMe team, and representer of true crime enthusiasts, @federicanevevig and @drbarbateba, signing off -
ERA - European Renal Association
@ERAkidney
Between Graft and Brain: The Neurological Toll of Immunosuppression
🗣️ Dr. Jolanta Malyszko
#era26Post not available here, view on X
ERA - European Renal Association
@ERAkidney
6/
Screening & management framework
ERA - European Renal Association
@ERAkidney
-
ERA - European Renal Association
@ERAkidney
Recurrence of Glomerular Diseases After Kidney Transplantation
🗣️ Dr. Safak Mirioglu
#era26Post not available here, view on X
ERA - European Renal Association
@ERAkidney
6/
Take-home messages
ERA - European Renal Association
@ERAkidney
-
ERA - European Renal Association
@ERAkidney
📍 Now at #era2026
Session: Public Health and CKD
📝 Growing global burden of CKD, prevention strategies, and public health approaches to improve outcomes.
Chair : Peter Stenvinkel & Leva Ziedina
🗣️ Ronald Gansevoort ; Samira Bell ; Hans-Joachim Anders
🔍 Can population screening for albuminuria be implemented responsibly?
International screening criteria and their application in CKD prevention .
on behalf of social media team @AnnaTchika92 @LazaroIbrain
ERA - European Renal Association
@ERAkidney
🔴 High Albuminuria: An Early Warning Sign
📌 Strong predictor of:
CVD
CKD Progression
🔍 Early Detection Matters
🗣️ Ronald Gansevoort
#era2026 #kidneyhealth
ERA - European Renal Association
@ERAkidney
💻 Big data in CKD
🗣️Prof. Samira Bell
📊 Benefits and Harms of Medicines in CKD
📌 StoppinVs Continuing Metformin in Patients with advanced CKD ?
🔍 The continued use of metformin may be appropriate when Egfrfalls below 30mL/min/1.73m2
.
#era2026 #ckd #bigdata #kidneyhealth #nephrology
ERA - European Renal Association
@ERAkidney
🔄 A Paradigm shift in CKD
Damage accumulates over a lifetime
⚖️ Workload vs. Capacity
📌 Future Priorities :
✅ Prevention ✅ Risk-factor control ✅ Targeted therapies ✅ Advocacy & policy action
🎯 Maintain Kidney Health — Not Just Provide KR
🗣️ Hans-Joachim Anders -
ERA - European Renal Association
@ERAkidney
#era26 @ERAkidney
Symposium AKI & Critical Care Nephrology
📝Open your mind in Extracorporeal blood purification therapies in sepsis-associated AKI
Chair: Nicholas Selby & Ana Belen Sanz Bartolomé
1️⃣ Decoding AKI: Subphenotypes and Personalized Therapeutics
🗣️Greet De Vlieger
📍Sepsis associated AKI: almost 50% of all AKI in ICU❗️
📍why studies are negatives? ➡️ Different phenotypes ❗️
📕The phenotypes with the highest risk must be selected so that they can opt for more personalized treatments. -
ERA - European Renal Association
@ERAkidney
🧵1/ 💭 Open your mind- Newer agents for the treatment of resistant hypertension: what does the future hold?
Chairs: Pantelis Sarafidis, Matias Trillini
💊Session-3 RNA interfence agents targeting angiotensinogen: what is new?
🗣️ Speaker: A. H. Jan Danser
#era26Post not available here, view on X
ERA - European Renal Association
@ERAkidney
5/ reverse sRNA silencing developed in case angiotensinogen system needed ⚪️for example in pregnancy or hypovolemic shock
ERA - European Renal Association
@ERAkidney
6/#era26
Signing off, on behalf of ERA social media team, Rezzan Eren Sadioğlu @ErenRezzan -
ERA - European Renal Association
@ERAkidney
❓️Dihydropyridine calcium channel blockers can increase the risk of progression? #era26
Post not available here, view on X
ERA - European Renal Association
@ERAkidney
❗️No difference in dose of medication!
⬇️The negative impact of the kidney remains!
ERA - European Renal Association
@ERAkidney
🚫In patients with type 2 diabetes receiving RASi and SGLT2, DCCB increased risk of CKD progression. On behalf of social media team @AgavriloaeiB
-
ERA - European Renal Association
@ERAkidney
Efficacy and safety abd pharmacokinatics/ pharmacodynamics of Crovalimab for aHUS phase 3 Commute a trial by @DrBradleyDixon
#era26
ERA - European Renal Association
@ERAkidney
1/1🌸 study design and dosing regimen in adults and adolescents is different than the previous study discussed
ERA - European Renal Association
@ERAkidney
2/1🌸 the study met its primary efficacy end point and rapidly drop in complements was seen
ERA - European Renal Association
@ERAkidney
3/1🌸 side effects profile more than in pediatrics
ERA - European Renal Association
@ERAkidney
4/1🌸 more than 89% preferred to switch to Crovalimab
ERA - European Renal Association
@ERAkidney
5/1🌸 conclusion of the session thank you
-
ERA - European Renal Association
@ERAkidney
🧵1/ 💭 Open your mind- Newer agents for the treatment of resistant hypertension: what does the future hold?
Chairs: Pantelis Sarafidis, Matias Trillini
💊Session-2 Endothelin antagonism: a new era for resistant hypertension
🗣️Speaker: Neeraj Dhaun
#era26
ERA - European Renal Association
@ERAkidney
2/ ⚪️Resistant hypertension has multiple reasons and using endotelin antagonism is one of the treatment targets.
💊🧪Aprocicentan is a selective endotelin A blocker but macicentan its active metabolite blocks A+B and it has low fluid retention impacts.
#era26Post not available here, view on X
ERA - European Renal Association
@ERAkidney
4/ Summary for endotelin antagonism for hypertension 👇🏻
ERA - European Renal Association
@ERAkidney
5/#era26 👋🏻Signing off, on behalf of ERA social media team, Rezzan Eren Sadioğlu @ErenRezzan
-
ERA - European Renal Association
@ERAkidney
⚠️Drug target mendelian randomization in diabetic kidney disease! #era26
Post not available here, view on X
ERA - European Renal Association
@ERAkidney
Therapies in DKD!
⬇️SCL5A2 - OR 0.73
⬇️GLP1R - OR 0.79
⬇️ACE - OR 0.82
⬇️GIPR -OR 0.82 #era26
ERA - European Renal Association
@ERAkidney
❗️For every drug under investigation in DKD, the human genome already holds a preliminary verdict
By ERA social media team @AgavriloaeiB -
ERA - European Renal Association
@ERAkidney
🔥Coming next in Late Breaking Clinical Trials 2, last presentation#ERA26
⏩Efficacy, safety and pharmacokinetics/pharmacodynamics of crovalimab for paediatric atypical haemolytic uraemic syndrome: Phase III COMMUTE-p trial 🎙️Presented by Maria Helena Vaisbich
📍aHUS: rare complement-mediated TMA
💉Crovalimab: SC C5 inhibitor dosed every 4 weeksPost not available here, view on X
ERA - European Renal Association
@ERAkidney
4/ Safety #era26
⚠️Well tolerated; no new safety signals
⚠️No deaths or treatment discontinuations
⚠️Serious infections: 33% (naïve) vs 20% (switch)
ERA - European Renal Association
@ERAkidney
5/ Conclusion: effective TMA control, favorable safety profile, and strong patient/caregiver preference for SC administration
#era26
🧵 by @CristinaDeReins -
ERA - European Renal Association
@ERAkidney
Late breaking trials 2
Efficacy, safety and pharmacokinetics/pharmacodynamics of crovalimab for paediatric atypical haemolytic uraemic syndrome: Phase III COMMUTE-p trial
By Maria Helena Vaisbich
#era26Post not available here, view on X
ERA - European Renal Association
@ERAkidney
2/2🌸 the study design
Post not available here, view on X
ERA - European Renal Association
@ERAkidney
6/1🌸 the median time for complete response 1-2 weeks
ERA - European Renal Association
@ERAkidney
7/1🌸all patients were off dialysis !!!!
ERA - European Renal Association
@ERAkidney
8/1🌸 serum concentration if Crovalimab concentration remained above the target level and complements are low rapidly
ERA - European Renal Association
@ERAkidney
9/1🌸 amazing safety profile
ERA - European Renal Association
@ERAkidney
10/1🌸 79% of care givers preferred Crovalimab
ERA - European Renal Association
@ERAkidney
11/1🌸 conclusions
-
ERA - European Renal Association
@ERAkidney
🧵1/ 💭Open your mind- Newer agents for the treatment of resistant hypertension: what does the future hold?
Chairs: Pantelis Sarafidis, Matias Trillini
💊Session-1 Aldosterone synthase inhibition for uncontrolled hypertension
🗣️Speaker: Roberto Minutolo
#era26Post not available here, view on X
ERA - European Renal Association
@ERAkidney
3/ ⚪️treatment with MRA leads aldosteron breakthrough.
And it has deterious effects. ⚪️Increased aldosteron is related to mortality.
⚪️Second generation selective aldosterone syntase inhibitors inhibit only aldosterone synthesis without doing so on cortisol.
#era26
ERA - European Renal Association
@ERAkidney
4/ 3 agents available: baxdrostat, vixadrostat, lorundrostat 🧪💊
Study results: they all decreased blood pressure both night and day.
And decreased albuminuria in CKD population
Hyperkalemia was higher but discontinuation due to it was low.
#era26
ERA - European Renal Association
@ERAkidney
5/ Although these drugs came out for resistant hypertension these will probably be disease modifying therapies for CKD.
Limitations and future studies are 👇🏻#era26
ERA - European Renal Association
@ERAkidney
6/ 👋🏻Signing off, on behalf of ERA social media team, Rezzan Eren Sadioğlu @ErenRezzan #era26
-
ERA - European Renal Association
@ERAkidney
Late breaking trials session 2:
Efficacy and Safety of Obinutuzumab Compared with Tacrolimus in Primary Membranous Nephropathy: Topline Results of the Phase III MAJESTY Trial
Fernando Custodio Fervenza (Rochester, US)
#era26 @fervenzaf
ERA - European Renal Association
@ERAkidney
2/2🌸 the design of the MAJESTY trial
Post not available here, view on X
ERA - European Renal Association
@ERAkidney
3/2🌸 randomization was 1:1 on each arms
Post not available here, view on X
ERA - European Renal Association
@ERAkidney
6/2🌸 data of patients meeting escape critetia based on time
Patients with persistent proteinuria at week 52 to 104 in the obinutuzumab received retreatment doses
ERA - European Renal Association
@ERAkidney
7/2🌸 Patients Demographics , both arms had patients with heavy proteinuria
Post not available here, view on X
ERA - European Renal Association
@ERAkidney
10/2🌸 Prolonged remission maintained in the Obinutuzumab group
ERA - European Renal Association
@ERAkidney
11/2🌸 side effects profile most likely infusion reactions in Obinutuzumab arm
ERA - European Renal Association
@ERAkidney
12/2🌸 Conclusions
-
ERA - European Renal Association
@ERAkidney
Another sim publication during #era26
👏Congrats @fervenzaf & team
NEJM
@NEJM
Presented at #era26:
In this 104-week trial involving patients with primary membranous nephropathy, the type II anti-CD20 antibody obinutuzumab was superior to the calcineurin inhibitor tacrolimus in inducing complete remission. Full phase 3 MAJESTY trial results: www.nejm.org/doi/full/10.1056/NEJMoa2602678
@ERAkidney -
ERA - European Renal Association
@ERAkidney
🔥During LBCT2 #era26 @brendonneuen presented a prespecified exploratory analysis of FIND-CKD
▪️randomized clinical trial that enrolled 903 participants with non-DM CKD
🎯Primary: total eGFR slope.
🎯Secondary: chronic slope, UACR, kidney failure/≥40% eGFR declinePost not available here, view on X
ERA - European Renal Association
@ERAkidney
7/ #era26
Safety
⚠️Any AE: 68.6% vs 65.6%.
⚠️Serious AE: 19.5% vs 21.4%.
⚠️Hyperkalemia: 16.4% vs 15.3% (serious: 0.9% both groups)
ERA - European Renal Association
@ERAkidney
🏠Take-home #era26
📍Finerenone slowed eGFR decline.
📍Reduced albuminuria by ~42%
📍Lowered risk of kidney failure/≥40% eGFR decline
📍Effects consistent across major glomerular diseases
📍Safety profile broadly similar to place
✍️ by @CristinaDeReins
ERA - European Renal Association
@ERAkidney
👏Simultaneous @JAMA_current publication #era26
jamanetwork.com/journals/jama/fullarticle/2850123?guestAc… -
ERA - European Renal Association
@ERAkidney
Late breaking clinical trials 2:
The Use of Rituximab In the treatment of Nephrotic Glomerulonephritis (TURING): a multicentre, double-blind, randomised, placebo-controlled trial
By Lisa Willcocks (Cambridge, UK) &
Megan Griffith @megan_griffith1 (London, UK)
#era26
ERA - European Renal Association
@ERAkidney
2/1🌸 survival is concerning
Post not available here, view on X
ERA - European Renal Association
@ERAkidney
5/1🌸 study design
ERA - European Renal Association
@ERAkidney
4/1🌸 the relapse is high despite treatment
Post not available here, view on X
ERA - European Renal Association
@ERAkidney
8/1🌸 baseline data for the relapsing patients
ERA - European Renal Association
@ERAkidney
9/1🌸
ERA - European Renal Association
@ERAkidney
10/1🌸 regimens of treatment
ERA - European Renal Association
@ERAkidney
🌸 no difference in median days in all groups
Post not available here, view on X
ERA - European Renal Association
@ERAkidney
12/1🌸 adverse effects were more in Ritux group but because they were followed for more time but when adjusted it is the same
ERA - European Renal Association
@ERAkidney
13/1🌸 Summary
-
ERA - European Renal Association
@ERAkidney
JAMA
@JAMA_current
Among adults with chronic #kidney #disease (#ckd) due to glomerular diseases, finerenone slowed eGFR decline, reduced albuminuria, and lowered risk of kidney failure, with consistent benefits across disease subtypes and in those using #sglt2 inhibitors.
#era26 @ERAkidney -
ERA - European Renal Association
@ERAkidney
The Lancet
@TheLancet
Presented today at #era2026, the INFINITY trial found that finerenone reduced the risk of chronic kidney disease progression, including kidney failure alone, and reduced heart failure hospitalisation, cardiovascular death, and all-cause death.
Explore the research: www.thelancet.com/journals/lancet/article/PIIS0140-6736(2… @ERAkidney -
ERA - European Renal Association
@ERAkidney
🔥Late Breaking Clinical Trials 2 #era26
The first presentation will be about finerenone in patients with chronic kidney disease
@VladoPerkovic emphasized that 400-500 million people worldwide have non-diabetic CKD
💊Finerenone, a nonsteroidal mineralocorticoid receptor antagonist, improved CV and kidney outcomes in diabetic kidney disease. But does it work in non-diabetic CKD?Post not available here, view on X
ERA - European Renal Association
@ERAkidney
7/ Take-home message #era26
📍Finerenone slowed CKD progression in non-diabetic CKD
📍Reduced eGFR decline and kidney-CV events
📍Generally well tolerated despite more hyperkalemia
ERA - European Renal Association
@ERAkidney
8/ Simultaneous publication @NEJM #era26
🧵 by @CristinaDeReins
www.nejm.org/doi/10.1056/NEJMoa2604625 -
ERA - European Renal Association
@ERAkidney
❗️Kidney and lipid droplets!
New apolipoprotein and novel therapies! #era26Post not available here, view on X
ERA - European Renal Association
@ERAkidney
❗️Apolipoprotein M - a new target!
✅️Apolipoprotein M is a protein which is mainly located in HDL particles
ERA - European Renal Association
@ERAkidney
⬇️If you reduce glomerular lipotoxicity you can reduce kidney progression!
⬇️Reduced droplets accumulation have impact on proteinuria! #era26
By ERA social media team @AgavriloaeiB -
ERA - European Renal Association
@ERAkidney
#era26 @ERAkidney
Symposium AKI & Critical Care Nephrology
📝Open your mind in Extracorporeal blood purification therapies in sepsis-associated AKI
Chair: Nicholas Selby & Ana Belen Sanz Bartolomé
2️⃣ Beyond Renal Support: Strategies for Bacteria, Virus, and Endotoxin Removal
🗣️: Thomas Rimmelé
🧵1 /5 Hemoadsortion
📍polymyxin B hemoperfusion-> CT: old negative trials❗️(Unselected patients?)
📍TIGRIS trial: positive trial! ➡️ Precision medicine 👍Post not available here, view on X
ERA - European Renal Association
@ERAkidney
#era26 🧵4/5
📕Seraph 100 heparin therapy
❗️Useful in COVID-19
❗️be careful with antibiotic removal
❗️septic vascular surgery patients
ERA - European Renal Association
@ERAkidney
#era26 🧵5/5 when to use seraph❓
*️⃣ Suspicion of bacteriemia!
Signing off, on behalf of #era social media team, Francisco Valga @Nefrogeek -
ERA - European Renal Association
@ERAkidney
🔥Next at #era26 Emerging Trial Evidence in Hypertension, CKD, and Transplantation
⏩ Safety and synergy of finerenone and empagliflozin in lowering blood pressure 🎙️ Presented by @AgarwalRajivMD
🏆1st simultaneous publication of the day
⚠️Finerenone + empagliflozin may have complementary BP-lowering effects
🔎This analysis assessed BP reduction, safety, and UACR mediationPost not available here, view on X
ERA - European Renal Association
@ERAkidney
5/ Conclusion #era26
👉Combination therapy produced the largest BP reductions
👉BP lowering occurred mainly when baseline SBP was ≥130 mmHg
BP reduction did not explain UACR lowering
👉SGLT2i + finerenone may offer additive kidney protection
🧵 by @CristinaDeReins
ERA - European Renal Association
@ERAkidney
#era26 sim publication @HyperAHA
Safety and Synergy of Finerenone and Empagliflozin in Lowering Blood Pressure
www.ahajournals.org/doi/10.1161/HYPERTENSIONAHA.126.27036 -
ERA - European Renal Association
@ERAkidney
#era26 @ERAkidney
Symposium AKI & Critical Care Nephrology
📝Open your mind in Extracorporeal blood purification therapies in sepsis-associated AKI
Chair: Nicholas Selby & Ana Belen Sanz Bartolomé
3️⃣ Filtering the Fire: Modulation of Complement and Cytokines
🗣️: Rossana Franzin (Italy)
🧵1 /5 Sepsis-associaed -AKI Pathophysiology!
Acute inflammatory phase: cytokine storm :
📍Innate inmune cells interact with adaptive inmunePost not available here, view on X
ERA - European Renal Association
@ERAkidney
#era26 🧵4/5
📍CER-001 therapy:
📕Clinical trial: RACERS study aims to reduce systemic inflammation and the cytokine storm, and improve survival.
ERA - European Renal Association
@ERAkidney
#era26 🧵5/5 Conclusions
Signing off, on behalf of #era social media team, Francisco Valga @Nefrogeek -
ERA - European Renal Association
@ERAkidney
#era26
#dialysislife
🪑🪑Philip Ali, Elle Schaffer
🧵Life on Dialysis: Transitions, Registries and Risk Stratification
1/
Examining the short-term safety and efficacy of the portable WEarable Artificial KIDney (WEAKID) for peritoneal dialysis – a first-in-human trial
🗣️Dian Bolhuis
🤨Issue with APD machines are heavy and solute clearance.
🎯Improve QOL, Better clearance , Longer treatment tolerances (1 XC/ day)
🚀
Reduce diasylate recirculation
Modelling to understand treatment
Redesign with patient focus groupPost not available here, view on X
ERA - European Renal Association
@ERAkidney
Conclusion:
🚩Shared decision making with individual stakeholders impact outcomes
ERA - European Renal Association
@ERAkidney
-
ERA - European Renal Association
@ERAkidney
#era2026
39,750 patients. 583,457 HDF sessions.
🏋️ Lean tissue mass → higher substitution volume
🫃 Fat tissue mass → no independent association
💡Perhaps it's time to move beyond body size and consider body composition when evaluating and comparing convective dose delivery in HDF.
#nephrology #dialysis #hdf #bodycomposition -
ERA - European Renal Association
@ERAkidney
1st simultaneous publication of the day #era26 @HyperAHA
📍Safety and Synergy of Finerenone and Empagliflozin in Lowering Blood Pressure
✍️By @AgarwalRajivMD and co
www.ahajournals.org/doi/10.1161/HYPERTENSIONAHA.126.27036 -
ERA - European Renal Association
@ERAkidney
Immune Drivers of Graft Loss: Beyond Histology with Imaging Mass Cytometry | #era26
Immunological causes are the most important reason for graft loss. Conventional microscopy is not enough. Mariam Alexander showed how imaging mass cytometry plus artificial intelligence reveals the true pathogenesis.
The Problem: Histology Misses Complexity
Banff limits: Banff classification does not consider cellular composition of inflammatory infiltrate, only intensity and localization
Rejection costs grafts: Both first and second T cell mediated rejection events correlate with death-censored and all-cause graft loss. After first T cell mediated rejection, 64 percent of recipients develop persistent or subsequent rejection on follow up biopsies
Alloimmune dominates: Alloimmune causes account for 214 of 553 total graft failures 38.7 percent. After year 1, alloimmune injury is the main driver: 1 to 5 years 49.9 percent, more than 5 years 43.3 percent
Imaging Mass Cytometry Reveals Heterogeneity
2D kidney atlas: Full nephron mapped with specific markers. Each segment has distinct immune cell neighborhoods
Rejection is not one disease: Antibody mediated rejection and T cell mediated rejection are highly heterogeneous, not single entities. Machine learning identifies different patterns within each
Disease-specific cells:
- T cell mediated rejection: memory T cells persist in allografts with interstitial fibrosis and tubular atrophy
- BK nephropathy: B cell enrichment
- Acute kidney injury: CD4 memory T cells and T helper cells
- Lupus nephritis: macrophages are important
Why This Matters
Better diagnosis: Quantifies immune cell types, spatial relationships, and cell-cell interactions across entire tissue sections
Better prognosis: Subtyping leukocytes helps refine prognosis and predict treatment response
Unmet needs: Prophylaxis for rejection and better treatment of acute rejection still needed
Takeaway: Graft loss is immune-driven but histology is blind to cellular complexity. Imaging mass cytometry maps the full immune landscape at single cell resolution. Alloimmune injury dominates after year 1, and rejection heterogeneity explains treatment failures. Molecular mapping will reshape how we diagnose and treat kidney transplant rejection.
Presentation: Mariam Alexander | Tweet: @eroldemir83 on behalf of SoMe Team -
ERA - European Renal Association
@ERAkidney
New devices and technologies for dialysis access.
🪑: Dimitrios Goumenos, Maria João Teixeira Guedes Marques
3/3 PD catheter insertion: different approaches
📌 Different options (percutaneous, mini-laparotomy, laparoscopy…) = different involvement and autonomy of the nephrologist
📌 Importance of a pre-operative mapping for PD catheter insertion with US (as well as for fistulas)
📌 No technique showed clear superiority over the others
📌 A personalized approach is the best solution
🎤 Jernej Pajek
✍️ @FedericaNeveVig on behalf of SoMe team #era26 -
ERA - European Renal Association
@ERAkidney
#era2026
💡Interesting work comparing HV-HDF and HDx using different β2-microglobulin clearance metrics.
✅As expected, HV-HDF achieved higher β2M clearance.
✅The novel aspect was the evaluation of eCDCβ2M, an equivalent continuous clearance metric that may better reflect middle-molecule kinetics than traditional reduction ratios or urea-derived measures.
The next challenge: proving that these metrics predict clinical outcomes, not just toxin removal.
#nephrology #dialysis #hdf #hdx -
ERA - European Renal Association
@ERAkidney
🔥Next at #era26 Emerging Trial Evidence in Hypertension, CKD, and Transplantation
Moderated
⏩ EKFC outperforms CKD-EPI 2009 and 2021 in Kidney Transplant Recipients when Compared to Iohexol Serum Clearance (mGFR) – a National Cohort Study
🎙️Presented by Ingrid Charlotte Kongerud
🔎EKFC was compared with CKD-EPI 2009/2021 against iohexol-measured GFR
🎯Goal: identify the most accurate eGFR equation in transplant recipientsPost not available here, view on X
ERA - European Renal Association
@ERAkidney
5/ #era26
📍EKFC performed best (P30 77.1%, bias 4.9)
📍Accuracy improved at higher mGFR
📍Outperformed all other equations
📍Maintained performance at 8 weeks and 12 months post-transplant
ERA - European Renal Association
@ERAkidney
6/ Conclusion #era26
📍EKFC was the most accurate equation
📍Only EKFC and MDRD-4 achieved P30 >75%
📍mGFR remains preferred for key clinical decisions
⚠️Example
▪️CKD-EPI: +27% GFR overestimation
▪️EKFC: +15% overestimation
ERA - European Renal Association
@ERAkidney
✍️ Signing off, on behalf of #era26 social media team @CristinaDeReins
-
ERA - European Renal Association
@ERAkidney
Live from #era26
Starting early in the morning with New ways of treating lupus nephritis 🦋
📍Concludes with: How to overcome drug non-adherence in LN as a cause for ""refractory LN""?
Speaker 🗣️: Ioannis Parodis @IoannisParodis
ERA - European Renal Association
@ERAkidney
2/ ‼️Adherence is a treatment target ‼️
⏩ Non-adherence motives: logistics, age, not trusting the treatment
⏩ High rates of Non-adherence
ERA - European Renal Association
@ERAkidney
3/ Addressing Non-adherence
⏩ Differentiating between true refractory vs. apparent refractory Lupus
⏩ Identifying the problem, transparency, discussing the issues with the patient
ERA - European Renal Association
@ERAkidney
4/ Need for new outcome definitions?
⏩ Lower threshold for proteinuria in complete remission
⏩ Actively ask about adherence
On behalf of SOME team, @AncaSt13 ✨🎙️ -
ERA - European Renal Association
@ERAkidney
💡Is the benefit of #hdf partly a vascular access story?
⚠️High-volume #hdf is associated with lower mortality and hospitalizations, but a substantial part of this benefit may be linked to vascular access type.
🤖Using mediation analysis in >27,000 patients, AVF use explained
✅46% of the mortality benefit and
✅63% of the hospitalization benefit.
#era26 #nephrology -
ERA - European Renal Association
@ERAkidney
Kidney outcome in type 2 diabetes!
What if you add GLP 1 in patients with CKD and type 2 diabetes? #era26Post not available here, view on X
ERA - European Renal Association
@ERAkidney
🎯GLP 1 is associated with lower risk of kidney outcomes! #era26
ERA - European Renal Association
@ERAkidney
🎯GLP 1 is associated with lower risk of MACE and HF!
So, start GLP 1 in type 2 diabetes! #era26, by ERA social media team @AgavriloaeiB -
ERA - European Renal Association
@ERAkidney
🔴 Happening Today at #era26: Late Breaking Clinical Trials II
🕚 11:15–12:45 (BST)
📺 Livestream available to anyone with a My ERA account, no Congress registration needed 👉 era-congress.virtual-meeting.org/pag/session/86188 -
ERA - European Renal Association
@ERAkidney
CMV Immunity in Transplant: Gamma Delta T Cells & Adoptive Therapy | #era26
Drug resistance in cytomegalovirus treatment is a serious problem. New data from Lionel Couzi shows maribavir is effective, and T cell immunotherapy restores viral control even under immunosuppression.
Why T Cells Matter in CMV
Key players: CD8 alpha beta T cells and gamma delta T cells are key players in cytomegalovirus-specific cell-mediated immunity. Both show concomitant expansion after cytomegalovirus infection
Protection shown in mice: Cytomegalovirus infection occurs in mice without T cell response. CD3 deficient mice had 0% survival by day 50, while mice with only gamma delta T cells or only CD8 alpha beta T cells survived. Gamma delta T cells use major histocompatibility complex-independent antigen sensing vs CD8 T cells use major histocompatibility complex-dependent sensing
Predicts recurrence: After curative treatment with undetectable viral load, patients with positive cytomegalovirus-cell mediated immunity by QuantiFERON-CMV assay had no recurrence without prophylaxis. Patients with negative immunity had high recurrence and needed prophylaxis
Adoptive T Cell Therapy Restores Control
Concept: Anti-cytomegalovirus immunotherapy restores potent anti-cytomegalovirus cell immunity. After refractory cytomegalovirus infection, adoptive T cell transfer leads to lifelong control of the virus
Clinical data: 21 solid organ transplant recipients with persistent cytomegalovirus infection or disease were included. Blood was collected, peripheral blood mononuclear cells stimulated with cytomegalovirus peptide pools from pp65, pp50, IE-1, glycoprotein H, glycoprotein B, plus interleukin 21 and interleukin 2 for 14 days culture
Results: 13 patients received maximum 6 doses of adoptive T cell therapy with 42 to 240 x 10 to the power 6 amplified cytomegalovirus-specific CD4 and CD8 T cells. Graph shows cytomegalovirus load dropped dramatically after therapy while interferon gamma positive CD8 T cells increased. Immune reconstitution occurred despite continuation of immunosuppressive therapies
Gamma Delta T Cell Therapy - DOT Cells
Clonal expansion protects: Clonal expansion of gamma delta T cells was absent in patients who developed cytomegalovirus disease. Gamma delta T cells display cytomegalovirus-induced interferon gamma secretion and control cytomegalovirus dissemination in vitro
Works under immunosuppression: DOT cells respond to cytomegalovirus despite tacrolimus, cyclosporine, everolimus. Only mycophenolate mofetil strongly suppressed interferon gamma production
Autologous approach: Cytomegalovirus reactive DOT cells can be expanded from solid organ transplant recipients for autologous adoptive cell therapy. Good Manufacturing Practice production and phase 1 safety trial planned
Takeaway: For drug resistant cytomegalovirus, maribavir is an option. But restoring T cell immunity is the long term solution. Adoptive CD8/CD4 T cell therapy and gamma delta DOT cell therapy can rebuild viral control even with immunosuppression. Measuring cytomegalovirus-cell mediated immunity can predict who needs prophylaxis vs who is protected.
Slides shown: Adoptive T cell therapy workflow and results, gamma delta T cell protection, immunity assay predicts recurrence | Presentation: Lionel Couzi | Tweet: @eroldemir83 on behalf of SoMe Team -
ERA - European Renal Association
@ERAkidney
🔥Next into Emerging Trial Evidence in Hypertension, CKD, and Transplantation
⏩ Reductions in albuminuria in patients with hypertensive renal disease after radiofrequency renal denervation: results from Global SYMPLICITY Registry 🎙️Presented by @markus_schlaich
#era26
🎯 Current analysis examines whether renal denervation (RDN) reduces albuminuriaPost not available here, view on X
ERA - European Renal Association
@ERAkidney
4/ #era26
📍Office SBP fell by ~9–22 mmHg after RDN
📍Antihypertensive medication burden remained stable
📍eGFR remained largely stable through 24 months in both groups
ERA - European Renal Association
@ERAkidney
Conclusion #era26
🧵 by @CristinaDeReins -
ERA - European Renal Association
@ERAkidney
Association of arterial hypertension with larger kidney size!
This association is stronger in males compared to females! #era26Post not available here, view on X
ERA - European Renal Association
@ERAkidney
Large study with 1916 pts where they have kidney size by MRI! #era26
ERA - European Renal Association
@ERAkidney
🎯Hypertension is associated with larger kidney size!
This association were stronger in males! By ERA social media team @AgavriloaeiB -
ERA - European Renal Association
@ERAkidney
💡Could improved ultrafiltration tolerance explain the survival benefit of high-dose HDF?
⚠️Post-hoc analysis of #convince (n=1360) found:
🔹 No difference in ultrafiltration rate over time between high-dose #hdf and high-flux HD
🔹 Similar association between UFR and mortality in both groups
👉 UFR does not appear to explain the survival benefit observed with HDF.
#era26 #nephrology -
ERA - European Renal Association
@ERAkidney
New devices and technologies for dialysis access.
🪑: Dimitrios Goumenos, Maria João Teixeira Guedes Marques
2/3
The burden of CKD and KRT is growing worldwide, but there are big differences in the distribution of vascular accesses (VA) among countries.
A well functioning VA is critical for adequacy of HD and survival, so a careful selection and a constant follow up are needed. Current scientific advances and n VA are fascinating, but the most important thing to bear in mind is quality of life of patients.
🎤 Tamara Jemcov
✍️ @FedericaNeveVig on behalf of SoMe team #era26 -
ERA - European Renal Association
@ERAkidney
Live from #era26
Starting early in the morning with New ways of treating lupus nephritis 🦋
Moderators: Miriam Zacchia and Francesco Trepiccione @tr3po
📍 First: Voclosporin or Tacrolimus?
Speaker 🗣️: Eleni FrangouPost not available here, view on X
ERA - European Renal Association
@ERAkidney
4/ Conclusions:
⏩ Voclosporin offers predictable exposure without drug-level monitoring
⏩ Tacrolimus offers flexibility, familiarity, and lower cost.
⏩ Which CNI best fits the patient in front of you.
⏩ No direct comparison between the two
ERA - European Renal Association
@ERAkidney
5/ On behalf of SOME team, @AncaSt13 ✨🎙️
-
ERA - European Renal Association
@ERAkidney
Association between blood pressure and kidney function in a longitudinal population!
Can something predict eGFR decline?
#era26Post not available here, view on X
ERA - European Renal Association
@ERAkidney
Exposure to hypertension will predict eGFR decline!
See in thr figure how is the impact of hypertension on eGFR decline! #era26
ERA - European Renal Association
@ERAkidney
In conclusion - arterial hypertension is associated with fasyer eGFR decline!
#era26, by ERA social media @AgavriloaeiB -
ERA - European Renal Association
@ERAkidney
Next in Emerging Trial Evidence in Hypertension, CKD, and Transplantation #era26
⏩ High-Dose vs. Standard-Dose Influenza Vaccine in Chronic Kidney Disease: A prespecified FLUNITY-HD Subgroup Analysis
🎙️Presented by Katja Bartholdy
🔎Premise:
🦠Influenza triggers respiratory, CV, neurologic, metabolic, and kidney complications, including AKI
💉Influenza vaccination reduces major CV events by ~34%
ERA - European Renal Association
@ERAkidney
2/ #era26
💉High-dose influenza vaccines generate stronger and more durable antibody responses in hemodialysis patients
🔎FLUNITY-HD pooled data from DANFLU-2 (332k) and GALFLU (134k) to assess severe outcomesPost not available here, view on X
ERA - European Renal Association
@ERAkidney
5/ Limitations: the study was not powered for subgroup analysis #era26
ERA - European Renal Association
@ERAkidney
✨Conclusion: HD-IIV provided greater protection than SD-IIV against a wide range of hospitalization outcomes, with consistent findings regardless of preexisting CKD #era26
🧵by @CristinaDeReins -
ERA - European Renal Association
@ERAkidney
⚠️Intradialytic hypotension remains one of the most frequent complications of hemodialysis.
✅At #era26, investigators from Taiwan presented an explainable real-time AI system trained on >175,000 HD sessions.
💡Beyond predicting IDH (AUC 0.88), prospective implementation reduced IDH events from 16.4% to 13.1% (p=0.03).
🤖AI may soon move from prediction to prevention in dialysis care.
#nephrology #hemodialysis #ai -
ERA - European Renal Association
@ERAkidney
Extracellular Vesicles in Transplant & Kidney Disease | #era26
Extracellular vesicles are released from all cells. They play roles in antigen presentation, immune regulation, and metabolic signaling.
Biology & Measurement
Can be measured in blood but not in urine
Appear after ischemia and are linked to ferroptosis, a type of cell death
Involved in both induction of immune response and induction of immune tolerance
Role in Transplant Rejection
Donor-derived extracellular vesicles cause B cell activation and donor specific antibody production
Complement system activation has been shown through extracellular vesicles
In acute kidney injury of the graft, aquaporin 2 release has been demonstrated via extracellular vesicles
Complement activation can be detected using extracellular vesicles
Role in Autoimmune Kidney Disease
Carry autoantigen-antibody complexes in autoimmune kidney diseases
Associated with glomerulosclerosis
Takeaway: Extracellular vesicles act as messengers between cells in transplant rejection and kidney disease. They link immune activation, complement activation, and tissue injury. Potential biomarkers and therapeutic targets.
Presentation: Fabian Braun | Tweet: @eroldemir83 on behalf of SoMe Team -
ERA - European Renal Association
@ERAkidney
Live from #era26
Starting early in the morning with New ways of treating lupus nephritis 🦋
Moderators: Miriam Zacchia and Francesco Trepiccione @tr3po
📍 First: Obinutuzumab or Belimumab?
Speaker 🗣️: Luis Fernando Quintana PorrasPost not available here, view on X
ERA - European Renal Association
@ERAkidney
4/ Combination OBI+BELI: why not?
⏩ Targeted B-cell depletion + BAFF blockade may offer more durable immunological control than either approach alone.
ERA - European Renal Association
@ERAkidney
5/ Time to open your mind and dream on
⏩ Going beyond standard of care in Lupus
On behalf of SOME team, @AncaSt13 🎙️✨ -
ERA - European Renal Association
@ERAkidney
New devices and technologies for dialysis access.
🪑: Dimitrios Goumenos, Maria João Teixeira Guedes Marques
1/3
From glass needles and Scribner’s shunt to endoFAV, drug coated balloons and new devices: since the beginning of HD, vascular accesses (VA) have represented a crucial issue for nephrologists.
Many aspects can be considered in improving the outcomes of VA, including industry pressure, epidemiological changes in patients population, cost/benefits balance.
Open your mind to new opportunities in VA, but at the same time open your mind to the necessity of RCT (which are lacking) in this field.
🎤 David Kingsmore
✍️ @FedericaNeveVig on behalf of SoMe team #era26 -
ERA - European Renal Association
@ERAkidney
Etiology of kidney failure across 11 world rrgions!
🌍ApolloDialDb - a large database!Post not available here, view on X
ERA - European Renal Association
@ERAkidney
Etiologh od ESRD!
⚡️First causes - diabetes and hypertension!
ERA - European Renal Association
@ERAkidney
🎯Conclusion!
Why is important to have a large database!
Hypertension ans diabetes are the first etiology across this data base!
From ERA social media team @AgavriloaeiB -
ERA - European Renal Association
@ERAkidney
Conclusion #era26
🧵 by @CristinaDeReins -
ERA - European Renal Association
@ERAkidney
🔥Happening now at #era26 Emerging Trial Evidence in Hypertension, CKD, and Transplantation
💬Moderated by @KateIsabelle24 and Patrick Mark 🏁 Starting with: Zilebesiran as Add-on Treatment to RAAS Inhibitors for Patients with Hypertension: Data From KARDIA-2 and KARDIA-3 Phase 2 Trials 🎙️Presented by David C. Wheeler
#era26
💊 Zilebesiran is an investigational RNA interference therapeutic, which suppresses the RAAS pathwayPost not available here, view on X
ERA - European Renal Association
@ERAkidney
3/ #era26
📍Prior dual RAAS blockade: minimal BP benefit, no CV benefit, more adverse events
🔎Analysis pooled KARDIA-2/3 patients already on ACEi/ARB
👥Population: high-risk HTN, mean SBP ~145 mmHg, median eGFR ~76 mL
ERA - European Renal Association
@ERAkidney
4/
📍Pooled KARDIA-2/3 patients on ACEi/ARB
⚠️Safety generally acceptable; most events were mild
⚠️More hyperkalemia, hypotension, and eGFR declines with zilebesiran
👉Events were usually manageable and reversible
#era26 -
ERA - European Renal Association
@ERAkidney
📣 DAY 3 is starting soon!
Plan your Congress Day at #era26!
Read our Daily Congress Bulletin 👉 r.mail.era-online.org/mk/mr/sh/1t6AVsd2XFnIGIVzcmU66oI9M0… -
ERA - European Renal Association reposted
ERA - European Renal Association
@ERAkidney
5/ #era26 Signing off, on behalf of ERA social media team, Rezzan Eren Sadioğlu @ErenRezzan
-
ERA - European Renal Association
@ERAkidney
1/ 🧵—AI in AKI & CRRT: Revolution Now or Caution First?
Chairs: Vincenzo Cantaluppi
Mariadelina Simeoni
Session2: AI in AKI & CRRT: Revolution Now or Caution First? - Caution first
🗣️Speaker: Lui Forni. #era26
ERA - European Renal Association
@ERAkidney
🤖 2/ Although AI looks so good in terms of early prediction and intervention BUT be careful what you wish for: Korean example
ERA - European Renal Association
@ERAkidney
🤖3/- Hallucination of AI is a concerning thing to think about
-Accountability should be taken seriously
-AI uses enourmous environmental sources
#era26
ERA - European Renal Association
@ERAkidney
4/ 🤖 Conclusion:
#era26
ERA - European Renal Association
@ERAkidney
Signing off, on behalf of ERA social media team, Rezzan Eren Sadioğlu @ErenRezzan #era26
-
ERA - European Renal Association
@ERAkidney
🩺 Why should HDF be the first choice?
@ACarinaFerreira presented two key strategies demonstrating the clinical superiority of high-volume HDF. The proven benefits include:
Better removal of middle molecules
📈 Proven mortality reduction
🧠 Improved cognitive function
🩺 Better hemodynamic stability
#era26Post not available here, view on X
ERA - European Renal Association
@ERAkidney
2/Take home mesages! #era26
ERA - European Renal Association
@ERAkidney
3/ On behalf SoME Team @damasjulianaf 👋
-
ERA - European Renal Association
@ERAkidney
🏠 Why are home therapies better?
🗣️ Speaker Gaetano Alfano discussed the role of residual renal function in home dialysis, highlighting key benefits:
✅ Better patient & technique survival
🧪 Clearance of middle-size molecules
💧 Maintenance of euvolemia
🧬 Intrinsic anti-inflammatory effects
#era26
ERA - European Renal Association
@ERAkidney
1/ Frequent dialysis shows major benefits for left ventricular hypertrophy & physical symptoms.
Key takeaway: survival rates increase with more treatment hours! 📈
Intensive HHD provides:
✅ Better hypertension control
✅ Reduced peripheral resistance
✅ Lower sympathetic overactivity
✅ Restoration of endothelial function
#era26
ERA - European Renal Association
@ERAkidney
2/ On behalf of SoME Team @damasjulianaf 👋
-
ERA - European Renal Association
@ERAkidney
1/ Fantastic session at #era26 FC8: Simon Leclerc re-frames idiopathic nephrotic syndrome as a spectrum of autoimmune podocytopathies—where autoantibody avidity, not just titer, drives disease severity
Post not available here, view on X
ERA - European Renal Association
@ERAkidney
3/ Over the last few years, multiple podocyte-directed autoantibodies have emerged: anti-nephrin, anti-podocin, anti-Kirrel1, anti-slit diaphragm components, and anti-CRB2, with different age distributions and histologic correlates
ERA - European Renal Association
@ERAkidney
4/ Anti-nephrin appears more prevalent in children with MCD and shows higher levels in active disease vs remission, with correlations to albuminuria—though not all cohorts show a simple linear relationship to severity.
Post not available here, view on X
ERA - European Renal Association
@ERAkidney
11/ Clinically, this means two patients with similar “positive” autoantibody titers may have very different risks if one harbours high-avidity, strongly signalling antibodies while the other has low-avidity antibodies.
ERA - European Renal Association
@ERAkidney
12/ Take-home messages: the link between autoantibody presence and disease activity is complex; avidity and germinal centre quality appear central to severity; and these data support early, targeted therapies directed at B cells/GCs in INS. #mcd #fsgs #nephtwitter
Stay tuned to #era26 for updates!
Signing off @NaveenNephro - For ERA Social Medial team -
ERA - European Renal Association
@ERAkidney
1/ At #era26 FC8, Sian Griffin @toomuchaltitude presents long-term data from the DUPLEX open-label extension (OLE) on sparsentan in FSGS—non-immunosuppressive, dual endothelin–angiotensin receptor blockade with sustained antiproteinuric effects.
Post not available here, view on X
ERA - European Renal Association
@ERAkidney
11/ Blood pressure remained stable throughout the OLE in both cohorts, and sparsentan was generally well tolerated: TEAEs were common but mostly manageable, with relatively low discontinuation and death rates and expected events such as hyperkalaemia, hypotension, oedema, and infections
ERA - European Renal Association
@ERAkidney
12/ Conclusions: long-term sparsentan in FSGS maintains antiproteinuric efficacy, supports achievement of low UPCR thresholds, and shows no new safety signals—positioning DEARA therapy as an important kidney-protective option alongside or independent of IST. #fsgs #ckd #nephtwitter
Stay tuned for updates and follow #era26 !
Signing off @NaveenNephro For ERA Social Medial team -
ERA - European Renal Association reposted
ERA - European Renal Association
@ERAkidney
If you are attending #era26 congress, join the Nephrology Training Hub on Hall 3 and approach interventional nephrology:
🩺ultrasounds
🩺central catheter placement
🩺peritoneal catheter
A great occasion to safely start to practice!
✍️ @FedericaNeveVig on behalf of SoMe team #era26 -
ERA - European Renal Association
@ERAkidney
🧵1/ 🧵—AI in AKI & CRRT: Revolution Now or Caution First?
Chairs: Vincenzo Cantaluppi
Mariadelina Simeoni
AI in AKI & CRRT: Revolution Now or Caution First? - Revolution now
🗣️Speaker: Kianoush Kashani @kianoushbk #era26
ERA - European Renal Association
@ERAkidney
2/#era26
⚪️AI is inevitable
We should enjoy the energy to have and use it as a tool to upgrade our clinical practice
⚪️ If nephrologist is a pilot, AI is the radar
⚪️AI vs Hospital bed as a medical tool
ERA - European Renal Association
@ERAkidney
3/🤖#era26 predicting intradialytic hypotension prior it happening is possible with AI models and the study is on the way!
ERA - European Renal Association
@ERAkidney
4/ 🤖#era26 ⚪️AI gives signal and physicians interpret it.
⚪️AI doesn’t de-skill us it re-skill us.
⚪️AI lacks causal reasoning, judgement, accountability so clinicians using AI will outperform who are not.
ERA - European Renal Association
@ERAkidney
5/ 🤖 Conclusion
ERA - European Renal Association
@ERAkidney
6/ #era26 Signing off, on behalf of ERA social media team, Rezzan Eren Sadioğlu @ErenRezzan
-
ERA - European Renal Association
@ERAkidney
1/ Live from #era26 FC8 “Podocytes Under Pressure”: Carolina Bigatti explores how complement–neutrophil crosstalk shapes kidney injury in Adriamycin-induced FSGS in mice. By @NaveenNephro on behalf of ERA Social Media Team
Post not available here, view on X
ERA - European Renal Association
@ERAkidney
11/ Next steps include qPCR for C5aR in DAF-deficient neutrophils and double knockout (DAF–C5aR) models to test whether protection is truly mediated via C5a–C5aR signalling.
ERA - European Renal Association
@ERAkidney
12/ Take-home: targeting the complement–neutrophil axis, not just podocytes, may offer novel strategies to limit proteinuria in FSGS. Translational work will need to balance infection risk with anti-inflammatory benefit. #fsgs #nephtwitter #era26
-
ERA - European Renal Association
@ERAkidney
1/🧵—RNA and cell therapeutics for kidney disease
Chairs: Melanie Chan, Jan Halbritter
Session 3 -Human iPSC derived progenitor cells for the treatment of kidney disease
🗣️Speaker: Kenji Osafune
#era26
ERA - European Renal Association
@ERAkidney
2/#era26
🧫🧠imduced Pluripotent stem cells are being studied largely.
⚪️İPDC derived regenerative therapy and deug discovery for kidney disease, as well.Post not available here, view on X
ERA - European Renal Association
@ERAkidney
4/ #era26
Clinical trials are planned to cell therapies
⚪️It is invasive to native kidneys but transplant kidneys are more approachable and they already have immunosuppressants this make them more suitable for it.
ERA - European Renal Association
@ERAkidney
5/ #era26 Signing off, on behalf of ERA social media team, Rezzan Eren Sadioğlu @ErenRezzan
-
ERA - European Renal Association
@ERAkidney
1/ 🧵—RNA and cell therapeutics for kidney disease
Chairs: Melanie Chan, Jan Halbritter
Session 2- Long-non coding RNAs: role in aging and disease
🗣️Speaker: Jurg BahlerPost not available here, view on X
ERA - European Renal Association
@ERAkidney
5/Conclusion 👇🏻
ERA - European Renal Association
@ERAkidney
Signing off, on behalf of ERA social media team, Rezzan Eren Sadioğlu @ErenRezzan
-
ERA - European Renal Association
@ERAkidney
1/ 🧪🧵—RNA and cell therapeutics for kidney disease
Chairs: Melanie Chan, Jan Halbritter
Session 1: Targeted delivery of RNA therapeutics to kidney cells
🗣️Speaker: Jørgen Kjems @kjems_rgen
ERA - European Renal Association
@ERAkidney
2/ 🧪 We have a lot of type of rna and systems
⚪️Today’s focus is lipid nanoparticles (LNPs) #era26
ERA - European Renal Association
@ERAkidney
3/ 🧵 Ischemia reperfusion injury on donor kidney can may be less severe with normothermic machine perfusion.
⚪️Adding mRNA LNP to normothermic machine perfusion solution studied here.#era26
ERA - European Renal Association
@ERAkidney
🧵4/ 🧪mRNA LNP successfully reached to pig’s urine after ototransplantation.
⚪️Keypoints 👇🏻#era26
ERA - European Renal Association
@ERAkidney
5/ #era26 Signing off, on behalf of ERA social media team, Rezzan Eren Sadioğlu @ErenRezzan
-
ERA - European Renal Association
@ERAkidney
🧵 1/9: The Great Debate of Cardiovascular burden in CKD at #era26! 🥊
Cardiovascular burden in CKD: Genetic or Epigenetic - Who is the real culprit? We heard stellar arguments from @UofGRegiusAnna (Genetics) and Christian Delles (Epigenetics). Let’s break down the evidence! 👇
ERA - European Renal Association
@ERAkidney
2/9: Team Genetics - The Blueprint 🧬
Prof. Anna Dominiczak argues that "genes come 1st". The mechanistic blueprints for precision medicine start with the genome, moving through transcriptomics to targeted therapies.
A prime example is APOL1-mediated kidney disease, where specific G1/G2 variants drive pathology, leading to emerging targeted channel inhibitors like inaxaplinPost not available here, view on X
ERA - European Renal Association
@ERAkidney
8/9: Proteomics & Clinical Utility 🧪
The end-product of this regulation—the proteome—is highly actionable.
Urinary peptide signatures are powerful tools that reflect the molecular pathophysiology of conditions like CKD and hypertension.
The PRIORITY trial demonstrated that urinary proteomics can effectively detect diabetic kidney disease early and successfully identify high-risk patients for intervention.
ERA - European Renal Association
@ERAkidney
9/9: The Verdict? ⚖️
While genes provide the essential blueprint and shared architecture for CKD and CVD, transcription and translation are highly regulated by the environment. Epigenetics and downstream multiomics provide the real-time insights into disease processes and true targets for intervention.
Stay tuned for updates and follow #era26!
Signing off @NaveenNephro For ERA Social Medial team -
ERA - European Renal Association
@ERAkidney
#era26 @ERAkidney
Free Comunication 10: Salt, Smog & Sugar: Lifestyle Signals Shaping CKD
Chair: Magdalena Jankowska and Michele Eisenga
🧵1 /5
1️⃣ The Obesity Paradox is Primarily Driven by Decreased Non-cardiovascular Mortality Risk among the Oldest Old with Chronic Kidney Disease
🗣️ Changyuan Yang
📍 Research Gap: Whether these patterns (of obesity) extend to oldest-old CKD patients remains unknown.Post not available here, view on X
ERA - European Renal Association
@ERAkidney
#era26 🧵4/5
4️⃣ Plant-based versus ultra-processed dietary patterns and mortality in chronic kidney disease: a multicohort analysis
🗣️ Guido Gembillo
📍 Pooling NHANES and HRS-HCNS into a single CKD population
📍Mortality risk diverges ➡️ depending on the diet ❗️
ERA - European Renal Association
@ERAkidney
#era26 🧵5/5
5️⃣ Interplay Between Fibroblast Growth
Factor-19, Beta-Klotho, and Receptors
Impacts Cardiovascular Risk in Chronic
Kidney Disease
🗣️ Laura Gonzalez Rodriguez
📍Study aims:
➡️Endocrine FGFs could be potential biomarkers of chronic kidney disease and its comorbidities
➡️ investigate the relevance of the FGF19/B-Klotho/FGFR system in CKD by evaluating the impact of:
📕its circulating levels
📕genetic variants on these patients.
📍Alterations in the FGF19/B-Klotho system are independently associated with cardiovascular risk in CKD.
Signing off, on behalf of #era social media team, Francisco Valga @Nefrogeek -
ERA - European Renal Association
@ERAkidney
Treatment of chronic hyponatraemia and preventiom kf overcorrection! #era26
Post not available here, view on X
ERA - European Renal Association
@ERAkidney
Hyponatraemia is treatment by symptoms! #era26
ERA - European Renal Association
@ERAkidney
Preventing and treatment of overcorrection! #era26
by ERA social media team @AgavriloaeiB -
ERA - European Renal Association
@ERAkidney
If you are attending #era26 congress, join the Nephrology Training Hub on Hall 3 and approach interventional nephrology:
🩺ultrasounds
🩺central catheter placement
🩺peritoneal catheter
A great occasion to safely start to practice!
✍️ @FedericaNeveVig on behalf of SoMe team #era26 -
ERA - European Renal Association
@ERAkidney
🧵 1/9
As Nephrology Dialysis Transplantation @NDTsocial celebrates 40 years 🎉, a new editorial ✨ highlights how biological sex shapes CV benefits of exercise in CKD.
@VanAmaryllis @olgabalafa @anagarcp #wera
Read the full article at 🔗academic.oup.com/ndt/advance-article/doi/10.1093/ndt/gfag…
Read the thread for a sneak peek 👇👇 👇 -
ERA - European Renal Association
@ERAkidney
🌍 ERA supports #worldkidneyday
🔍 Some kidney treatments, like dialysis, require significant water and energy
🌱 By promoting prevention, early detection and greener healthcare practices, we can reduce the burden on both patients and our planet -
ERA - European Renal Association
@ERAkidney
📌The ERA & @ESEndocrinology representatives met on September 25-26, 2025, at the ERA HQ in Parma to develop the 2026 joint hyponatraemia guideline, chaired by Mark Sherlock (ESE) and Ewout Hoorn (ERA). The guideline will provide practical recommendations to help clinicians diagnose and treat this common and challenging electrolyte disorder.
📸 Here's a snapshot of the meeting! -
ERA - European Renal Association
@ERAkidney
🎉 We're proud to share the latest Impact Factors and CiteScores for our leading nephrology journals Nephrology Dialysis Transplantation (NDT) and Clinical Kidney Journal (CKJ).
🙏 Thanks to the exceptional contributions of our authors, reviewers, readers, and editorial board. -
Post not available here, view on XPost not available here, view on X
ERA - European Renal Association
@ERAkidney
The decrease in transplantation rates was not homogeneous, with different approaches taken by countries.
#era22







































































































































































































































































































































































































































































































































































































































































































































































































































